{"_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgL6steMLDA","lastupdate":"2024-03-18T00:00:00.000Z","update_date":"2024-03-18T00:00:00.000Z","lastModified":"Oct 27, 2025","active":1,"confidence_score":91,"confidence_score_reason":"markets, not claimed","urlname":"protalix","minimal_profile":null,"status":"Public","fullstatus":"Public on AMEX on Dec, 2006;Public on TASE on Nov, 2010;Public on NYSE on Mar, 2011;","acquired":0,"hide_reason":null,"hide_reason_data":null,"hide_reasons":[{"id":"8257rxn4P8EFQOmS5hAAauHyYMhhxrA5u6yWX4XUShpybX3AMNo3Y9","reason":"Pending approval - External entity"},{"id":"aOIaOiiqfpA8UMw6VCTh8ueRmkG3lzDy1NGqEOaJbe11OrCzMTCCd6","reason":"The company is a service provider"},{"id":"ddgjKuc3GgH8E5UehSVJviRl471BCajL1plO8HtGoOojy2NivYqQ7x","reason":"Owner asked to delete"},{"id":"EjOKM211H1ira9J63oaGPuUxvr7Oba55TZo3NWsFO5uhbNu7o4x4zD","reason":"The company is not Israeli"},{"id":"J7fQJtnT3GdWWSE3MD8rzaW65LJ4jEIKxSZnneQiReONdZjG3zIqWe","reason":"Owner asked to hide in the meantime"},{"id":"NxlAC3ReFb5ksiYNLp2FnUyluoJzwRCYfcF7xpTZaPM53SdWQ5kv0B","reason":"Pending approval"},{"id":"RhC1tlwXzioK0MfzBII3H2wepEfQOfKVktmdwqeqTJjGi3ZaBWUqZo","reason":"The company is not innovative"},{"id":"S0Ed46vNI6vZYVxLedANWGjas23K6hY0QdsCtiGYL7lshqIEdLV3sA","reason":"The company ceased operations in Israel"},{"id":"VTANq7bEvlsEcPjp0ghelXfShaCosgndONGjgU730aAOxXtaDIF5j3","reason":"This is a product of an existing company"}],"type":"Startup","logokey":"$Fh4vCEadZAfTP5ZZNbudPyVHatYvtFo3F2XHvMoM5PmIkjwUU5Js0T","name":"Protalix BioTherapeutics","oneliner":"Plant-based Proteins with Improved Therapeutic Profiles","registrar":"511903288","website":"https://protalix.com","careerspage":"https://protalix.com/about/careers","founded_month":1,"founded_year":1994,"formernames":[],"sociallinks":{"twitter":"https://twitter.com/protalix_bio","youtube":"","facebook":"https://www.facebook.com/ProtalixBio","linkedin":"https://www.linkedin.com/company/739969","instagram":""},"social":["https://www.linkedin.com/company/739969","https://www.facebook.com/ProtalixBio","https://twitter.com/protalix_bio"],"flattenedsociallinks":"https://www.linkedin.com/company/739969|https://www.facebook.com/ProtalixBio|https://twitter.com/protalix_bio","apps":{"appstore":"","googleplay":""},"is_claimed_by_owner":null,"employees":"51-200","employees_exact":194,"patent":1,"raised":159900000,"stage":"Public","public_stage":"Public","primary_sector_key":"agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","primary_sector":"Health Tech & Life Sciences","alternativenames":[""],"about":"Protalix BioTherapeutics is a biopharmaceutical company focused on the development, production, and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx plant-cell-based protein expression system. The company's pipeline consists of proprietary, potentially clinically superior versions of recombinant therapeutic proteins that target established pharmaceutical markets.\r\n\r\nProtalix gained FDA approval for a plant-cell culture-expressed protein. Elelyso (taliglucerase alfa for injection) is the company's first drug product produced by ProCellEx. Elelyso was approved for marketing by the FDA in May 2012, soon followed by approval from multiple regulatory agencies including the EMA, Australian TGA, Brazilian ANVISA, and the Israeli Ministry of Health. The product has been licensed to Pfizer.\r\n\r\nThe Protalix ProCellEx platform has the ability to manufacture complex proteins, antibodies, and vaccines and to orally deliver certain therapeutic proteins as demonstrated in animal models.","climatetech_description":null,"is_climatetech_relevant":null,"phone":"+97249028100","country":null,"address":{"israeli":[{"id":"7eb93f57-ca36-4c92-bf88-ddfd833694b6","city":"Karmiel","type":null,"address":"Snunit St 2, Karmiel, Israel","placeid":null,"notactive":0,"openeddate":null,"registrarid":null,"firstrdcenter":0,"registrarname":null}],"officesabroad":null},"headquarter_address":null,"district":"North District","news":[{"id":"TqyyLf3EqLNnkEy5SKbl4PGtw4Sgz3SbaVdCnvZ1eDdsgZkH8KKDFl","date":"Oct 27, 2025","link":"https://finance.yahoo.com/news/3-compelling-penny-stocks-market-121514800.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"regenerative medicine","round":null,"company":"Organogenesis Holdings Inc.","layoffs":null,"summary":"Organogenesis Holdings Inc., a company in the regenerative medicine sector, is facing challenges typical for its industry. Despite setbacks in Phase 3 trials for its product ReNu, the product maintains a favorable safety profile and holds a Regenerative Medicine Advanced Therapy designation from the FDA. The company, with a market cap of $540.41 million, remains unprofitable but has improved its net loss and forecasts revenue growth up to $510 million by the end of 2025. Organogenesis operates debt-free but faces cash runway constraints if free cash flow grows at historical rates.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["stock market","penny stocks","investment","financial health","regenerative medicine"],"date_of_event":"October 2025","product_stage":"Phase 3 trials","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-negative","investment_amount":null,"structured_issues":["Product Stage","FDA approved/pending approval"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":null,"structuredIssuesShow":"#Product Stage  #FDA approved/pending approval","entityGrowthIconPath":"url(/assets/circle-red.svg);"},"sentiment":"growth-negative","analysisId":"6loAuEalIgE3MKXoKQ9NRBtOI5U2ZRKOIN46C6VoioURjE2h6mFlZS","news_summary":"3 Compelling Penny Stocks With Market Caps Under $600M","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"jXDqANbMPqLRI0OOa7JtXXtbjKS42vf629zyNOoKp5n017MZeMQsYu","date":"Oct 19, 2025","link":"https://finance.yahoo.com/news/protalix-plx-turn-regulatory-setbacks-111441764.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"regulatory setback","round":null,"company":"Protalix BioTherapeutics","layoffs":null,"summary":"The European Medicines Agency (EMA) issued a negative opinion on Protalix BioTherapeutics and Chiesi Groups request for a less frequent dosing schedule for Elfabrio in Fabry disease, citing insufficient data. This regulatory setback highlights challenges in modifying dosing regimens to reduce patient treatment burdens. Despite this, the FDAs approval of Elfabrio in May 2025 underscores its commercial potential, with ongoing efforts for label expansion. The EMAs decision raises questions about short-term revenue growth but does not affect the initial FDA approval in the US. Protalix is projected to reach significant revenue and earnings growth by 2028, with a fair value estimate suggesting a substantial upside to its current stock price.","partners":"Chiesi Group","customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["EMA opinion","Elfabrio dosing","regulatory hurdles","FDA approval","market expansion"],"date_of_event":"October 2025","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-negative","investment_amount":null,"structured_issues":["FDA approved","Product Stage","Partners"],"acquisition_amount":null,"FDA approved/pending approval":"approved","AI technology developing/using":"developing","structuredIssuesShow":"#FDA approved  #Product Stage  #Partners","entityGrowthIconPath":"url(/assets/circle-red.svg);"},"sentiment":"growth-negative","analysisId":"fhmYvOABlCWPB1I0HBUrGUSdEAjv1x6HI8Ey3LtPMORNKExFCQ86vy","news_summary":"Can Protalix (PLX) Turn Regulatory Setbacks Into a Competitive Advantage in Rare Disease Markets?","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"pnwS4kUF1y4ptTWVHXDxXSgDh4sq4B6JPWRvLFkvCfmMmq6c8cdzTF","date":"Oct 18, 2025","link":"https://finance.yahoo.com/news/protalix-biotherapeutics-plx-evaluating-valuation-091140149.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"regulatory challenges","round":null,"company":"Protalix BioTherapeutics","layoffs":null,"summary":"Protalix BioTherapeutics experienced a significant drop in share price following a negative opinion from the European Medicines Agency (EMA) regarding a proposed dosing schedule for its Fabry disease therapy, Elfabrio. The companys stock fell by 22.5% in a single day, erasing recent gains. Despite this setback, Protalix has shown a 1-year total shareholder return of over 70%. The market is currently debating whether the company is undervalued, with shares trading below analyst targets. The companys future growth prospects are influenced by ongoing regulatory challenges and geopolitical instability. Protalix has no debt and potential lucrative therapies in its pipeline, which could drive future growth if approved.","partners":null,"customers":null,"eventType":null,"investors":[],"confidence":9,"key_topics":["EMA opinion","share price","Fabry therapy","investor sentiment","valuation"],"date_of_event":null,"product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-negative","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"not mentioned","entityGrowthIconPath":"url(/assets/circle-red.svg);"},"sentiment":"growth-negative","analysisId":"3ag7YEHB8KmxoD1A9pQp0pQHcXCYhkFrKGAI4Dx9Mw2CU34bTfKYSz","news_summary":"Protalix BioTherapeutics (PLX): Evaluating Valuation After EMA Setback on Elfabrio Dosing Regimen","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"cG820DelQ6gFEYIxDz4Pq2ZDawlTNPGO4ErI8WSiTyOv9rHjcS5wE0","date":"Oct 17, 2025","link":"https://finance.yahoo.com/news/chiesi-global-rare-diseases-protalix-105800864.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"regulatory setback","round":null,"company":"Protalix Biotherapeutics","layoffs":null,"summary":"Chiesi Global Rare Diseases and Protalix Biotherapeutics have received a negative opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) regarding the approval of a new dosing regimen for Elfabrio. The proposed regimen of 2 mg/kg every four weeks was not approved, maintaining the current regimen of 1 mg/kg every two weeks. Despite the setback, both companies remain committed to reducing the treatment burden for Fabry disease patients. The decision was based on data from clinical trials and modeling analyses, which were deemed insufficient to demonstrate similar efficacy. The companies plan to continue their efforts in supporting the Fabry disease community.","partners":["Chiesi Global Rare Diseases"],"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["Fabry disease","clinical trial","EMA decision","dosing regimen","patient community"],"date_of_event":"October 17, 2025","product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-negative","investment_amount":null,"structured_issues":["Product Stage","Customers"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"not mentioned","structuredIssuesShow":"#Product Stage  #Customers","entityGrowthIconPath":"url(/assets/circle-red.svg);"},"sentiment":"growth-negative","analysisId":"1ba3LYagdoIeFlOnqBqRn6dYyRQrJXYqXl8f8oVWuKiuldEaxKdUND","news_summary":"Chiesi Global Rare Diseases and Protalix Biotherapeutics Acknowledge CHMP Negative Opinion on Every Four Week Dosing Regimen of Elfabrio® (pegunigalsidase alfa) in the EU","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"zMw4cshMkCayaqj0kTNonzwZVU0tIMNIArACJlZOo3fwiRp5UO317Q","date":"Sep 29, 2025","link":"https://finance.yahoo.com/news/protalix-biotherapeutics-inc-plx-gains-225033570.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"investment","round":null,"company":"Protalix BioTherapeutics, Inc.","layoffs":null,"summary":"Protalix BioTherapeutics, Inc., a New Jersey-based biopharmaceutical company, is gaining attention as a promising investment opportunity. Goldman Sachs Group Inc. significantly increased its holdings in the company by 482.3% during the first quarter, now owning 289,461 shares valued at approximately $741,000. Protalix specializes in developing recombinant therapeutic proteins through its ProCellEx platform, focusing on rare genetic diseases. The company is expanding its platform to optimize drug delivery, which is seen as a potential game-changer in the industry. Despite the positive outlook for Protalix, some analysts suggest that certain AI stocks may offer greater upside potential.","partners":null,"customers":null,"eventType":null,"investors":"Goldman Sachs Group Inc.","confidence":9,"key_topics":["investment","biopharmaceutical","ProCellEx","therapeutic proteins","expansion"],"date_of_event":"first quarter","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":"$741,000","impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Investment"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"developing","structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"s1NBGqf1szaUHuRKztcNVlqpAbFWD1DNE7xMJFUBCwGB4lBsMs3HPo","news_summary":"Protalix BioTherapeutics, Inc. (PLX) Gains Investor Confidence With Major Stake Increase","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"leqSiL8NuUuuo83gHVFXgjO9ncRZMlS70ZNFG7Tr44cn30Mi721ltA","date":"Sep 16, 2025","link":"https://finance.yahoo.com/news/3-penny-stocks-market-caps-120507344.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"biotechnology","round":null,"company":"Protalix BioTherapeutics, Inc.","layoffs":null,"summary":"Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing recombinant therapeutic proteins using its ProCellEx plant cell-based protein expression system. The company has recently turned profitable, reporting a net income of $0.164 million in Q2 2025. With no debt and strong short-term assets, Protalix is in a solid financial position. Recent management changes include the appointment of Gilad Mamlok as CFO, which is expected to bring extensive capital markets experience to the company. Protalixs addition to multiple Russell indices highlights growing investor recognition. The company operates in the biotechnology sector, with a market cap of $144.32 million.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["biotechnology","penny stocks","financial health","management","revenue"],"date_of_event":null,"product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Management Changes"],"acquisition_amount":null,"FDA approved/pending approval":null,"AI technology developing/using":null,"structuredIssuesShow":"#Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"LudPeaUJBYgbrqRD45q0Wrqdin7Afy37Ei4eNdAkcw2ceszKAki7wv","news_summary":"3 Penny Stocks With Market Caps Over $30M To Consider","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"mIILb9qXFZpYIW2t0sdEuFCASM8PZYGFGmzqLMp9PTEb26qTJQczSE","date":"Sep 16, 2025","link":"https://finance.yahoo.com/news/presenting-investor-summit-q3-2025-120000864.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"conference","round":null,"company":"Investor Summit Group","layoffs":null,"summary":"The Investor Summit Group is hosting its Q3 Investor Summit Virtual on September 16, 2025. This event is designed to enhance visibility for issuers and efficiency for investors by showcasing companies with strong leadership and innovative products. The summit serves as a platform for connecting quality companies with serious investors. The event features a schedule of presentations from various companies across different sectors, providing an opportunity for these companies to present their growth strategies and innovations to potential investors. The summit is a significant opportunity for companies to gain exposure and for investors to discover promising investment opportunities.","partners":null,"customers":null,"eventType":null,"investors":[],"confidence":9,"key_topics":["conference","investors","visibility","leadership","growth"],"date_of_event":"September 16, 2025","product_stage":"N/A","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"FDA approved/pending approval":null,"AI technology developing/using":null,"entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"VSFxbr5YDYRzaJhG6MpvFgYFpLK1CBPUtDqE0ecPHOjWTe5NnPkysb","news_summary":"Presenting at the Investor Summit Q3 2025 on September 16; Watch the Live Stream for Free","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"l9S2EMhYQJI9jPem4TIjWZFpdal4BjnzHBrQHBljfIvwTqeSIUPZYX","date":"Sep 11, 2025","link":"https://finance.yahoo.com/news/protalix-biotherapeutics-present-investor-summit-145500119.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"growth strategies","round":null,"company":"Protalix BioTherapeutics, Inc.","layoffs":null,"summary":"Protalix BioTherapeutics, Inc., a biopharmaceutical company, is set to present at the Investor Summit Virtual on September 16, 2025. The company focuses on developing recombinant therapeutic proteins using its proprietary ProCellEx plant cell-based expression system. Protalix has achieved FDA approval for its products, including taliglucerase alfa and Elfabrio, the latter also approved by the European Medicines Agency. The company has partnered with Pfizer for the global commercialization of taliglucerase alfa and with Chiesi Farmaceutici for Elfabrio. Protalixs pipeline includes products targeting pharmaceutical markets, such as PRX-115 and PRX-119. The Investor Summit will highlight growth strategies and market opportunities for small and microcap stocks.","partners":["Pfizer Inc.","Chiesi Farmaceutici S.p.A."],"customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["biopharmaceutical","FDA approval","partnerships","investment","growth"],"date_of_event":"September 16, 2025","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Management Changes","Partners","FDA approved"],"acquisition_amount":null,"FDA approved/pending approval":"FDA approved","AI technology developing/using":null,"structuredIssuesShow":"#Management Changes  #Partners  #FDA approved","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"S6AIL3sAtrw6dgjl3GVkcXx0MBAyS0PskRsv9riO8NDPFfCJ7J375y","news_summary":"Protalix BioTherapeutics to Present at Investor Summit Virtual","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"RdLQ4PD3HOYVhG1bnUlH5d81pkpNM2Zu6ZwFygj9INGGhVAqe3OVej","date":"Sep 2, 2025","link":"https://www.prnewswire.com/news-releases/protalix-biotherapeutics-to-present-at-the-hc-wainwright-27th-annual-global-investment-conference-302543639.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"conference","round":null,"company":"Protalix BioTherapeutics, Inc.","layoffs":null,"summary":"Protalix BioTherapeutics, Inc., a biopharmaceutical company, announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference in September 2025. The company focuses on developing recombinant therapeutic proteins using its proprietary ProCellEx plant cell-based expression system. Protalix has achieved FDA approval for its products, including Elfabrio, which was approved in May 2023. The company has partnered with Chiesi Farmaceutici S.p.A. for the global development and commercialization of Elfabrio. Protalixs pipeline includes products targeting established pharmaceutical markets, such as treatments for uncontrolled gout and NETs-related diseases.","partners":["Chiesi Farmaceutici S.p.A.","Pfizer Inc."],"customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["biopharmaceutical","conference","FDA approval","partnerships","product pipeline"],"date_of_event":"September 8, 2025","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners","FDA approved"],"acquisition_amount":null,"FDA approved/pending approval":"FDA approved","AI technology developing/using":null,"structuredIssuesShow":"#Partners  #FDA approved","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"xV8X1vSkjpEVf6HCAeNbJulVGs7zTQ7kXb5k7CieAOA4aP8ZSiR52u","news_summary":"Protalix BioTherapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"Nxxi2LUUX2o9wAWdgP67pNXNdo80Tuzf87fgU2ukzz2jqBlbPl6TFU","date":"Sep 2, 2025","link":"https://www.prnewswire.com/il/news-releases/protalix-biotherapeutics-to-present-at-the-hc-wainwright-27th-annual-global-investment-conference-302543639.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"conference, presentation","round":null,"company":"Protalix BioTherapeutics, Inc.","layoffs":null,"summary":"Protalix BioTherapeutics, Inc., a biopharmaceutical company, is set to present at the H.C. Wainwright 27th Annual Global Investment Conference in New York City from September 8–10, 2025. The company focuses on developing and commercializing recombinant therapeutic proteins using its proprietary ProCellEx plant cell-based expression system. Protalix has achieved FDA approval for its plant cell-based protein production and has licensed rights to Pfizer for taliglucerase alfa, excluding Brazil. Additionally, Protalixs product Elfabrio has been approved by both the FDA and the European Medicines Agency. The company has partnered with Chiesi Farmaceutici for the global development of Elfabrio and continues to develop other therapeutic proteins targeting established pharmaceutical markets.","partners":["Pfizer Inc.","Chiesi Farmaceutici S.p.A."],"customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["biopharmaceutical","FDA approval","partnerships","conference","therapeutic proteins"],"date_of_event":"September 8, 2025","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["FDA approved/pending approval","Partners","Product Stage"],"acquisition_amount":null,"FDA approved/pending approval":"FDA approved","AI technology developing/using":"not mentioned","structuredIssuesShow":"#FDA approved/pending approval  #Partners  #Product Stage","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"cGWj4fxqXJvjLNMPKdXfxRHdE2q6P6TRDvsef9FIMkQb3SPil0BObp","news_summary":"/PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development, production and commercialization of...","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"7xKCSeGuY2VAwNxZqjqqLr6ePE6xRh3ZgNfWMIMc9VYxasXRIK7SZn","date":"Aug 15, 2025","link":"https://finance.yahoo.com/news/plx-cfo-reins-170900660.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"financial results","round":null,"company":"Protalix BioTherapeutics, Inc.","layoffs":null,"summary":"Protalix BioTherapeutics, Inc. reported its second quarter 2025 financial and operational results, highlighting a 16% increase in revenues driven by higher sales of Elfabrio, despite a decline in Elelyso sales. The company plans to launch the PRX-115 trial in the second half of the year. A new CFO, Gilad Mamlok, will take over from Eyal Rubin. Protalix aims to achieve $100 million in royalty revenues by 2030, targeting a 15% to 20% market share in the Fabry market. The company experienced a net income of $164,000 compared to a net loss in the previous year, and it was added to the Russell 2000 and 3000 indices.","partners":null,"customers":["Chiesi","Pfizer"],"eventType":null,"investors":null,"confidence":9,"key_topics":["revenue growth","clinical trial","management change","financial performance","market share"],"date_of_event":"August 14th, 2025","product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Management Changes","Customers","Product Stage"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"using","structuredIssuesShow":"#Management Changes  #Customers  #Product Stage","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"ddjw6tQkjTU24lSEmwmEypyroO0XlDqUFcNu9Hir8ck1Xfgy6Bb0DQ","news_summary":"PLX: New CFO to Take the Reins","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"jPr0Ukf9ued5kIgzQ6P5hu11Tfw0xJMIyFNrP2YjtnxoeRfOZSuSzj","date":"Aug 14, 2025","link":"https://finance.yahoo.com/news/protalix-biotherapeutics-reports-second-quarter-105000636.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":["financial-results","management-changes"],"round":null,"company":"Protalix BioTherapeutics, Inc.","layoffs":null,"summary":"Protalix BioTherapeutics, Inc. reported a 50% increase in revenues for the first half of 2025, driven by sales of Elfabrio® to Chiesi. The company is in the early launch phase for Elfabrio, targeting the Fabry disease market, which is expected to grow significantly by 2030. Protalix is also advancing its PRX-115 product candidate for uncontrolled gout, with a Phase 2 trial anticipated in late 2025. The company announced a management change, with Eyal Rubin stepping down as CFO, to be succeeded by Gilad Mamlok. The company is confident in its growth trajectory and strategic plans.","partners":["Chiesi"],"customers":["Chiesi"],"eventType":null,"investors":null,"confidence":9,"key_topics":["revenue","partnership","clinical-trial","management","growth"],"date_of_event":"June 30, 2025","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers","Partners","Management Changes"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"using","structuredIssuesShow":"#Customers  #Partners  #Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"Okl83LxYLNJLPY4dtlB8R1o7XZnYHtd5CoIGDkcMGKzJWgmkwjfayX","news_summary":"Protalix BioTherapeutics Reports Second Quarter 2025 Financial and Business Results","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"xtqWgO353o2oZokzkZybafOFvutQcTHfsAPgZKsVqU5rJA5Hdl1TB6","date":"Aug 7, 2025","link":"https://www.prnewswire.com/il/news-releases/protalix-biotherapeutics-to-announce-second-quarter-2025-financial-and-business-results-on-august-14-2025-302524577.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"financial results","round":null,"company":"Protalix BioTherapeutics, Inc.","layoffs":null,"summary":"Protalix BioTherapeutics, Inc., a biopharmaceutical company, announced it will release its financial results for the quarter ended June 30, 2025, and provide a business and clinical update on August 14, 2025. The company focuses on developing recombinant therapeutic proteins using its proprietary plant cell-based expression system, ProCellEx. Protalix has achieved FDA approval for its products, including taliglucerase alfa and Elfabrio. The company has partnered with Pfizer for the global rights to taliglucerase alfa, excluding Brazil, and with Chiesi Farmaceutici for the global development of Elfabrio. Protalixs pipeline includes products targeting established pharmaceutical markets, such as PRX–115 and PRX–119.","partners":["Pfizer Inc.","Chiesi Farmaceutici S.p.A."],"customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["conference call","financial results","clinical update","FDA approval","partnerships"],"date_of_event":"August 14, 2025","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage","Partners","FDA approved/pending approval"],"acquisition_amount":null,"FDA approved/pending approval":"approved","AI technology developing/using":"using","structuredIssuesShow":"#Product Stage  #Partners  #FDA approved/pending approval","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"74MDQxjPC9bHiLzuhxUTQ6uyp8DUNkiQnbTG5RQl0f28xlwgNvFJK0","news_summary":"/PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization...","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"L9kqGszC1php9G97QlN1irpyPgjQUyCCwySZHvSoSsJKLzKKKbGeDT","date":"Aug 7, 2025","link":"https://finance.yahoo.com/news/protalix-biotherapeutics-announce-second-quarter-165300213.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"financial update","round":null,"company":"Protalix BioTherapeutics, Inc.","layoffs":null,"summary":"Protalix BioTherapeutics, Inc., a biopharmaceutical company, announced it will release its financial results for the quarter ended June 30, 2025, and provide a business and clinical update on August 14, 2025. The company focuses on developing recombinant therapeutic proteins using its proprietary ProCellEx plant cell-based expression system. Protalix has achieved FDA approval for its plant cell-based protein production system and has licensed worldwide rights to taliglucerase alfa to Pfizer Inc., except in Brazil. Additionally, its product Elfabrio® received FDA and European Medicines Agency approval in May 2023. The company will host a conference call to discuss its financial results and recent developments.","partners":"Pfizer Inc.","customers":"Pfizer Inc.","eventType":null,"investors":null,"confidence":10,"key_topics":["financial results","conference call","clinical update","FDA approval","partnership"],"date_of_event":"August 14, 2025","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage","Customers","Partners","FDA approved/pending approval"],"acquisition_amount":null,"FDA approved/pending approval":"FDA approved","AI technology developing/using":null,"structuredIssuesShow":"#Product Stage  #Customers  #Partners  #FDA approved/pending approval","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"nkcEkvRim5dajH9u9pVpQRfjr2FlTbtnMuTgZSDnYVPrVG6VQUMxNm","news_summary":"Protalix BioTherapeutics to Announce Second Quarter 2025 Financial and Business Results on August 14, 2025","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"FNehKa66JMmJCJL1HDTVTmpvnoqOOgGvQnfdbkwEYqOuYDNiJexV7g","date":"Jul 21, 2025","link":"https://finance.yahoo.com/news/protalix-biotherapeutics-appoints-gilad-mamlok-105000736.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Management Changes","round":null,"company":"Protalix BioTherapeutics, Inc.","layoffs":null,"summary":"Protalix BioTherapeutics, Inc. announced the appointment of Gilad Mamlok as the new Senior Vice President and Chief Financial Officer, effective August 24, 2025. This management change is part of Protalixs strategy to strengthen its financial and capital status. Mamlok brings extensive experience in healthcare and technology sectors, having previously served as CFO at TytoCare Ltd. and Sol-Gel Technologies Ltd. Protalix is known for its proprietary ProCellEx plant cell-based protein expression system and has achieved FDA approval for its products, including taliglucerase alfa and Elfabrio®. The company has a partnership with Pfizer for the worldwide commercialization of taliglucerase alfa, except in Brazil.","partners":["Pfizer Inc."],"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["appointment","growth","FDA approval","ProCellEx","partnership"],"date_of_event":"August 24, 2025","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Management Changes"],"acquisition_amount":null,"FDA approved/pending approval":"FDA approved","AI technology developing/using":"using","structuredIssuesShow":"#Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"LdBa1d4ScXR4LvC1uBdaE5zYVF28H69q05cYM37k9ML1YlgzvPGV03","news_summary":"Protalix BioTherapeutics Appoints Gilad Mamlok as its New Senior Vice President and Chief Financial Officer","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"1bjbziMtNH4FzTelNaMqiM4AtYKozBLmznyY4tbymzIzQ3oADcW5Lk","date":"Jul 21, 2025","link":"https://www.prnewswire.com/il/news-releases/protalix-biotherapeutics-appoints-gilad-mamlok-as-its-new-senior-vice-president-and-chief-financial-officer-302509411.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"Management Changes","round":null,"company":"Protalix BioTherapeutics, Inc.","layoffs":null,"summary":"Protalix BioTherapeutics, Inc., a biopharmaceutical company, announced the appointment of Gilad Mamlok as the new Senior Vice President and Chief Financial Officer, effective August 24, 2025. Mamlok, with extensive experience in healthcare and technology companies, will succeed Eyal Rubin, who will remain available until October 2025. Protalix focuses on developing recombinant therapeutic proteins using its proprietary plant cell-based expression system, ProCellEx. The company has FDA approval for its products, including Elfabrio, and has partnered with Chiesi Farmaceutici for global commercialization. The management change is expected to support Protalixs growth strategy.","partners":["Chiesi Farmaceutici S.p.A.","Pfizer Inc."],"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["management","partnership","FDA approval","product development","financial strategy"],"date_of_event":"August 24, 2025","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Management Changes","Partners","FDA approved"],"acquisition_amount":null,"FDA approved/pending approval":"FDA approved","AI technology developing/using":null,"structuredIssuesShow":"#Management Changes  #Partners  #FDA approved","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"SZwqN7w8qW82gxSdbbcl8swkzz05rWVPAUaHO5zWvfTwLDbQJXwTZv","news_summary":"/PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization...","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"ZFkGJapoXSM0rmFPZMYsTcCZgouyoE62iAmiT6fLb8JQ5wfoXo1blL","date":"Jul 18, 2025","link":"https://finance.yahoo.com/news/fabry-disease-treatment-analysis-report-105700362.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Fabry disease","round":null,"company":"Amicus Therapeutics","layoffs":null,"summary":"The global Fabry disease treatment market is expected to grow significantly from USD 2.22 billion in 2024 to USD 3.86 billion by 2030. This growth is driven by the increasing prevalence of Fabry disease, advancements in therapies, and heightened awareness. Key players in this market include Sanofi, Amicus Therapeutics, and Protalix BioTherapeutics. Recent developments include UniQure Biopharmas completion of enrollment in a Phase I/IIa trial, FDAs Orphan Drug Designation for EXG110, and Sangamo Therapeutics alignment with the FDA for accelerated approval of isaralgagene civaparvovec. The enzyme replacement therapy remains the standard of care, while chaperone treatment and substrate reduction therapy are gaining traction.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["Fabry disease","enzyme replacement","chaperone treatment","gene therapy","market growth"],"date_of_event":"July 18, 2025","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage","FDA approved/pending approval"],"acquisition_amount":null,"FDA approved/pending approval":"approved","AI technology developing/using":"using","structuredIssuesShow":"#Product Stage  #FDA approved/pending approval","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"8a5CXuqUROEJrlpP3VtV4TzB19iz60i9GE3qTGVzr63yqZKgOPjZm4","news_summary":"Fabry Disease Treatment Analysis Report 2025 | Market to Reach $3.86 Billion by 2030, Rising Fabry Disease Prevalence and Demand for Targeted Therapies Drive Growth","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"SRV3WZQgIayauw7hRyApBwizU6CfaHnEjXZUbIjoFDgNHF0A7vpecw","date":"Jun 30, 2025","link":"https://finance.yahoo.com/news/protalix-biotherapeutics-added-russell-3000-105000090.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"index inclusion","round":null,"company":"Protalix BioTherapeutics, Inc.","layoffs":null,"summary":"Protalix BioTherapeutics, Inc., a biopharmaceutical company, has been added to the Russell 3000® and Russell 2000® Indexes as part of the 2025 Russell indexes annual reconstitution. This inclusion, effective June 27, 2025, enhances the companys visibility and is expected to positively impact its strategic growth. Protalix focuses on developing recombinant therapeutic proteins using its proprietary ProCellEx® plant cell-based protein expression system. The company has achieved FDA approval for its products, including taliglucerase alfa for Gaucher disease and Elfabrio®, which was approved by both the FDA and the European Medicines Agency in May 2023. The inclusion in these indexes is significant as they are widely used by investment managers and institutional investors for benchmarking and active investment strategies.","partners":["Pfizer Inc."],"customers":[],"eventType":null,"investors":[],"confidence":10,"key_topics":["Russell Indexes","market capitalization","FDA approval","ProCellEx system","Gaucher disease"],"date_of_event":"June 27, 2025","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"FDA approved/pending approval":"approved","AI technology developing/using":"not mentioned","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"XlW0o7Rj1HfL6E1RkwZAOJ6hRzdDPLi63lzAUWaD60P7Pgqf5UkvEw","news_summary":"Protalix BioTherapeutics Added to Russell 3000® and 2000 Indexes®","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"vcnLAeGTXytQYLqXf2i2Myq60dYp9FGpQwLY91SFnXpRA4ylwyn9vU","date":"May 14, 2025","link":"https://www.prnewswire.com/il/news-releases/protalix-biotherapeutics-to-present-at-the-3rd-annual-hc-wainwright-bioconnect-investor-conference-at-nasdaq-nyc-302455102.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"conference","round":null,"company":"Protalix BioTherapeutics, Inc.","layoffs":null,"summary":"Protalix BioTherapeutics, Inc., a biopharmaceutical company, will participate in the 3rd Annual H.C. Wainwright BioConnect Investor Conference on May 20, 2025, at Nasdaq headquarters in New York City. The company focuses on developing and commercializing recombinant therapeutic proteins using its proprietary ProCellEx plant cell-based expression system. Protalix has achieved FDA approval for its plant cell-based protein production system and has partnered with Chiesi Farmaceutici S.p.A. for the global development and commercialization of Elfabrio. The company has a pipeline of products targeting established pharmaceutical markets, including treatments for Gaucher disease and uncontrolled gout.","partners":["Chiesi Farmaceutici S.p.A.","Pfizer Inc."],"customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["conference","presentation","partnership","FDA approval","biopharmaceutical"],"date_of_event":"May 20, 2025","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners","FDA approved/pending approval"],"acquisition_amount":null,"FDA approved/pending approval":"FDA approved","AI technology developing/using":"not mentioned","structuredIssuesShow":"#Partners  #FDA approved/pending approval","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"IngrKXCITfpHqTR4AzyC4iUoAAj8DbxII0TNyLKj1jvRAOAYjPLdON","news_summary":"/PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization...","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"CEKWvEMeL5pypmhVcsuwULWaKhnDr0rjynWbBK41RnHtWksdlI0wal","date":"May 14, 2025","link":"https://finance.yahoo.com/news/protalix-biotherapeutics-present-3rd-annual-105000039.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"conference","round":null,"company":"Protalix BioTherapeutics, Inc.","layoffs":null,"summary":"Protalix BioTherapeutics, Inc., a biopharmaceutical company, will participate in the 3rd Annual H.C. Wainwright BioConnect Investor Conference on May 20, 2025, at Nasdaq headquarters in New York City. The company, known for its proprietary ProCellEx plant cell-based protein expression system, has achieved FDA approval for its products, including Elfabrio®, which is also approved by the European Medicines Agency. Protalix has partnered with Chiesi Farmaceutici S.p.A. for the global development and commercialization of Elfabrio. The company has licensed Pfizer Inc. for the worldwide rights to taliglucerase alfa for Gaucher disease, excluding Brazil. Protalixs pipeline includes products targeting established pharmaceutical markets.","partners":["Pfizer Inc.","Chiesi Farmaceutici S.p.A."],"customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["conference","FDA approval","partnership","biopharmaceutical","recombinant proteins"],"date_of_event":"May 20, 2025","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners","FDA approved/pending approval"],"acquisition_amount":null,"FDA approved/pending approval":"FDA approved","AI technology developing/using":"using","structuredIssuesShow":"#Partners  #FDA approved/pending approval","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"9tQgK2c3KRxFqzQ1qNPNvppsgwedHA7VxellJMNcYeqPH8twL5b4ga","news_summary":"Protalix BioTherapeutics to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"kMvhx9YNASjQxx6NjPTSK8HI9LIZ1IMTeh22DEEzT9WVcp7bjVbm5d","date":"May 13, 2025","link":"https://finance.yahoo.com/news/plx-first-quarter-results-092500953.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"financial results","round":null,"company":"Protalix Biotherapeutics, Inc.","layoffs":null,"summary":"Protalix Biotherapeutics, Inc. reported its first-quarter 2025 financial and operational results, highlighting significant growth in Elelyso sales to Pfizer and Brazil. However, the company did not recognize any Elfabrio revenues, which could impact its 2025 revenue estimates. The company is advancing towards a Phase II trial for PRX-115, expected to start in the second half of 2025. Financially, Protalix saw a 170% increase in revenues to $10.1 million, driven by Elelyso sales, but also experienced a net loss of $3.6 million. The lack of Elfabrio revenues and managements lack of revenue visibility for the year have led to a reduction in the companys valuation.","partners":["Chiesi"],"customers":["Pfizer","Brazil"],"eventType":null,"investors":null,"confidence":9,"key_topics":["financial results","Elelyso sales","clinical trials","Elfabrio revenues","valuation reduction"],"date_of_event":"May 9th, 2025","product_stage":"Phase II trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-negative","investment_amount":null,"structured_issues":["Customers","Product Stage"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"developing","structuredIssuesShow":"#Customers  #Product Stage","entityGrowthIconPath":"url(/assets/circle-red.svg);"},"sentiment":"growth-negative","analysisId":"FnnZDMJhhtPbiyDrigKHRNI6ijSc8SSgm1P2yVIfYwR01PDz9Hsiqx","news_summary":"PLX: First Quarter Results","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"NqUBChsRVKgerDeA4QnM9r1SD49DsFImDnf5viC2DKividy2mDDQ9C","date":"May 10, 2025","link":"https://finance.yahoo.com/news/protalix-biotherapeutics-inc-plx-q1-070454427.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"earnings, clinical development","round":null,"company":"Protalix BioTherapeutics Inc","layoffs":null,"summary":"Protalix BioTherapeutics Inc reported a significant revenue increase, reaching $10 million, a 170% rise from the previous year. The company is advancing its clinical development, with plans to initiate a phase two trial for PRX 115 for gout. Protalix is also evaluating other pipeline candidates like PRX 119. The company has a strong partnership with PSE Global Rural Diseases, which is investing in its programs. Despite increased costs and potential competition in the gout market, Protalix maintains a solid financial position with $34.7 million in cash and equivalents. The company faces uncertainty regarding the approval of a dosing frequency change for El Faulo by the EMA.","partners":["PSE Global Rural Diseases"],"customers":["Pfizer","Cruz in Brazil"],"eventType":null,"investors":"PSE Global Rural Diseases","confidence":10,"key_topics":["revenue increase","clinical trials","partnerships","competition","financial position"],"date_of_event":"May 09, 2025","product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage","Customers","Partners"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"not mentioned","structuredIssuesShow":"#Product Stage  #Customers  #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"aJjYrMPOv7UfYfPu300o1UGxWrB9SRweXxdT4OItXgbshU4JAdm8No","news_summary":"Protalix BioTherapeutics Inc (PLX) Q1 2025 Earnings Call Highlights: Revenue Surge and ...","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"VSDuJ0X2XCy7JW3Tkn3keTG27LDzSnBhBVKrMBcFFVtHXFW9X35zsP","date":"May 9, 2025","link":"https://finance.yahoo.com/news/protalix-q1-earnings-snapshot-110248685.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"financial results","round":null,"company":"Protalix BioTherapeutics Inc.","layoffs":null,"summary":"Protalix BioTherapeutics Inc., a drug development company based in Hackensack, New Jersey, reported a financial loss of $3.6 million in its first quarter. The loss translates to 5 cents per share. Despite the loss, the company generated $10.1 million in revenue during the same period. The report was generated using data from Zacks Investment Research and highlights the financial challenges faced by the company in the current quarter.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["loss","revenue","drug developer","financial","quarter"],"date_of_event":null,"product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-negative","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"FDA approved/pending approval":null,"AI technology developing/using":null,"entityGrowthIconPath":"url(/assets/circle-red.svg);"},"sentiment":"growth-negative","analysisId":"uaNYvTGZaTGxsc0YZ7vj0tUzMeMnvtOeqxsuTG7nOg6LrAjPkVvKOS","news_summary":"Protalix: Q1 Earnings Snapshot","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"lTnAVdnhcafxED7pJw1wFEF6Yml0gcGMhDKkbiop2f8JIsY2I5sOiy","date":"May 9, 2025","link":"https://finance.yahoo.com/news/protalix-biotherapeutics-reports-first-quarter-105000133.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"clinical trial","round":null,"company":"Protalix BioTherapeutics, Inc.","layoffs":null,"summary":"Protalix BioTherapeutics, Inc. reported financial results for Q1 2025, highlighting increased revenues and progress in its clinical pipeline. The company is advancing its PRX-115 candidate for gout treatment, having completed a successful phase I trial in 2024 and preparing for a phase II trial in 2025. The promising results suggest potential for effective uric acid-lowering treatment. Additionally, Protalixs partner, Chiesi Global Rare Diseases, presented on pegunigalsidase alfa for Fabry Disease at a recent symposium. The companys focus on clinical advancements and partnerships indicates a positive growth trajectory.","partners":"Chiesi Global Rare Diseases","customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["financial results","clinical trial","gout treatment","pipeline development","partnership"],"date_of_event":"March 31, 2025","product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage","Partners"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"not mentioned","structuredIssuesShow":"#Product Stage  #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"m67QWjFLc6fv5cy01QusIPCZ6cKpoesRnlXPrPgvEUpkxluNjL1U3x","news_summary":"Protalix BioTherapeutics Reports First Quarter 2025 Financial and Business Results","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"gy1gixncShuvyV2RQMQcPktb8rtYi42MUlgSChWUBE2tKoCRkO5QUG","date":"May 5, 2025","link":"https://finance.yahoo.com/news/protalix-biotherapeutics-announce-first-quarter-105000306.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"financial results","round":null,"company":"Protalix BioTherapeutics, Inc.","layoffs":null,"summary":"Protalix BioTherapeutics, Inc., a biopharmaceutical company, announced it will release its financial results for the quarter ended March 31, 2025, and provide a business and clinical update on May 9, 2025. The company will host a conference call to discuss these results and recent corporate and regulatory developments. Protalix focuses on developing and commercializing recombinant therapeutic proteins using its proprietary plant cell-based expression system, ProCellEx. Notably, Protalix is the first company to receive FDA approval for a protein produced through a plant cell-based suspension expression system. The company has licensed worldwide rights to taliglucerase alfa to Pfizer, except in Brazil. Additionally, its second product, Elfabrio®, received FDA and European Medicines Agency approval in May 2023.","partners":"Pfizer Inc.","customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["conference call","financial results","clinical update","FDA approval","ProCellEx system"],"date_of_event":"May 9, 2025","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"FDA approved/pending approval":"FDA approved","AI technology developing/using":"not mentioned","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"vZXrY9plK43UxACzLD5IHGpkxM9FeW32QuqvM7340RaXXJwSbMRAeW","news_summary":"Protalix BioTherapeutics to Announce First Quarter 2025 Financial and Business Results on May 9, 2025","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"ImLXC5d9wxPinKD2aAJMtpNvtDGw7IylvuoJFbTf0tAVVRzZAEu3CB","date":"Apr 24, 2025","link":"https://finance.yahoo.com/news/top-penny-stocks-watch-april-180511198.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"penny stocks","round":null,"company":"Origin Materials, Inc.","layoffs":null,"summary":"Origin Materials, Inc., a carbon-negative materials company with a market cap of $102.24 million, is facing challenges typical of penny stocks. Despite generating $31.28 million in revenue from its Specialty Chemicals segment, the company remains unprofitable and has seen increased losses over five years. The stock is at risk of delisting from Nasdaq due to a prolonged sub-$1 bid price, with a deadline of October 2025 to regain compliance. However, the company has improved its financial health by reducing its debt-to-equity ratio and has short-term assets exceeding liabilities. Future growth is anticipated with new production lines and expected revenue increases in 2026.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["stock market","penny stocks","financial health","revenue","delisting risk"],"date_of_event":"October 2025","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":"$102.24 million","impact_on_company":"growth-negative","investment_amount":null,"structured_issues":["Public Trading"],"acquisition_amount":null,"FDA approved/pending approval":null,"AI technology developing/using":null,"structuredIssuesShow":"#Public Trading","entityGrowthIconPath":"url(/assets/circle-red.svg);"},"sentiment":"growth-negative","analysisId":"gza6DOqkgzPMRiGr1JQdJbhBfKgc2g17KOC7R7knDIbzkw21FL3oeQ","news_summary":"Top Penny Stocks To Watch In April 2025","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"q4llbhqdvTX91vMBnOegVEKorUWRtwpIa5GToAPrkhJxwveNpMwXTo","date":"Mar 26, 2025","link":"https://finance.yahoo.com/news/protalix-biotherapeutics-2-other-promising-110503762.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"financial performance","round":null,"company":"Protalix BioTherapeutics, Inc.","layoffs":null,"summary":"Protalix BioTherapeutics, Inc., a biopharmaceutical company with a market cap of $202.88 million, focuses on developing recombinant therapeutic proteins using its proprietary ProCellEx system. Despite a decline in revenue from $65.49 million to $53.4 million and a drop in net income to $2.93 million, the company remains profitable with high-quality earnings. The company has avoided shareholder dilution and maintains no debt, with short-term assets covering liabilities. Recent bylaw changes aim to strengthen corporate governance, and upcoming conference presentations may offer insights into strategic directions amidst challenges like reduced profit margins.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["stock market","investment","financial health","biopharmaceutical","revenue decline"],"date_of_event":null,"product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-negative","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"developing","entityGrowthIconPath":"url(/assets/circle-red.svg);"},"sentiment":"growth-negative","analysisId":"V3fZHxWjIwZ1iKu1HThflkmP6oxiSYQLmtdrq0xyJpxgEuIbJ3yGxM","news_summary":"Protalix BioTherapeutics And 2 Other Promising Penny Stocks","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"mpVXZfXibi2UM2ZOyOPZsTFVfAbkgVpLvZhR3FvJMCFbMbL4aUyoso","date":"Mar 24, 2025","link":"https://www.prnewswire.com/il/news-releases/protalix-biotherapeutics-to-present-at-the-iaccess-alpha-virtual-best-ideas-spring-conference-2025-302409050.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"investment conference","round":null,"company":"Protalix BioTherapeutics, Inc.","layoffs":null,"summary":"Protalix BioTherapeutics, Inc., a biopharmaceutical company, will participate in the iAccess Alpha Virtual Best Ideas Spring Investment Conference 2025. The company focuses on developing and commercializing recombinant therapeutic proteins using its proprietary ProCellEx plant cell-based expression system. Protalix has achieved FDA approval for its products, including Elfabrio, which is also approved by the European Medicines Agency. The company has partnered with Chiesi Farmaceutici for the global development and commercialization of Elfabrio. Protalixs pipeline includes products targeting established pharmaceutical markets, such as treatments for uncontrolled gout and NETs-related diseases. The conference will feature webcast presentations and one-on-one meetings with investors.","partners":["Pfizer Inc.","Chiesi Farmaceutici S.p.A."],"customers":[],"eventType":null,"investors":[],"confidence":10,"key_topics":["biopharmaceutical","conference","FDA approval","partnership","investment"],"date_of_event":"March 25-26, 2025","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners","FDA approved/pending approval"],"acquisition_amount":null,"FDA approved/pending approval":"FDA approved","AI technology developing/using":"using","structuredIssuesShow":"#Partners  #FDA approved/pending approval","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"klX5TKOY2uwDtjtWWQkUCIvc5pYQvGbF3UgEm9KJIjFFXYfcr6sLN2","news_summary":"/PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization...","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"EIbgJkA7uIvOB15zjUAyZFytcvWn9sWRSaimyTkkoQsl1g7jxZ1wek","date":"Mar 24, 2025","link":"https://finance.yahoo.com/news/protalix-biotherapeutics-present-iaccess-alpha-105000503.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"investment conference","round":null,"company":"Protalix BioTherapeutics, Inc.","layoffs":null,"summary":"Protalix BioTherapeutics, Inc., a biopharmaceutical company, announced its participation in the iAccess Alpha Virtual Best Ideas Spring Investment Conference 2025. The company focuses on developing and commercializing recombinant therapeutic proteins using its proprietary ProCellEx plant cell-based expression system. Protalix has achieved FDA approval for its plant cell-based protein production, with its first product, taliglucerase alfa, licensed to Pfizer for global commercialization, excluding Brazil. Its second product, Elfabrio®, received FDA and European Medicines Agency approval in May 2023. The conference will feature webcast presentations and one-on-one meetings with investors, highlighting Protalixs innovative approach and potential growth opportunities.","partners":"Pfizer Inc.","customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["biopharmaceutical","investment","conference","FDA approval","partnership"],"date_of_event":"March 25-26, 2025","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["FDA approved/pending approval","Partners"],"acquisition_amount":null,"FDA approved/pending approval":"FDA approved","AI technology developing/using":"developing","structuredIssuesShow":"#FDA approved/pending approval  #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"rZEkCYcGfjbPmI0nU1AfGpT8FCU2t4bNsLNbNNXKIpoatnW0KvyjHf","news_summary":"Protalix BioTherapeutics to Present at the iAccess Alpha Virtual Best Ideas Spring Conference 2025","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"QuLPJEt7jP7qoliYkNfw8LJkNKRXdxbBUEiNUBkNcW8IVbOlxJ1x96","date":"Mar 22, 2025","link":"https://finance.yahoo.com/news/protalix-biotherapeutics-plx-high-growth-214234788.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"investment strategy","round":null,"company":"Protalix BioTherapeutics, Inc.","layoffs":null,"summary":"The article discusses the investment potential of Protalix BioTherapeutics, Inc. (NYSEAMERICAN:PLX) as a high-growth, low-debt stock amidst current market volatility. It highlights the advantages of investing in companies with low debt levels, which include financial stability, reduced bankruptcy risk, and greater flexibility for growth opportunities. The article emphasizes the importance of focusing on asset quality and financial resilience in the current economic climate. It also notes that historically, low-debt growth companies have outperformed their high-debt counterparts, making them attractive to investors seeking robust earnings growth and operational flexibility.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["high growth","low debt","financial stability","investment strategy","market volatility"],"date_of_event":null,"product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"FDA approved/pending approval":null,"AI technology developing/using":null,"entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"BCSpi2NfPNIpH3oomNgtkBdI4MqQrVctlwdJZXoC5KtqzoQXeJk25b","news_summary":"Is Protalix BioTherapeutics (PLX) The High Growth Low Debt Stock to Invest in Now?","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"d6N32u6TYRxEDjfUOaTzbMKKIWjVgIAz1j8hqVFxVg3vATTypXaE4D","date":"Mar 21, 2025","link":"https://finance.yahoo.com/news/iaccess-alphas-virtual-best-ideas-130000757.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"investment conference","round":null,"company":"iAccess Alpha","layoffs":null,"summary":"iAccess Alpha is hosting its Virtual Best Ideas Spring Investment Conference on March 25-26, 2025. The event aims to connect micro-cap companies with investors, offering live-streamed presentations and exclusive 1x1 meetings. The conference is part of a series held quarterly, focusing on high-potential investment opportunities. iAccess Alpha has been organizing these events since 2019, facilitating connections between investors and promising companies. The event is expected to enhance networking and investment opportunities for participating companies and investors.","partners":null,"customers":null,"eventType":null,"investors":[],"confidence":10,"key_topics":["investment","conference","micro-cap","networking","presentations"],"date_of_event":"March 25-26, 2025","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"FDA approved/pending approval":null,"AI technology developing/using":null,"entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"z0KxXsVNbXhA3iLrhUOm1GT8qz8SHK0wSH1J5laZC1Rvuyhc9wsRQ8","news_summary":"iAccess Alpha's Virtual Best Ideas Spring Investment Conference March 25-26, 2025","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"hBNlS27FdRzKpSLWT5Qc0o6ml8Wvm5SrUeIC7ATy1boMy73nSfJpRA","date":"Mar 18, 2025","link":"https://finance.yahoo.com/news/protalix-biotherapeutics-inc-plx-q4-070117373.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"financial performance","round":null,"company":"Protalix BioTherapeutics Inc","layoffs":null,"summary":"Protalix BioTherapeutics Inc (PLX) reported record revenues for 2024, driven by increased sales to partners like Chiesi and Pfizer. The company has fully repaid its outstanding debt, strengthening its financial position. Protalix is advancing its R&D efforts, particularly with PRX-115, which completed a successful Phase 1 trial and is preparing for Phase 2. The European Medicines Agency validated a new dosing regimen for Elfabrio, potentially expanding its market in the EU. Despite a decrease in net income and R&D expenses, the company anticipates significant revenue growth from royalties by 2030. The collaboration with Chiesi is progressing well, with expectations of revenues exceeding $100 million by 2030. However, Protalix did not provide specific revenue guidance for 2025, creating some uncertainty about future financial performance.","partners":["Chiesi","Pfizer"],"customers":["Chiesi","Pfizer"],"eventType":null,"investors":null,"confidence":9,"key_topics":["revenue","R&D","partnerships","profitability","market expansion"],"date_of_event":"March 17, 2025","product_stage":"Phase 2","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers","Partners","Product Stage"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"developing","structuredIssuesShow":"#Customers  #Partners  #Product Stage","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"EQCGoVKol5jh8Asud9bw44RkwwNlxlfbALZOaCIjsZCKYuLGAOYZWY","news_summary":"Protalix BioTherapeutics Inc (PLX) Q4 2024 Earnings Call Highlights: Record Revenue Growth ...","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"FqmxTU9848DtiUeG1nZBCrzji5Emjv1JW0upOVTaXh8LsiW06R9q5w","date":"Mar 18, 2025","link":"https://finance.yahoo.com/news/plx-2024-results-093300180.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"financial-results","round":null,"company":"Protalix Biotherapeutics, Inc.","layoffs":null,"summary":"Protalix Biotherapeutics, Inc. reported its 2024 financial and operational results, highlighting a 31% increase in product revenues driven by Elfabrio sales to Chiesi. The company completed the Phase I trial of PRX-115 for gout and plans a Phase II study in the second half of 2025. Despite a decline in overall revenues due to a previous milestone recognition, Protalix achieved a net income of $3.2 million. The company repaid its convertible debt and raised additional funds through equity issuance and warrant exercises. Partnerships with Chiesi, Pfizer, and Fiocruz contributed to revenue growth. The cash balance at year-end was $34.8 million, reflecting positive cash flow and strategic financial management.","partners":["Chiesi","Pfizer","Fiocruz"],"customers":["Chiesi","Pfizer","Fiocruz"],"eventType":"PO","investors":null,"confidence":9,"key_topics":["financial results","clinical trials","revenue growth","debt repayment","equity issuance"],"date_of_event":"March 17th, 2024","product_stage":"Phase I completed","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage","Customers","Partners","PIPE/PO"],"acquisition_amount":null,"FDA approved/pending approval":"approved","AI technology developing/using":"not mentioned","structuredIssuesShow":"#Product Stage  #Customers  #Partners  #PIPE/PO","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"9oIplIppd3c45WX6aFmPUwhEcmTCYk7yYTyaZnWKpoahZMbzAUX0rI","news_summary":"PLX: 2024 Results","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"uVztCs0zb8sXWPfNlhDAaP2cn7mt4Db3ZUo0YWSanVfhwvxRCoRNXi","date":"Mar 17, 2025","link":"https://www.prnewswire.com/il/news-releases/protalix-biotherapeutics-reports-fiscal-year-2024-financial-and-business-results-302402919.html","source":"www.prnewswire.com","visible":1,"analysis":{"date":"Mon Mar 17 2025","status":-1,"message":"","entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"02oBH4ULE9GukN53s49YJVpQzHB1DwBwf34W52jFuf5ewuMSTsY0Su","news_summary":"/PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization...","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"VtqTIpZ4yUaSbRTDjj9WIfj5boiXRTsYrgEjpnHqgzenX681OLqxUx","date":"Mar 17, 2025","link":"https://finance.yahoo.com/news/protalix-biotherapeutics-reports-fiscal-2024-105000104.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"clinical update","round":null,"company":"Protalix BioTherapeutics, Inc.","layoffs":null,"summary":"Protalix BioTherapeutics, Inc. reported a record year in revenues for 2024, with increases in all revenue streams from partners Chiesi, Pfizer, and Brazil. The company successfully completed a phase I clinical trial for its gout treatment candidate, PRX-115, and plans to initiate a phase II trial in 2025. Protalix also announced that the European Medicines Agency validated a variation submission for pegunigalsidase alfa, a treatment for Fabry disease, in collaboration with Chiesi Global Rare Diseases. The company has strengthened its financial position by fully repaying its debt and eliminating outstanding warrants, positioning itself for continued strategic execution.","partners":["Chiesi Global Rare Diseases"],"customers":["Chiesi","Pfizer","Brazil"],"eventType":null,"investors":null,"confidence":10,"key_topics":["financial results","clinical trials","gout treatment","Fabry disease","debt repayment"],"date_of_event":"December 31, 2024","product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers","Product Stage","Partners"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"using","structuredIssuesShow":"#Customers  #Product Stage  #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"4cqkfXO0FNCyYm1i3OmffNY9pqyebNfLQi6TP7UkWx9SgBU7yc9W5d","news_summary":"Protalix BioTherapeutics Reports Fiscal Year 2024 Financial and Business Results","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"MMBsTOerJcd5p4vTVb3AfSMII0Okw0RpsPxPT853nPVVU5xnjgElW8","date":"Mar 10, 2025","link":"https://finance.yahoo.com/news/protalix-biotherapeutics-announce-fiscal-2024-105000870.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"financial update","round":null,"company":"Protalix BioTherapeutics, Inc.","layoffs":null,"summary":"Protalix BioTherapeutics, Inc., a biopharmaceutical company, announced it will release its financial results for the fiscal year ending December 31, 2024, and provide a business and clinical update on March 17, 2025. The company focuses on developing and commercializing recombinant therapeutic proteins using its proprietary ProCellEx® plant cell-based expression system. Protalix is notable for being the first to gain FDA approval for a protein produced through this method. The company has licensed worldwide rights to taliglucerase alfa to Pfizer, excluding Brazil. Additionally, Protalixs second product, Elfabrio®, received FDA and European Medicines Agency approval in May 2023.","partners":"Pfizer Inc.","customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["conference call","financial results","clinical update","FDA approval","partnership"],"date_of_event":"March 17, 2025","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["FDA approved/pending approval","Partners"],"acquisition_amount":null,"FDA approved/pending approval":"FDA approved","AI technology developing/using":"developing","structuredIssuesShow":"#FDA approved/pending approval  #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"lfZEwHbq4XI4VcSGaThlDxDGeuVJ8bFjCo5oDgsstxzfNtSxPCW30O","news_summary":"Protalix BioTherapeutics to Announce Fiscal Year 2024 Financial and Business Results on March 17, 2025","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"M9XC5NTlGhgyQnrTU3ZDtrmJciYfQ5VknnwlT7gFTOQoUUkk4qGBbl","date":"Mar 10, 2025","link":"https://www.prnewswire.com/il/news-releases/protalix-biotherapeutics-to-announce-fiscal-year-2024-financial-and-business-results-on-march-17-2025-302396854.html","source":"www.prnewswire.com","visible":1,"analysis":{"date":"Wed Mar 12 2025","status":-1,"message":"","entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"LOjPyxRrBcLNoyr71VHdbXk4DeAgOQATuykT5AEh0uZQ5HOrxdGGKx","news_summary":"/PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization...","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"wFpPOM630LM3GoohSIFJ1DmI5qQUuOo7qNwFxQarKHkbTm1gOP54lG","date":"Feb 6, 2025","link":"https://finance.yahoo.com/news/3-us-penny-stocks-market-130738838.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"penny stocks","round":null,"company":"GoPro, Inc.","layoffs":null,"summary":"GoPro, Inc. is navigating the challenges of being a penny stock with a market cap of approximately $0.15 billion. Despite facing financial hurdles due to unprofitability and increased losses over recent years, the company has maintained a stable debt position with more cash than total debt. GoPro has reduced its debt-to-equity ratio significantly over the past five years. The company is focusing on recent product upgrades and strategic partnerships, such as those in the MotoGP racing series, to enhance its brand visibility and appeal in the action camera market. These efforts aim to support future revenue streams despite current financial challenges.","partners":["MotoGP"],"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["penny stocks","market cap","financial health","strategic partnerships","product upgrades"],"date_of_event":null,"product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-negative","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"FDA approved/pending approval":null,"AI technology developing/using":null,"structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-red.svg);"},"sentiment":"growth-negative","analysisId":"1tjGkxGpW4I0TIiLHzxwG4nyiGwUlzkNeTt2pFui3i0viSrFuB3k1o","news_summary":"3 US Penny Stocks With Market Caps Under $400M To Watch","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"fs6yZVOjIe8HnZwX9Wni3LBKwpTGhaA3AIRzGaZWwjqKzc1Ygmn3Hz","date":"Feb 4, 2025","link":"https://www.prnewswire.com/il/news-releases/protalix-biotherapeutics-to-participate-in-the-2025-bio-ceo--investor-conference-302367286.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"conference, presentation","round":null,"company":"Protalix BioTherapeutics, Inc.","layoffs":null,"summary":"Protalix BioTherapeutics, Inc., a biopharmaceutical company, is set to present at the 2025 BIO CEO & Investor Conference in New York City. The company specializes in developing recombinant therapeutic proteins using its proprietary ProCellEx® plant cell-based expression system. Protalix has achieved FDA approval for its plant cell-based protein production and has licensed rights to Pfizer for taliglucerase alfa, excluding Brazil. Additionally, Protalixs Elfabrio® received FDA and European Medicines Agency approval in May 2023. The company has partnered with Chiesi Farmaceutici S.p.A. for Elfabrios global development and commercialization. Protalixs pipeline includes products targeting pharmaceutical markets, such as PRX–115 for gout and PRX–119 for NETs-related diseases.","partners":"Chiesi Farmaceutici S.p.A., Pfizer Inc.","customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["biopharmaceutical","FDA approval","partnerships","conference","recombinant proteins"],"date_of_event":"February 11, 2025","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners","FDA approved/pending approval"],"acquisition_amount":null,"FDA approved/pending approval":"FDA approved","AI technology developing/using":"not mentioned","structuredIssuesShow":"#Partners  #FDA approved/pending approval","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"Q8iNpPLkMTDZhksIuyd4Qhb9QNhqSHIk2XO7FLqXJf0uTwXtiGsXDX","news_summary":"/PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development, production and commercialization of...","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"flFrS5Pp60ZZxz7uLsEZhQF5rh9coWeB51IfVSKAdcLDuRY9nUKV9C","date":"Feb 4, 2025","link":"https://finance.yahoo.com/news/protalix-biotherapeutics-participate-2025-bio-115000376.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"conference","round":null,"company":"Protalix BioTherapeutics, Inc.","layoffs":null,"summary":"Protalix BioTherapeutics, Inc., a biopharmaceutical company, is set to present at the 2025 BIO CEO & Investor Conference in New York City. The company focuses on developing and commercializing recombinant therapeutic proteins using its proprietary ProCellEx® plant cell-based expression system. Protalix has achieved FDA approval for its plant cell-based protein production method, with products like taliglucerase alfa and Elfabrio® already approved. The company has partnered with Pfizer for the global rights to taliglucerase alfa, excluding Brazil, and with Chiesi Farmaceutici for Elfabrio. Protalixs pipeline includes products targeting gout and NETs-related diseases. The conference will provide opportunities for Protalix to engage with investors and potential partners.","partners":["Pfizer Inc.","Chiesi Farmaceutici S.p.A."],"customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["biopharmaceutical","FDA approval","partnerships","conference","recombinant proteins"],"date_of_event":"February 11, 2025","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners","FDA approved/pending approval"],"acquisition_amount":null,"FDA approved/pending approval":"approved","AI technology developing/using":"not mentioned","structuredIssuesShow":"#Partners  #FDA approved/pending approval","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"ikIuPypXbuwsYMI2uWtApnNqgRXWw86PAamlr2VvYi6vmRIZqz8Cjx","news_summary":"Protalix BioTherapeutics to Participate in the 2025 BIO CEO & Investor Conference","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"AAaJ2V5nEtriTYR2Idm9SzwuMvIA87aVrwy8t1MsdC0V9qDYKxLOG6","date":"Feb 3, 2025","link":"https://finance.yahoo.com/news/plx-revisiting-thesis-093800682.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"biotechnology","round":null,"company":"Protalix Biotherapeutics, Inc.","layoffs":null,"summary":"Protalix Biotherapeutics, Inc. is in a strong position as of 2025, with two approved products generating revenue and a promising pipeline. The company uses its ProCellEx platform to produce therapeutic proteins and has eliminated all debt, holding over $27 million in cash. Its product Elelyso, approved for Gaucher disease, is sold globally through agreements with Pfizer and Fiocruz. Elfabrio, approved by the FDA and EMA for Fabry disease, targets a $2 billion market. A new dosing regimen for Elfabrio is under review by the EMA, potentially reducing administration frequency and offering a competitive advantage. The companys financial health and strategic partnerships position it for continued growth.","partners":["Pfizer","Fiocruz","Chiesi"],"customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["FDA approval","product pipeline","partnerships","market expansion","debt elimination"],"date_of_event":"2025","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage","Partners","FDA approved/pending approval"],"acquisition_amount":null,"FDA approved/pending approval":"approved","AI technology developing/using":"not mentioned","structuredIssuesShow":"#Product Stage  #Partners  #FDA approved/pending approval","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"PhOuSDHDzhRmlIO4NYEoFG6xk81M5j9eF2tdMc5hBLbwoK6Z0Tf2Xf","news_summary":"PLX: Revisiting the Thesis","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"AKa4gZfFdujzhKwLQF3EBDOOdpRIqUZ2luQKGrju1E6YfA79sPkPNK","date":"Jan 8, 2025","link":"https://finance.yahoo.com/news/us-penny-stocks-arbe-robotics-000916422.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"collaboration","round":null,"company":"Arbe Robotics Ltd.","layoffs":null,"summary":"Arbe Robotics Ltd., a semiconductor company specializing in 4D imaging radar solutions, is gaining attention due to its recent collaboration with NVIDIA. Despite being pre-revenue with sales of US$0.67 million for the first nine months of 2024, the company has a market cap of US$340.27 million. Arbe Robotics is positioned as a potential innovator in vehicle safety and autonomy sectors, thanks to its advanced radar technology. The company faces challenges such as unprofitability and a high net debt to equity ratio, but it maintains financial stability with short-term assets exceeding liabilities. Shareholder dilution is a concern due to recent equity offerings aimed at increasing cash reserves amidst growing losses.","partners":"NVIDIA","customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["Penny stocks","Financial health","Market cap","Revenue","Collaboration"],"date_of_event":"January 2025","product_stage":"pre-revenue","investment_date":null,"acquired_company":null,"valuation_amount":"US$340.27 million","impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"developing","structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"18AVCXYshicCYBrl4fjYEGC8hBeiiCZJ4GaGlB90m2kQKFKAbLB1SM","news_summary":"US Penny Stocks: Arbe Robotics And 2 More Promising Picks","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"V85ZyeWc4dnheKgepjIxikJL6sjkbAnCtHI19bcyKixoJMUzNnveCQ","date":"Dec 23, 2024","link":"https://www.prnewswire.com/il/news-releases/protalix-biotherapeutics-issues-2025-letter-to-stockholders-302338258.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"milestones","company":"Protalix BioTherapeutics, Inc.","layoffs":null,"summary":"Protalix BioTherapeutics, Inc., a biopharmaceutical company, has achieved significant milestones in 2024, positioning itself for long-term growth. The company has made progress in its pipeline programs, including a phase I clinical trial for PRX 115, a treatment for uncontrolled gout, and plans to advance to phase II in 2025. Protalixs commercial partner, Chiesi Global Rare Diseases, has had its Variation Submission for pegunigalsidase alfa validated by the European Medicine Agency, exemplifying their commitment to reducing treatment burdens for Fabry disease patients. Protalix has also maintained uninterrupted operations despite military conflicts in Israel. The company is debt-free after repaying all outstanding convertible notes, and it continues to grow its sales through partnerships with Chiesi, Pfizer, and Brazil.","partners":["Chiesi Global Rare Diseases","Chiesi Farmaceutici S.p.A."],"customers":["Pfizer Inc.","Brazil"],"investors":null,"confidence":9,"key_topics":["clinical trials","partnerships","financial health","product pipeline","market expansion"],"date_of_event":"December 23, 2024","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"rXBAqmAI9M8zxkI0akKjdr6CYZHSn0IrPExrVauVCqBKedfqyxzKPy","news_summary":"/PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE-American: PLX), a biopharmaceutical company focused on the development, production and commercialization...","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"mSk3u21CRjcNTL3WoStUXhHTaPdByBT9Om3NPtDyYuOw3h8JPppbaY","date":"Dec 23, 2024","link":"https://finance.yahoo.com/news/protalix-biotherapeutics-issues-2025-letter-115000300.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"pipeline progress","company":"Protalix BioTherapeutics, Inc.","layoffs":null,"summary":"Protalix BioTherapeutics, Inc. has made significant progress in 2024, positioning itself for long-term growth. The company, in collaboration with its commercial partner Chiesi Global Rare Diseases, has achieved a milestone with the European Medicine Agency validating a less frequent dosing regimen for pegunigalsidase alfa for Fabry disease. Protalix has also completed a phase I clinical trial for PRX-115, a potential treatment for uncontrolled gout, and plans to advance to phase II trials in 2025. The company is focusing on its R&D strategy, leveraging its ProCellEx platform for renal rare diseases. Protalix has seen growth in sales to Chiesi, Pfizer Inc., and Brazil, contributing to its revenue streams.","partners":["Chiesi Global Rare Diseases"],"customers":["Chiesi Global Rare Diseases","Pfizer Inc.","Brazil"],"investors":null,"confidence":10,"key_topics":["Fabry disease","clinical trials","R&D strategy","ProCellEx platform","revenue growth"],"date_of_event":"December 23, 2024","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners","Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Partners  #Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"Qva0Fg2jBEgc96svQWeGoIuHimdkRtaDwYz6oY55aDi9FuangzVr3H","news_summary":"Protalix BioTherapeutics Issues 2025 Letter to Stockholders","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"gtuFT4637p2e8Fnq0ziJxeIG3WBBYSAEVSe1XiqfDa0FYaErVhfKhG","date":"Dec 10, 2024","link":"https://www.pharmaceutical-technology.com/news/ema-chiesi-protalix-submission/","source":"www.pharmaceutical-technology.com","visible":1,"analysis":{"tags":"therapy approval","company":"Protalix BioTherapeutics","layoffs":null,"summary":"Protalix BioTherapeutics, in partnership with Chiesi Global Rare Diseases, has received validation from the European Medicines Agency (EMA) for a new dosing regimen of pegunigalsidase alfa, a therapy for Fabry disease. The proposed regimen, which suggests a dose of 2 mg/kg every four weeks, is backed by clinical data from the Phase III BRIGHT trial. This new regimen aims to reduce the treatment burden for adults with Fabry disease. The partnership between Protalix and Chiesi focuses on the global development and commercialization of this therapy. The validation marks a significant milestone in providing innovative solutions for patients with unmet medical needs.","partners":["Chiesi Global Rare Diseases"],"customers":null,"investors":null,"confidence":9,"key_topics":["Fabry disease","dosing regimen","clinical trial","EMA validation","partnership"],"date_of_event":"December 10, 2024","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"aKke334Qk2THIOURDjUgbltFULgepFh4HLnUahSXlicNcC0pxgXEkh","news_summary":"EMA validates Chiesi and Protalix’s dose variation for Fabry disease","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"E1XKZsEXINlkHmpcGKQbi5blugVgUtv5bq1UlqhqMQKqnN9nVoNfuo","date":"Dec 10, 2024","link":"https://finance.yahoo.com/news/promising-us-penny-stocks-watch-131030616.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"financial health","company":"Tandy Leather Factory, Inc.","layoffs":null,"summary":"Tandy Leather Factory, Inc., a company in the penny stock market, has shown resilience with a market cap of $33.77 million and revenue of $74.76 million from its Apparel segment. Despite maintaining strong financial health with short-term assets exceeding liabilities and operating debt-free, the company reported a net loss in Q3 2024, contrasting with profits from the previous year. Over the past five years, Tandys earnings growth has been robust at an average of 66.6% annually, although it has recently slowed to 6.7%. A strategic decision to sell its headquarters for $26.5 million and relocate by September 2025 is part of its recent moves. The article highlights the companys financial position and potential in the penny stock market.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["penny stocks","financial health","market cap","revenue","earnings growth"],"date_of_event":"Q3 2024","valuation_amount":null,"impact_on_company":"growth-negative","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"entityGrowthIconPath":"url(/assets/circle-red.svg);"},"sentiment":"growth-negative","analysisId":"d46Xq8xbfKuxJekJ1otZJnhLMKho69bKxM0JGQQ4n5cn60RkBSQSyJ","news_summary":"Promising US Penny Stocks To Watch In December 2024","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"BKUkjtgz6vfJbjJl4WIy6Bh73OyRKgyUQb7DVoO39Dvdxjt5NBJ0w3","date":"Dec 9, 2024","link":"https://finance.yahoo.com/news/chiesi-global-rare-diseases-protalix-113000031.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"dosing regimen","company":"Chiesi Global Rare Diseases","layoffs":null,"summary":"Chiesi Global Rare Diseases, in partnership with Protalix BioTherapeutics, announced that the European Medicines Agency (EMA) has validated a Variation Submission for a new dosing regimen of pegunigalsidase alfa for Fabry disease. The new regimen involves a 2 mg/kg dose administered every four weeks, compared to the current 1 mg/kg every two weeks. This change is based on a revised Population-PK model, new exposure-response analyses, and clinical data from the Phase 3 study PB-102-F50 and its extension study. The validation marks a significant milestone in reducing treatment burdens for patients with Fabry disease. Both companies are committed to providing innovative therapies and look forward to working with the EMA to bring this alternative dosing option to market.","partners":["Protalix BioTherapeutics"],"customers":null,"investors":null,"confidence":9,"key_topics":["Fabry disease","dosing regimen","clinical study","EMA validation","therapeutic options"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"343s3R1L6ISmYm6y5Dkpf3d5OfbMEwdYAhQtdg6l2DGnp7VMhPQqog","news_summary":"Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce Validation of Variation Submission by European Medicines Agency for pegunigalsidase alfa","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"qiGw2RJYQgzY1xHdgoEaOwuoyvELFCNU68utSiwjFIvN8hl8YUJrT2","date":"Nov 15, 2024","link":"https://finance.yahoo.com/news/protalix-biotherapeutics-inc-plx-q3-071050102.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"financial performance","company":"Protalix BioTherapeutics Inc (PLX)","layoffs":null,"summary":"Protalix BioTherapeutics Inc (PLX) reported a significant increase in revenue from selling goods, driven by increased sales to Chiesi and Pfizer, marking a 75% rise compared to the previous year. The company has become debt-free after repaying all outstanding principal and interest under its senior secured convertible promissory notes. Protalix completed all eight cohorts of the Phase I clinical trial for PRX-115, showing promising results, and is preparing for a Phase II trial in 2025. Despite a decrease in license and R&D service revenues and an increase in the cost of goods sold, the company reported a net income of $3.2 million. Protalix maintains a strong balance sheet with $27.4 million in cash and cash equivalents. The company faces competitive challenges in the treatment of refractory gout and is not pursuing manufacturing contracts with other companies.","partners":null,"customers":["Chiesi","Pfizer"],"investors":null,"confidence":9,"key_topics":["Revenue","Clinical Trials","Debt Repayment","Cash Reserves","Profit Margins"],"date_of_event":"November 14, 2024","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"UZVdMMhR0H8O2nZtaq74yx0nH4SXJ9RwtRUycAV88EZH7Er4mEdjr8","news_summary":"Protalix BioTherapeutics Inc (PLX) Q3 2024 Earnings Call Highlights: Revenue Surge and ...","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"tl2kKyTAynOMqM1PwbkuxzNSASdBgOThJ0uFZN9B1STUEAionnUBSZ","date":"Nov 15, 2024","link":"https://finance.yahoo.com/news/plx-self-sustaining-rise-lead-141200581.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"financial results","company":"Protalix Biotherapeutics, Inc.","layoffs":null,"summary":"Protalix Biotherapeutics, Inc. reported its third quarter 2024 financial and operational results, highlighting a 74% increase in revenues to $18.0 million, primarily driven by strong sales from Chiesi related to Elfabrio. The company achieved a net income of $3.2 million, a significant turnaround from a net loss in the previous year. Protalix has repaid its convertible debt and completed the eighth cohort of its Phase I PRX-115 trial in gout, with Phase II planned for the second half of 2025. The companys financial performance was bolstered by increased Elelyso sales to Pfizer and Brazil, although research and development expenses decreased due to the completion of the Fabry clinical program. Overall, the results indicate a positive growth trajectory for Protalix.","partners":null,"customers":["Chiesi","Pfizer","Brazil"],"investors":null,"confidence":10,"key_topics":["financial results","clinical updates","revenue growth","debt repayment","product development"],"date_of_event":"November 14, 2024","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"9ylA88RGogE9zN7PQ09wnBzNYscvAVgGRUiFFw3HDjVzvA9qDOKgXB","news_summary":"PLX: Self-Sustaining Rise to Lead in Renal Rare Disease","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"hlJxYQt7pvILRsQ4ba4Tl9CbRcHfA5zSZMrUM73E2QlbBtX59bfGQj","date":"Nov 14, 2024","link":"https://finance.yahoo.com/news/protalix-biotherapeutics-reports-third-quarter-115000006.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"clinical trial","company":"Protalix BioTherapeutics, Inc.","layoffs":null,"summary":"Protalix BioTherapeutics, Inc. reported financial results for Q3 2024 and provided updates on its clinical pipeline. The company completed its phase I study of PRX-115, a recombinant uricase candidate for treating uncontrolled gout. Preliminary results are promising, showing potential as a uric-acid lowering treatment. The study involved 64 subjects across eight cohorts, with PRX-115 demonstrating dose-dependent efficacy and being well-tolerated. Protalix plans to initiate a phase II trial in the second half of 2025. The positive results and future plans indicate a growth-positive impact for the company.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["clinical trial","gout treatment","PRX-115","study results","phase I"],"date_of_event":"September 30, 2024","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"Mtew78YLf1mZ9n9DbHy8DAE0thlzXwoXHi9SHiz1Bbd9DFXBfY7o6o","news_summary":"Protalix BioTherapeutics Reports Third Quarter 2024 Financial and Business Results","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"zXPSL2ek8qedkVidEXMbAlsSr2l5DGIGlfgSIyhqxMrp1hm8h8178z","date":"Nov 14, 2024","link":"https://www.prnewswire.com/il/news-releases/protalix-biotherapeutics-reports-third-quarter-2024-financial-and-business-results-302305544.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"clinical trial","company":"Protalix BioTherapeutics, Inc.","layoffs":null,"summary":"Protalix BioTherapeutics, Inc., a biopharmaceutical company, reported positive preliminary results from its phase I clinical trial of PRX-115, a treatment for uncontrolled gout. The study demonstrated promising uric acid-lowering effects and was well-tolerated by participants. The company plans to initiate a phase II trial in 2025. Financially, Protalix saw a 75% increase in revenue from selling goods in Q3 2024, primarily due to increased sales to partners Chiesi Farmaceutici S.p.A. and Pfizer Inc. The company also repaid its convertible notes using available cash. These developments indicate a positive growth trajectory for Protalix, supported by strong partnerships and promising clinical advancements.","partners":["Chiesi Farmaceutici S.p.A.","Pfizer Inc."],"customers":["Chiesi Farmaceutici S.p.A.","Pfizer Inc."],"investors":null,"confidence":10,"key_topics":["clinical trial","financial results","gout treatment","partnerships","revenue growth"],"date_of_event":"November 14, 2024","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers","Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Customers  #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"nEto4qufYaAlkfgCmw0K1AdhIKYanaIzqCIBbhLWmsURjIpGLrrk4l","news_summary":"/PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE-American: PLX), a biopharmaceutical company focused on the development, production and commercialization...","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"hkK3lkdUxZ5TA7A9btz2YbaQ2oyhLpiFZQSvJjyhkmu8wUOhcIDxqo","date":"Nov 14, 2024","link":"https://finance.yahoo.com/news/protalix-q3-earnings-snapshot-120305280.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"earnings","company":"Protalix BioTherapeutics Inc.","layoffs":null,"summary":"Protalix BioTherapeutics Inc., a biotechnology company based in Hackensack, New Jersey, reported a profit of $3.2 million for its third quarter. This translates to earnings of 3 cents per share. The company also posted revenue of $18 million during this period. The report was generated using data from Zacks Investment Research and highlights a positive financial performance for the company in the third quarter.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["earnings","revenue","profit","biotechnology","quarterly report"],"date_of_event":"Not specified","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"XlXHuT12EPJla5HVqzfhpHsTNmH6WQloGuwrJbxlkVYQn4cC4jVpie","news_summary":"Protalix: Q3 Earnings Snapshot","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"rBMVX1dXv2M1D3O0AFbvxZlp64rMesMo4mxxX8demR1kHjgSLHpeuk","date":"Nov 7, 2024","link":"https://finance.yahoo.com/news/protalix-biotherapeutics-announce-third-quarter-115000568.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"financial update","company":"Protalix BioTherapeutics, Inc.","layoffs":null,"summary":"Protalix BioTherapeutics, Inc., a biopharmaceutical company, announced it will release its financial results for the quarter ending September 30, 2024, and provide a business and clinical update on November 14, 2024. The company will host a conference call and webcast to discuss these results and recent corporate and regulatory developments. Protalix focuses on developing recombinant therapeutic proteins using its proprietary ProCellEx plant cell-based expression system. The company has achieved FDA approval for its plant cell-based protein production method and has licensed worldwide rights to taliglucerase alfa to Pfizer, excluding Brazil. Protalixs second product, Elfabrio, received FDA and European Medicines Agency approval in May 2023.","partners":["Pfizer Inc."],"customers":null,"investors":null,"confidence":10,"key_topics":["conference call","financial results","clinical update","regulatory developments","ProCellEx"],"date_of_event":"November 14, 2024","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"6bG1kjcVbLajtsDkfBP6hykC268bh6TJVUDXzlMdh4rWtxXtlaAo8H","news_summary":"Protalix BioTherapeutics to Announce Third Quarter 2024 Financial and Business Results on November 14, 2024","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"KfLFQ0AGwmioBBpzCWawNhhqUjwPd17WLwuMF2wYZmj2a2sDag9aLD","date":"Oct 31, 2024","link":"https://finance.yahoo.com/news/accolade-2-other-penny-stocks-200436798.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"investment opportunities","company":"Accolade, Inc.","layoffs":null,"summary":"The article discusses the interest in penny stocks as major U.S. indexes face a downturn due to disappointing earnings from big tech companies. Investors are looking for alternative opportunities, with penny stocks offering potential value and growth. Accolade, Inc. is highlighted as a company with a market cap of approximately $265.77 million, showing revenue growth despite being unprofitable. The company has a strong financial position with short-term assets exceeding liabilities and a cash runway for over three years. Accolades shares have recently been diluted, but it remains an intriguing investment option due to its financial resilience and growth potential.","partners":[],"customers":[],"investors":[],"confidence":9,"key_topics":["penny stocks","market downturn","investment","financial health","growth potential"],"date_of_event":"October 2024","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"Fdttiwu3jLHjEaoy48ur6e1ckufm5A9jwAdJUASR98zkva4iZhQOTS","news_summary":"Accolade And 2 Other Penny Stocks To Watch On US Exchanges","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"FI3K0MzSbUrf3tf0IO51zyOPO9tsJypRd5sYwYqzYatWnimPMFvPt7","date":"Oct 25, 2024","link":"https://finance.yahoo.com/news/protalix-biotherapeutics-present-phase-prx-105000588.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"clinical trial","company":"Protalix BioTherapeutics, Inc.","layoffs":null,"summary":"Protalix BioTherapeutics, Inc., a biopharmaceutical company, announced that data from its phase I clinical trial of PRX-115, a recombinant PEGylated uricase product candidate for treating uncontrolled gout, will be presented at the American College of Rheumatology (ACR) Convergence 2024. The event will take place from November 14-19, 2024, in Washington, D.C. Protalix is known for its proprietary ProCellEx plant cell-based protein expression system, which has been used to develop FDA-approved products. The company has a licensing agreement with Pfizer Inc. for the worldwide development and commercialization of taliglucerase alfa, except in Brazil. Protalixs second product, Elfabrio®, received FDA and European Medicines Agency approval in May 2023.","partners":["Pfizer Inc."],"customers":[],"investors":[],"confidence":10,"key_topics":["clinical trial","gout treatment","protein expression","FDA approval","partnerships"],"date_of_event":"November 18, 2024","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"B8n2Z58xPmC3ei2uWhxz8FUgMc97vUxRDOXnxDT9WKOONcQ2Kqutfg","news_summary":"Protalix BioTherapeutics to Present Phase I PRX-115 Data in Late-Breaking Poster at ACR Convergence 2024","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"laahtrI13fk7dEzGHp2iOAdHHktd4H4zSS5HWnvOBGyIAlQlEa51G8","date":"Oct 25, 2024","link":"https://www.prnewswire.com/il/news-releases/protalix-biotherapeutics-to-present-phase-i-prx-115-data-in-late-breaking-poster-at-acr-convergence-2024-302287205.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"clinical trial","company":"Protalix BioTherapeutics, Inc.","layoffs":null,"summary":"Protalix BioTherapeutics, Inc., a biopharmaceutical company, announced the presentation of data from its phase I clinical trial for PRX-115, a recombinant PEGylated uricase product candidate for treating uncontrolled gout. The presentation will occur at the ACR Convergence 2024 in Washington, D.C. Protalix uses its proprietary ProCellEx plant cell-based protein expression system to develop therapeutic proteins. The company has partnered with Chiesi Farmaceutici S.p.A. for the global development and commercialization of Elfabrio, another product in its pipeline. Protalixs innovative approach and partnerships indicate a positive growth trajectory, as it continues to advance its product candidates targeting established pharmaceutical markets.","partners":"Chiesi Farmaceutici S.p.A.","customers":null,"investors":null,"confidence":10,"key_topics":["biopharmaceutical","clinical trial","gout treatment","partnership","protein expression"],"date_of_event":"November 18, 2024","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"WoYhcGs7xMcVJ25mO2pQM7BLHVlIuOUy3OyIvDEDqaPiDGZaQf9FPh","news_summary":"/PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development, production and commercialization of...","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"64X2Lqjuin0Ntlp5vXnoiqGvL8hR70ngtFruCkD7VhSIVBBhelv7pK","date":"Oct 24, 2024","link":"https://finance.yahoo.com/news/otc-markets-hosts-virtual-investor-121900537.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"financial stability","company":"Protalix Biotherapeutics","layoffs":null,"summary":"Protalix Biotherapeutics, a biotech company trading under the symbol PLX, has successfully paid off its debt, showcasing a strong financial position with $45 million in cash. The company generates revenue from two commercialized products, Elfabrio and ELELYSO, targeting Fabry and Gaucher diseases. Elfabrio, approved in May 2023, has been launched in the US and Europe, with Chiesi as the commercial partner working to expand its market availability. Protalixs development pipeline includes treatments for gout and rare renal diseases. The companys financial stability and product commercialization efforts indicate a positive growth trajectory.","partners":"Chiesi","customers":null,"investors":null,"confidence":9,"key_topics":["biotech","products","financials","partnerships","diseases"],"date_of_event":"May 2023","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers","Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Customers  #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"vYRHVyuaPlrIGHqClzAno7eWYz71oRLRGF3dJw9RPV4Nq8zX374szo","news_summary":"OTC Markets Hosts Virtual Investor Presentation with Dror Bashan, President & CEO of Protalix Biotherapeutics, and John Vandermosten, Senior Analyst at Zacks SCR","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"DaSnXJjaKyTAz8BmvY1hYqOsbfpH1ab8BnWAuE5naCtai13rZ342Wr","date":"Sep 20, 2024","link":"https://finance.yahoo.com/news/life-sciences-virtual-investor-forum-123500670.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Investor Engagement","company":"Virtual Investor Conferences","layoffs":null,"summary":"Virtual Investor Conferences (VIC), a leading proprietary investor conference series, announced that presentations from the Life Sciences Virtual Investor Forum held on September 19, 2024, are now available for online viewing. The event was co-sponsored by Zacks Small-Cap Research. The presentations will be accessible 24/7 for 90 days, and select companies are accepting one-on-one management meeting requests through September 24th. VIC provides an interactive forum for publicly traded companies to present directly to investors, enhancing investor engagement through dynamic video content and targeted meetings.","partners":["Zacks Small-Cap Research"],"customers":[],"investors":[],"confidence":10,"key_topics":["Presentations","Investors","Life Sciences","Virtual Forum","Engagement"],"date_of_event":"2024-09-19","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"Yy10RMpbtnf9eCepMzP659Mb3faHsEVVtcXx2Mec2SuBF6czO3AsTH","news_summary":"Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"ZqARwYLUeqhYV67dQ4axfF8aRHiZVXvXYrNMiuet9LAp4HcksntUas","date":"Sep 16, 2024","link":"https://finance.yahoo.com/news/life-sciences-virtual-investor-forum-160700187.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Investor Forum","company":"Virtual Investor Conferences","layoffs":null,"summary":"Virtual Investor Conferences (VIC) announced the agenda for the Life Sciences Virtual Investor Forum, scheduled for September 19th, 2024. Co-sponsored by Zacks Small-Cap Research, the event invites individual and institutional investors, advisors, and analysts to attend. The forum aims to provide an efficient platform for companies to engage with their investor base through live presentations and one-on-one meetings. Jason Paltrowitz, Executive Vice President of Corporate Services at OTC Markets Group, emphasized the events role in enhancing investor relations. VIC offers a real-time engagement solution for publicly traded companies, replicating the components of an on-site investor conference.","partners":["Zacks Small-Cap Research"],"customers":[],"investors":[],"confidence":10,"key_topics":["Investor Forum","Life Sciences","Engagement","Presentations","Collaboration"],"date_of_event":"September 19, 2024","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"SQbEyRBxVB95ZaaJLPk39jQGE5drucNOeG6WSUcdXQEG0E5gitufZj","news_summary":"Life Sciences Virtual Investor Forum Agenda Announced for September 19th","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"1iLymA4cGWqH0pemYr6O6KNuDyxx5U8WVeUxZ1PoMgj8Rt9UMRV1Z6","date":"Sep 16, 2024","link":"https://finance.yahoo.com/news/protalix-biotherapeutics-present-life-sciences-123500130.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Investor Engagement","company":"Protalix BioTherapeutics, Inc.","layoffs":null,"summary":"Protalix BioTherapeutics, Inc., a biopharmaceutical company, announced that its President and CEO, Dror Bashan, will present at the Life Sciences Investor Forum on September 19, 2024. The event, hosted by VirtualInvestorConferences.com, will be an interactive online session where investors can ask questions in real-time. Protalix focuses on developing and commercializing recombinant therapeutic proteins using its proprietary ProCellEx plant cell-based expression system. The company has partnerships with Pfizer for the commercialization of taliglucerase alfa and with Chiesi Farmaceutici for Elfabrio. The event aims to enhance investor engagement and provide updates on Protalixs product pipeline and business strategy.","partners":["Pfizer","Chiesi Farmaceutici"],"customers":[],"investors":[],"confidence":10,"key_topics":["Investor","Conference","Presentation","Partnerships","Products"],"date_of_event":"September 19, 2024","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"d8qfgVCWnBY0mpOXDPmEATeF9PoxZchSgVPVFdxuHKGSK4hSQjiHz6","news_summary":"Protalix BioTherapeutics to Present at the Life Sciences Investor Forum September 19, 2024","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"i0eRbAS7godmb2H6MwFQtar5vbK9qaiNEDhoKUI2yeAOnADmNpScdA","date":"Sep 4, 2024","link":"https://www.prnewswire.com/il/news-releases/protalix-biotherapeutics-to-present-at-the-hc-wainwright-26th-annual-global-investment-conference-302237774.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"conference","company":"Protalix BioTherapeutics, Inc.","layoffs":null,"summary":"Protalix BioTherapeutics, Inc., a biopharmaceutical company specializing in recombinant therapeutic proteins, announced that its President and CEO, Dror Bashan, will present at the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, 2024, in New York City. The company focuses on developing proteins using its proprietary ProCellEx® plant cell-based expression system. Protalix has licensed the global rights for taliglucerase alfa to Pfizer, except in Brazil, and has partnered with Chiesi Farmaceutici S.p.A. for the global development and commercialization of Elfabrio®. The company’s pipeline includes products targeting established pharmaceutical markets.","partners":["Pfizer","Chiesi Farmaceutici S.p.A."],"customers":[],"investors":[],"confidence":10,"key_topics":["conference","presentation","partnership","product","development"],"date_of_event":"2024-09-11","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"HJhYf03ImfuESNyYTvvz6QjvIHHMmiDen4xcYDgimYlPudSwyhrRAt","news_summary":"/PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization...","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"vnZwgnLkcV3CxaKgzCoktRNS2bEZtODr9mhfvOzm5tTpWTPW70Qfqm","date":"Sep 4, 2024","link":"https://www.prnewswire.com/news-releases/protalix-biotherapeutics-to-present-at-the-hc-wainwright-26th-annual-global-investment-conference-302237774.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"conference","company":"Protalix BioTherapeutics, Inc.","layoffs":null,"summary":"Protalix BioTherapeutics, Inc., a biopharmaceutical company, announced that its President and CEO, Dror Bashan, will present at the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, 2024, in New York City. The company focuses on developing and commercializing recombinant therapeutic proteins using its proprietary ProCellEx plant cell-based expression system. Protalix has partnerships with Pfizer for the development and commercialization of taliglucerase alfa and with Chiesi Farmaceutici for Elfabrio. The company has a pipeline of products targeting established pharmaceutical markets.","partners":["Pfizer","Chiesi Farmaceutici"],"customers":[],"investors":[],"confidence":10,"key_topics":["conference","presentation","partnerships","products","FDA approval"],"date_of_event":"2024-09-11","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"dGI1rYTyLzssnlPrZw21zlW5CJnlS51sbvEaF44Q15FBrZkXKw3jsN","news_summary":"Protalix BioTherapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"ea9TjlCVXVgbiZIagHIyrPvD7fdZN89rlymUe2hvvxBnYV03DtpSyp","date":"Sep 3, 2024","link":"https://www.prnewswire.com/news-releases/protalix-biotherapeutics-announces-repayment-of-outstanding-senior-secured-convertible-promissory-notes-302236505.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"debt-free","company":"Protalix BioTherapeutics, Inc.","layoffs":null,"summary":"Protalix BioTherapeutics, Inc., a biopharmaceutical company, announced that it has fully repaid its 7.50% Senior Secured Convertible Promissory Notes, making the company debt-free. This repayment, financed entirely with available cash, marks a significant milestone for Protalix, strengthening its balance sheet and eliminating potential equity overhang. Protalix focuses on developing recombinant therapeutic proteins using its proprietary ProCellEx plant cell-based expression system. The company has partnerships with Pfizer Inc. for the commercialization of taliglucerase alfa and with Chiesi Farmaceutici S.p.A. for Elfabrio. Protalixs development pipeline includes products targeting various pharmaceutical markets.","partners":["Pfizer Inc.","Chiesi Farmaceutici S.p.A."],"customers":[],"investors":[],"confidence":10,"key_topics":["debt-free","repayment","partnerships","products","pipeline"],"date_of_event":"Not explicitly mentioned","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Investment","Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Investment  #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"EU5gf3krrSrUqlEIV2bK4peX0ybUM72SvlsSfuaJSp2CWxkhxQLoTV","news_summary":"Protalix BioTherapeutics Announces Repayment of Outstanding Senior Secured Convertible Promissory Notes","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"DDD6kqA5mAjXwq4EonrUorQSVjCsVAOewO4L5a7SIDYuJN1crsAR37","date":"Sep 3, 2024","link":"https://www.prnewswire.com/il/news-releases/protalix-biotherapeutics-announces-repayment-of-outstanding-senior-secured-convertible-promissory-notes-302236505.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"debt-free","company":"Protalix BioTherapeutics, Inc.","layoffs":null,"summary":"Protalix BioTherapeutics, Inc., a biopharmaceutical company, announced that it has fully repaid its 7.50% Senior Secured Convertible Promissory Notes, making the company debt-free. This repayment, financed entirely with available cash, marks a significant milestone for Protalix, strengthening its balance sheet to support ongoing operations. The company focuses on developing and commercializing recombinant therapeutic proteins using its proprietary ProCellEx® plant cell-based expression system. Protalix has partnerships with Pfizer Inc. for the global development and commercialization of taliglucerase alfa and with Chiesi Farmaceutici S.p.A. for Elfabrio. The company’s development pipeline includes products targeting established pharmaceutical markets.","partners":["Pfizer Inc.","Chiesi Farmaceutici S.p.A."],"customers":[],"investors":[],"confidence":10,"key_topics":["debt-free","repayment","partnerships","products","development"],"date_of_event":"2023-10-10","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Investment","Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Investment  #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"8wD8cQKn7KijKZ0lGyvKuCMzb6RYQrBBIed97ZTepL6RG9ByAJX5un","news_summary":"/PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization...","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"Zl21xS8lOmco8wsydVAK8DO6o8SltFGCTRoBHnI6QWwIwhlxWdD2fb","date":"Aug 30, 2024","link":"https://finance.yahoo.com/news/protalix-biotherapeutics-inc-plx-best-123823144.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"penny stocks","company":"Protalix BioTherapeutics, Inc.","layoffs":null,"summary":"Protalix BioTherapeutics, Inc. (NYSE:PLX), a biopharmaceutical company based in Israel, is highlighted as one of the best-rated penny stocks with an impressive upside potential of 1,422%. Despite reporting a Q2 2024 EPS of -$0.03 and revenue of $13.30 million, the company exceeded revenue expectations by $804,000. Protalix is advancing its clinical programs, particularly PRX-115 for treating uncontrolled gout, and is preparing for a Phase 2 trial in mid-2025. The company collaborates with Chiesi Global Rare Diseases on the commercialization of Elfabrio and is expanding its R&D efforts. Financially, despite a net loss of $2.2 million, Protalix maintains a strong cash position. The company remains optimistic about its future, focusing on innovation and long-term value creation.","partners":["Chiesi Global Rare Diseases"],"customers":["Chiesi","Brazil","Pfizer"],"investors":[],"confidence":10,"key_topics":["penny stocks","analyst ratings","economic outlook","clinical trials","revenue"],"date_of_event":"Q2 2024","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers","Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Customers  #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"HWi10BnkSYwkwPOR83ihJcVZ83lw3md5WNA89Iscb5EV2vXg9H4LCi","news_summary":"Is Protalix BioTherapeutics, Inc. (PLX) The Best Rated Penny Stock To Buy According to Analysts?","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"0gZMco7rQESmGEifFZJTNeVlwh764Erf0b1HWVc30pvbg6g9M35r2K","date":"Aug 22, 2024","link":"https://finance.yahoo.com/news/plx-focus-renal-rare-disease-094400565.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Financial Results, Research and Development","company":"Protalix Biotherapeutics, Inc.","layoffs":"N/A","summary":"Protalix Biotherapeutics, Inc. announced its Q2 2024 financial and operational results, reporting revenues of $13.5 million, a net loss of $2.3 million, and a cash balance of $45.0 million. The companys partner, Chiesi, has continued commercialization activities for Elfabrio (PRX-102), obtaining additional approvals and launching new studies. Protalix also provided an update on its PRX-115 Phase I trial in gout and launched an eighth cohort for a Phase II study. The company does not anticipate the need to raise capital in the next 12 months due to Elfabrios growth trajectory.","partners":"Chiesi","customers":"Pfizer, Brazil","investors":"N/A","confidence":9,"key_topics":["Financial Results","Research and Development","Partnerships","Product Sales","Clinical Trials"],"date_of_event":"August 14, 2024","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":["Customers","Partners","Management Changes"],"acquisition_amount":"N/A","structuredIssuesShow":"#Customers  #Partners  #Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"kbWmPKftaj6RInf38SdMXEKYQndfn3Dm6WZUawn4aIBFPLJQPDjC9p","news_summary":"PLX: A Focus on Renal Rare Disease","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"TD9rhMzTuRQ4AOXJEycCNNAmt52ELqTAPTFLGtejjYfeR70fiDYWcs","date":"Aug 14, 2024","link":"https://finance.yahoo.com/news/protalix-q2-earnings-snapshot-105736216.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Financial Report","company":"Protalix BioTherapeutics Inc.","layoffs":"Not mentioned","summary":"Protalix BioTherapeutics Inc. reported a loss of $2.2 million in its second quarter. The company, based in Hackensack, New Jersey, posted revenue of $13.5 million in the same period.","partners":"Not mentioned","customers":"Not mentioned","investors":"Zacks Investment Research","confidence":9,"key_topics":["Q2 Loss","Revenue"],"date_of_event":"Not specified","valuation_amount":"Not mentioned","impact_on_company":"growth-negative","investment_amount":"Not mentioned","structured_issues":["Investment"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-red.svg);"},"sentiment":"growth-negative","analysisId":"W1CByUTGKeLjakYH41AeJGh4vdC99v8w6PyrfBDflVTQQ9EzhGoERB","news_summary":"Protalix: Q2 Earnings Snapshot","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"y6fRw3a6spCgzIIqvmWILOInP5sWV9rG0SdOPABhYatVtZK8ldoQyG","date":"Aug 14, 2024","link":"https://www.prnewswire.com/news-releases/protalix-biotherapeutics-reports-second-quarter-2024-financial-and-business-results-302222090.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"Financial Results, Clinical Trials","company":"Protalix BioTherapeutics, Inc.","layoffs":"N/A","summary":"Protalix BioTherapeutics, Inc. has reported its financial results for Q2 2024, highlighting progress in its early-stage pipeline. The companys revenues from selling goods decreased by 12% compared to the same period in 2023, primarily due to a decrease in sales to Chiesi. However, this was partially offset by increased sales to Brazil and Pfizer. The company also reported positive topline results from the first-in-human Phase I clinical trial of PRX-115, a potential treatment for uncontrolled gout. The companys strong balance sheet allows for the repayment of convertible notes due in September 2024 while maintaining ongoing operations.","partners":"Chiesi Farmaceutici S.p.A., Pfizer Inc.","customers":"Chiesi, Brazil, Pfizer","investors":"N/A","confidence":9,"key_topics":["Financial Results","Clinical Trials","Partnerships","Sales","Investment"],"date_of_event":"June 30, 2024","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":["Investment","Customers","Partners"],"acquisition_amount":"N/A","structuredIssuesShow":"#Investment  #Customers  #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"lLvTDbc0d2eT7bP6a3Lj8C09lykQIkpOc5J5UK4l2saSjVGmOl3ga8","news_summary":"Protalix BioTherapeutics Reports Second Quarter 2024 Financial and Business Results","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"L3WpqPUHO7u0Hh7dmFrbBhvQ2wjLjIt5kbBpqDPN0jr7mXjvsJr9s6","date":"Aug 7, 2024","link":"https://www.prnewswire.com/news-releases/protalix-biotherapeutics-to-announce-second-quarter-2024-financial-and-business-results-on-august-14-2024-302216497.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"Financial Results, Business Update","company":"Protalix BioTherapeutics, Inc.","layoffs":"Not mentioned","summary":"Protalix BioTherapeutics, Inc., a biopharmaceutical company, has announced that it will release its financial results for the quarter ended June 30, 2024, and provide a business and clinical update on August 14, 2024. The companys management will host a conference call with investors to discuss the financial results and provide an update on recent corporate and regulatory developments. Protalix is focused on the development and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system.","partners":"Pfizer Inc., Chiesi Farmaceutici S.p.A.","customers":"Not mentioned","investors":"Not mentioned","confidence":8,"key_topics":"Financial Results, Business Update, Conference Call, Clinical Update, Regulatory Developments","date_of_event":"August 14, 2024","valuation_amount":"Not mentioned","impact_on_company":"Neutral","investment_amount":"Not mentioned","structured_issues":"Management Changes","acquisition_amount":"Not mentioned","structuredIssuesShow":"#Management Changes","entityGrowthIconPath":"none;"},"sentiment":"Neutral","analysisId":"EpXiYWA4ODrb2SR1GEBlPsIziSWyLZUF8WLWona1BvFguGiE3diPOF","news_summary":"Protalix BioTherapeutics to Announce Second Quarter 2024 Financial and Business Results on August 14, 2024","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"H00JgOvvtUFdTM6HWgIbNEV3aYze4C57CQSZKpGMiGtVoX06Ls5bL4","date":"Jun 13, 2024","link":"https://www.prnewswire.com/news-releases/protalix-biotherapeutics-to-host-in-person-investor-day-to-discuss-current-treatment-landscapes-and-clinical-results-for-fabry-disease-and-uncontrolled-gout-302171884.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"Biopharmaceutical, Investor Day","company":"Protalix BioTherapeutics, Inc.","layoffs":"Not mentioned","summary":"Protalix BioTherapeutics, Inc., a biopharmaceutical company, has announced that it will host an in-person investor day on June 26, 2024. The event will feature presentations by key opinion leaders Aleš Linhart and Naomi Schlesinger, who will discuss the treatment landscape for Fabry disease and uncontrolled gout respectively. The event will also include a corporate overview and strategy presentation by Dror Bashan, Protalixs President and CEO. Protalix focuses on the development and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx plant cell-based protein expression system.","partners":["Chiesi Farmaceutici S.p.A.","Pfizer Inc."],"customers":"Not mentioned","investors":"Not mentioned","confidence":9,"key_topics":["Investor Day","Fabry Disease","Uncontrolled Gout","ProCellEx","Therapeutic Proteins"],"date_of_event":"June 26, 2024","valuation_amount":"Not mentioned","impact_on_company":"Growth-Positive","investment_amount":"Not mentioned","structured_issues":["Partners"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"Growth-Positive","analysisId":"rq0iyqmomzdpiZ90X4kktvYaBiPA4tDasuSq5sGpNISKFQH6JqzKxy","news_summary":"Protalix BioTherapeutics to Host In-Person Investor Day to Discuss Current Treatment Landscapes and Clinical Results for Fabry Disease and Uncontrolled Gout","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"SkN57UIoOYUgSBATgMjfJqpFTc7mHZKoQw13UoazwraQSp9QtBlerZ","date":"May 29, 2024","link":"https://www.prnewswire.com/news-releases/protalix-biotherapeutics-to-present-at-the-2024-bio-international-convention-302158047.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"Corporate Presentation, Biotechnology","company":"Protalix BioTherapeutics, Inc.","layoffs":"Not mentioned","summary":"Protalix BioTherapeutics, Inc., a biopharmaceutical company, announced that its President and CEO, Dror Bashan, will present at the 2024 BIO International Convention. The presentation will provide an update on corporate matters. The company is known for its development and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx plant cell-based protein expression system. Protalix has partnered with Chiesi Farmaceutici S.p.A. for the global development and commercialization of its second product, Elfabrio. The companys development pipeline consists of proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets.","partners":["Chiesi Farmaceutici S.p.A.","Pfizer Inc."],"customers":"Not mentioned","investors":"Not mentioned","confidence":9,"key_topics":["Corporate Presentation","BIO International Convention","Recombinant Therapeutic Proteins","Partnership","Product Development"],"date_of_event":"Monday, June 3, 2024","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":["Management Changes","Partners"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Management Changes  #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"9H9VJIgxonvdZflybGogJ4adPhJoHlBweDNT2yGrUqLTeOXGsNxwbf","news_summary":"Protalix BioTherapeutics to Present at the 2024 BIO International Convention","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"NXcrWz3VmKxzpYdaeymTjqvNGcygHnTCG5ncFSTNigndUh0KFlbVF5","date":"May 15, 2024","link":"https://finance.yahoo.com/news/plx-first-quarter-152700120.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Financial Performance, Product Sales","company":"Protalix Biotherapeutics, Inc.","layoffs":"Not mentioned","summary":"Protalix Biotherapeutics, Inc. announced its Q1 2024 financial and operational results, reporting revenues of $3.7 million and a net loss of $4.6 million. The companys partner, Chiesi, has continued commercialization activities for Elfabrio (PRX-102), obtaining additional approvals and launching new studies. The companys cash and equivalents balance on March 31, 2024, totaled $48.5 million, an increase from $44.6 million at the end of 2023. Protalix also announced the receipt of $3.7 million from partners for Elelyso sales. The company is planning for a Phase II study and has completed seven cohorts with 42 subjects treated with PRX-115 and 14 with placebo.","partners":"Chiesi","customers":"Not mentioned","investors":"Not mentioned","confidence":9,"key_topics":["Financial Results","Product Sales","Partnership","Clinical Trials","Future Plans"],"date_of_event":"May 10, 2024","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":["Customers","Partners","Expand"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Customers  #Partners  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"9KvGtiJRsHzOoPkeWOE5iK32F0EZPb3vn3UOQDTJqXJqhHc2UxRfZj","news_summary":"PLX: First Quarter Update","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"KZEhR4AVuBGDYNBZIofVyBEclbFkX1485KZNG2x4PwckT619micnMB","date":"May 13, 2024","link":"https://finance.yahoo.com/news/protalix-biotherapeutics-inc-plx-q1-070549405.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Financial Report, Clinical Trials","company":"Protalix BioTherapeutics Inc (PLX)","layoffs":"N/A","summary":"Protalix BioTherapeutics Inc (PLX) reported a decrease in revenue from selling goods by 27% and from license and R&D services by 98% in Q1 2024 compared to Q1 2023. Despite this, the company maintains a strong cash position and is making progress in its development pipeline with PRX-115. The companys second approved drug, ELFABRIO, continues to gain regulatory approvals globally. Sales to Chiesi are expected to increase as future approvals and launches in additional countries are anticipated. However, there are ongoing financial challenges and potential safety concerns that need to be addressed.","partners":"N/A","customers":["Pfizer","Brazil","Chiesi"],"investors":"N/A","confidence":9,"key_topics":["Revenue Decrease","Clinical Trials","Financial Stability","Market Competition","Sales to Chiesi"],"date_of_event":"May 10, 2024","valuation_amount":"N/A","impact_on_company":"growth-negative","investment_amount":"N/A","structured_issues":["Customers","Investment"],"acquisition_amount":"N/A","structuredIssuesShow":"#Customers  #Investment","entityGrowthIconPath":"url(/assets/circle-red.svg);"},"sentiment":"growth-negative","analysisId":"kG67oC4qlOEETARV9WsySjw1oCcDnsDQvEiUrX0M0cHuELQaOJVdRg","news_summary":"Protalix BioTherapeutics Inc (PLX) Q1 2024 Earnings Call Transcript Highlights: Navigating ...","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"X2Pf4UPoPzgT3kpsgwP8xR4SjcnD7r8PAKPS3OkVAT1JHs9zJH4uWj","date":"May 11, 2024","link":"https://finance.yahoo.com/news/protalix-biotherapeutics-inc-amex-plx-142700095.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Earnings Call, Clinical Trials, Drug Approval","company":"Protalix BioTherapeutics, Inc.","layoffs":"N/A","summary":"Protalix BioTherapeutics, Inc. held its Q1 2024 earnings call, discussing financial results and business updates. The company announced the expansion of its Phase I study of PRX-115 due to encouraging initial results. Preparations for a Phase II clinical trial of PRX-115 have also begun. The companys second approved drug, Elfabrio, continues to gain regulatory approvals for the treatment of adult patients with Fabry disease. The companys strong cash position allows for the repayment of convertible notes due in September 2024. The company recorded revenues from selling goods of $3.7 million for Q1 2024, a decrease of $1.4 million compared to Q1 2023.","partners":"Pfizer, Chiesi Global Rare Diseases","customers":"Pfizer, Brazil, Chiesi Global Rare Diseases","investors":"N/A","confidence":9,"key_topics":["Earnings Call","Clinical Trials","Drug Approval","Financial Results","Partnerships"],"date_of_event":"May 10, 2024","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":["Customers","Partners","Management Changes"],"acquisition_amount":"N/A","structuredIssuesShow":"#Customers  #Partners  #Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"lEMsWaQE1qPBwakQyG48UxwQG2BQxP7cSuk6GmTHdsWqQZbJK9RJZK","news_summary":"Protalix BioTherapeutics, Inc. (AMEX:PLX) Q1 2024 Earnings Call Transcript","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"WTVEzuIstvuQiytHKHcVJfWA02M96cuMSADSvgcXZloStOiRGn9nHD","date":"May 10, 2024","link":"https://www.prnewswire.com/news-releases/protalix-biotherapeutics-reports-first-quarter-2024-financial-and-business-results-302142244.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"Financial Results, Clinical Trials","company":"Protalix BioTherapeutics, Inc.","layoffs":"Not mentioned","summary":"Protalix BioTherapeutics, Inc. reported its financial results for Q1 2024 and provided a business and clinical update. The company announced encouraging initial top-line results from the first seven cohorts of the first-in-human phase I clinical trial of its recombinant uricase candidate, PRX-115, enabling the expansion into an eighth cohort and planning for a phase II trial. The companys revenues from selling goods decreased by 27% compared to the same period in 2023, primarily due to a decrease in sales to Pfizer and Brazil. The companys net loss for Q1 2024 was approximately $4.6 million.","partners":"Pfizer Inc., Chiesi Farmaceutici S.p.A.","customers":"Pfizer, Brazil","investors":"Not mentioned","confidence":9,"key_topics":["Financial Results","Clinical Trials","PRX-115","Revenues","Net Loss"],"date_of_event":"May 10, 2024","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":["Investment"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"q4yFhcEMMUYHa6pD2c9ylcWu2Tju6r5LMfGOqR6ROiZ2QnldfQA0Cs","news_summary":"Protalix BioTherapeutics Reports First Quarter 2024 Financial and Business Results","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"6QwggYfbMtOiXtrxqcJ6bCratmtIKky4f0Nto6Ol8aXwvqGeIVdhy7","date":"May 3, 2024","link":"https://www.prnewswire.com/news-releases/protalix-biotherapeutics-to-announce-first-quarter-2024-financial-and-business-results-on-may-10-2024-302134924.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"Financial Results, Business Update","company":"Protalix BioTherapeutics, Inc.","layoffs":"Not mentioned","summary":"Protalix BioTherapeutics, Inc., a biopharmaceutical company, has announced that it will release its financial results for the quarter ended March 31, 2024, and provide a business and clinical update on May 10, 2024. The company will host a conference call with investors to discuss the financial results and provide an update on recent corporate and regulatory developments. Protalix has partnered with Chiesi Farmaceutici S.p.A. for the global development and commercialization of Elfabrio, one of its products.","partners":"Chiesi Farmaceutici S.p.A.","customers":"Not mentioned","investors":"Not mentioned","confidence":9,"key_topics":["Financial Results","Conference Call","Clinical Update","Partnership","Product Development"],"date_of_event":"May 10, 2024","valuation_amount":"Not mentioned","impact_on_company":"Neutral","investment_amount":"Not mentioned","structured_issues":["Management Changes"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Management Changes","entityGrowthIconPath":"none;"},"sentiment":"Neutral","analysisId":"UGDh1J2HpXurgDVtPnvDpYLh1o7N0nVC4RQTRptY8JYCxX08VGOkEk","news_summary":"Protalix BioTherapeutics to Announce First Quarter 2024 Financial and Business Results on May 10, 2024","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"JkQdVFPTKfjYEGb7UgeKqoSSX1KRYjLVuzh9EcWFU7mkvYmbGWpjeV","date":"Mar 15, 2024","link":"https://finance.yahoo.com/news/plx-elfabrio-geographic-expansion-094500615.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Financial Performance, Product Sales","company":"Protalix Biotherapeutics, Inc.","layoffs":"Not mentioned","summary":"Protalix Biotherapeutics, Inc. announced its full year 2023 financial and operational results, reporting a net income of $8.3 million, a significant improvement from a loss of $14.9 million in the previous year. Revenues for 2023 were $65.5 million, up 37% from $47.6 million in the prior year. The companys partner, Chiesi, has continued its commercialization activities, obtained additional approvals, and launched new studies for a pediatric indication and for approval in Japan. Protalix also announced that it had dosed its first patient in the Phase I clinical trial for PRX-115 in the treatment of severe gout.","partners":"Chiesi","customers":"Not mentioned","investors":"Chiesi","confidence":9,"key_topics":["Financial Results","Product Sales","Partnerships","Research and Development","Clinical Trials"],"date_of_event":"March 14, 2024","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":["Customers","Partners","Expand"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Customers  #Partners  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"30f1SzltxB7j8oWhb4vN8ZEg1Uu083uD83lKUzo5lXX7kuXnnLT5hD","news_summary":"PLX: Elfabrio Geographic Expansion","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"ER4kPV6dlPyD2MEo3vyXixpEt8sOYe15ZxJbDqMnueVhv0nKXFgfiP","date":"Mar 15, 2024","link":"https://finance.yahoo.com/news/protalix-biotherapeutics-inc-amex-plx-171754602.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Earnings Call, Drug Approval","company":"Protalix BioTherapeutics, Inc.","layoffs":"Not mentioned","summary":"Protalix BioTherapeutics, Inc. reported its Q4 2023 earnings, missing expectations with a reported EPS of $-0.07, compared to the expected $-0.03. Despite this, the company celebrated the approval of its second drug, Elfabrio, for the treatment of adult patients with Fabry disease. The drug has been approved by both the FDA and the EMA, and has also received regulatory approval in the UK, Sweden, and Israel. The companys commercial partner, Chiesi global rare diseases, is focused on the commercial launches of Elfabrio. Protalix also announced the initiation of a Phase 1 clinical trial for PRX-115, a potential treatment for severe gout.","partners":"Chiesi global rare diseases","customers":"Not mentioned","investors":"Not mentioned","confidence":9,"key_topics":["Earnings Report","Drug Approval","Partnership","Management Change","Financial Results"],"date_of_event":"March 14, 2024","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":["Customers","Partners","Management Changes"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Customers  #Partners  #Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"i8wiaXKkScC8akrrAwrYmYOS0jJUZLUQhxKz0GWWLKdcEqXeNqbUOm","news_summary":"Protalix BioTherapeutics, Inc. (AMEX:PLX) Q4 2023 Earnings Call Transcript","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"acgeDYgxtKNu4GB6e6TkFDdMLULa78MaGHqOT3D68nWrGzDjRlz4Yy","date":"Mar 14, 2024","link":"https://finance.yahoo.com/news/protalix-biotherapeutics-inc-reports-revenue-121147380.html","source":"finance.yahoo.com","visible":1,"analysis":null,"sentiment":null,"analysisId":"BNIYX5h2A5E9yPSXRJJT0xdjQjMkX3kF5xd3KwT7MQLrQtorb2U2Oo","news_summary":"Protalix BioTherapeutics Inc Reports Revenue Growth and Net Income Gain in FY 2023","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"none"},{"id":"eXJB2cdWFvPOo5a8JYXRrBpIhW5nO0oVQquNYJrLyO483TWzFB89Ai","date":"Mar 14, 2024","link":"https://www.prnewswire.com/news-releases/protalix-biotherapeutics-reports-fiscal-year-2023-financial-and-business-results-302089198.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"Financial Results, Drug Approval","company":"Protalix BioTherapeutics, Inc.","layoffs":"N/A","summary":"Protalix BioTherapeutics, Inc. reported its financial results for the fiscal year ended December 31, 2023, and provided a business update. The company received regulatory approvals for Elfabrio, a treatment for adult patients with Fabry disease, and advanced its pipeline. Its commercial partner, Chiesi Global Rare Diseases, is positioning Elfabrio for global success, with launches underway in the US, the EU, the UK, and other markets. The company also reported revenues from selling goods of $40.4 million for the year, an increase of 60% compared to the previous year. The companys net income for the year was approximately $8.3 million.","partners":"Chiesi Global Rare Diseases","customers":"Chiesi Global Rare Diseases","investors":"N/A","confidence":10,"key_topics":["Financial Results","Drug Approval","Partnership","Clinical Trials","Management Changes"],"date_of_event":"March 14, 2024","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":["Customers","Partners"],"acquisition_amount":"N/A","structuredIssuesShow":"#Customers  #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"dONR9wBeIk90fB0Zb59pls5NdZIWMgzFI0IXNKm7K361s24gzTFIkP","news_summary":"Protalix BioTherapeutics Reports Fiscal Year 2023 Financial and Business Results","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"CTzCdWpp33Efitqp67W101YMaN5ZwisK7erunhOa22BJHU6AWLYEYd","date":"Mar 7, 2024","link":"https://www.prnewswire.com/news-releases/protalix-biotherapeutics-to-announce-fiscal-year-2023-financial-and-business-results-on-march-14-2024-302082682.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"Financial Results, Business Update","company":"Protalix BioTherapeutics, Inc.","layoffs":"Not mentioned","summary":"Protalix BioTherapeutics, Inc., a biopharmaceutical company, has announced that it will release its financial results for the fiscal year ended December 31, 2023, and provide a business update on Thursday, March 14, 2024. The company is focused on the development, production, and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system. Protalix has partnered with Chiesi Farmaceutici S.p.A. for the global development and commercialization of its second product, Elfabrio®.","partners":"Chiesi Farmaceutici S.p.A.","customers":"Not mentioned","investors":"Not mentioned","confidence":9,"key_topics":"Financial Results, Conference Call, Business Update, Partnerships, Product Pipeline","date_of_event":"March 14, 2024","valuation_amount":"Not mentioned","impact_on_company":"Neutral","investment_amount":"Not mentioned","structured_issues":"Partners","acquisition_amount":"Not mentioned","structuredIssuesShow":"#Partners","entityGrowthIconPath":"none;"},"sentiment":"Neutral","analysisId":"YAOnuQFYeHb0D1oHPNTuQDUo64ZxT4smcABAX2iX3LN7hCKi1qmAA5","news_summary":"Protalix BioTherapeutics to Announce Fiscal Year 2023 Financial and Business Results on March 14, 2024","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"7NYxmqrEMjG8O9w4oVqyWLk5IRcMeeI5adenzrUlerTHM4SSfI6JYU","date":"Feb 23, 2024","link":"https://www.prnewswire.com/news-releases/protalix-biotherapeutics-to-participate-in-the-2024-bio-ceo--investor-conference-302069408.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"Conference Presentation, Partnerships","company":"Protalix BioTherapeutics, Inc.","layoffs":"Not mentioned","summary":"Protalix BioTherapeutics, Inc., a biopharmaceutical company, announced its participation in the 2024 BIO CEO & Investor Conference on February 26, 2024. The company will present a corporate overview and will be available for one-on-one partnering meetings with registered investors and other conference attendees. Protalix focuses on the development and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx plant cell-based protein expression system. It has partnered with Chiesi Farmaceutici S.p.A. for the global development and commercialization of its second product, Elfabrio.","partners":["Chiesi Farmaceutici S.p.A.","Pfizer Inc."],"customers":"Not mentioned","investors":"Not mentioned","confidence":9,"key_topics":["BIO CEO & Investor Conference","Corporate Presentation","ProCellEx","Partnership with Chiesi Farmaceutici","Product Pipeline"],"date_of_event":"Monday, February 26, 2024","valuation_amount":"Not mentioned","impact_on_company":"Growth-Positive","investment_amount":"Not mentioned","structured_issues":["Partners"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"Growth-Positive","analysisId":"HNdPY2JW9YBoYydoXaGLjcJBt36zwbbgTkC0YVC67iXN41XLRVmQxN","news_summary":"Protalix BioTherapeutics to Participate in the 2024 BIO CEO & Investor Conference","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"J2Dw9i30c2pjmVRAU0QOblnPMxjyyH8jPZiu3DnZyRaNeQOcayn9NU","date":"Dec 26, 2023","link":"https://www.prnewswire.com/news-releases/protalix-biotherapeutics-issues-2024-letter-to-stockholders-302022312.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"Partnership, Product Approval, Commercialization","company":"Protalix BioTherapeutics, Inc.","layoffs":"Not mentioned","summary":"Protalix BioTherapeutics, a biopharmaceutical company, has announced that its second development candidate, Elfabrio, has been approved for the treatment of adult patients with Fabry disease by the U.S. Food and Drug Administration and the European Medicines Agency. The company is confident that the commercialization of Elfabrio will improve its capital structure. Protalix has also acknowledged the role of its commercial partner, Chiesi Global Rare Diseases, in its success. The company is also making progress on its pipeline programs, including the phase I clinical trial of PRX-115 for the potential treatment of severe gout.","partners":"Chiesi Global Rare Diseases","customers":"Adult patients with Fabry disease","investors":"Not mentioned","confidence":9,"key_topics":["Elfabrio Approval","Commercialization","Partnership with Chiesi","Pipeline Progress","Future Prospects"],"date_of_event":"December 26, 2023","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":["Partners","Customers"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Partners  #Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"jdTMrK7bsdCOxfcUTkRcSBQNpMa6D6WgYkccmYVovMpCRF5pyGYTJ3","news_summary":"Protalix BioTherapeutics Issues 2024 Letter to Stockholders","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"aVhoHZBBoZgMYHmQCDo1nIWp7EQXf2wd60snoy7KNbrij9a0XOXUjO","date":"Nov 30, 2023","link":"https://finance.yahoo.com/news/levicept-appoints-eliot-forster-ceo-090000419.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Management Changes, Investment","company":"Levicept Ltd","layoffs":"Not mentioned","summary":"Levicept Ltd, a biotech company developing a treatment for chronic pain, has announced the appointment of Eliot Forster as CEO. Founder Simon Westbrook will become CSO. Forster brings over 30 years of experience in the biotech and pharmaceutical sectors. The company is currently advancing LEVI-04, a treatment for osteoarthritis and chronic pain, through a phase II clinical trial involving over 500 patients. Forster was previously CEO of F-star, a biotech company that was acquired by inovX Pharma in March 2023. The market for drugs that modulate neurotrophins is expected to be worth over $10 billion by 2033.","partners":"Not mentioned","customers":"Not mentioned","investors":["Medicxi","Advent Life Sciences","Gilde Healthcare","Pfizer Ventures"],"confidence":9,"key_topics":["CEO Appointment","Clinical Development","Chronic Pain Treatment","Phase II Trial","Market Opportunity"],"date_of_event":"Nov. 30, 2023","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":["Management Changes"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"6AmnpGMlyWYUtucSV62mgM4X8o3tIGqdz6yMQkLxOD3LgqNK7ngb3R","news_summary":"Levicept Appoints Eliot Forster as CEO","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"N7keau0b5I9tQYNlVgEcnS6Sifyd1qCfBrUCisUwfEJrRF1Zb4ipid","date":"Nov 7, 2023","link":"https://finance.yahoo.com/news/plx-more-regulatory-approvals-092500244.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Financial Performance, Management Changes","company":"Protalix Biotherapeutics, Inc.","layoffs":"Not mentioned","summary":"Protalix Biotherapeutics, Inc. announced its third quarter 2023 financial and operational results, reporting revenues of $10.3 million, a net loss of $1.9 million, and a cash balance of $41.0 million. The companys partners, Chiesi Rare Disease, Pfizer, and Fiocruz, contributed to the revenues. Protalix also announced the appointment of Dr. Eliot Richard Forster as the new Chairman of its Board of Directors. The company has been participating in investor and scientific conferences, and its partner, Chiesi Rare Disease, has been ramping up Elfabrio sales and obtaining approval in additional jurisdictions.","partners":"Chiesi Rare Disease, Pfizer, Fiocruz","customers":"Not mentioned","investors":"Chiesi Rare Disease, Pfizer, Fiocruz","confidence":9,"key_topics":["Financial Results","New Chairman","Scientific Presentations","Clinical Trials","Partnerships"],"date_of_event":"November 6, 2023","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":["Management Changes"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"uDrpx9iMnc52LLmKxevucWKM2GIYSIz0zFBkSxvIiqdNIzidkWF6El","news_summary":"PLX: More Regulatory Approvals","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"GsbGqKCA8lh3FU6yhbSOi30AdQ9w8nypdI2iWBfz5kcIaN3nnzPJLg","date":"Nov 7, 2023","link":"https://finance.yahoo.com/news/protalix-biotherapeutics-inc-amex-plx-140447799.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Earnings Call, Financial Results","company":"Protalix BioTherapeutics, Inc.","layoffs":"Not mentioned","summary":"Protalix BioTherapeutics, Inc. reported its Q3 2023 earnings, beating expectations with a reported EPS of $-0.04, compared to the expected $-0.07. The company has seen no disruptions to its facilities and does not anticipate any interruption to the supply of its products Elfabrio and Elelyso. The companys commercial partner, Chiesi, has focused on the commercial launch of Elfabrio in the United States and the European Union, with additional regulatory approvals in Great Britain and Switzerland. The company is also developing its pipeline assets, including PRX-115 for the potential treatment of severe gout and PRX-119 for the potential treatment of NETs-related diseases. The company also announced a change in its board of directors.","partners":"Chiesi","customers":"Not mentioned","investors":"Not mentioned","confidence":9,"key_topics":["Earnings Report","Product Launch","Pipeline Development","Management Change","Financial Stability"],"date_of_event":"November 6, 2023","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":["Customers","Partners","Management Changes"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Customers  #Partners  #Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"MNPCyVgrKXBXb32TKtH3xSZLfal941UN3u0AbnOrWqciiImArDk1la","news_summary":"Protalix BioTherapeutics, Inc. (AMEX:PLX) Q3 2023 Earnings Call Transcript","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"mIMsYBYFroKJw6paqtFDQpnn8EJCcTbKtaxomkgGhZXoOsaVFUPvMg","date":"Nov 6, 2023","link":"https://finance.yahoo.com/news/protalix-biotherapeutics-inc-plx-reports-130429189.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Financial Report, Clinical Trials","company":"Protalix BioTherapeutics Inc","layoffs":"N/A","summary":"Protalix BioTherapeutics Inc reported a net income of $14.36 million for Q3 2023, a significant improvement from a loss of $11.19 million in the same period last year. Total revenue for the period stood at $55.01 million, a 41% increase from $39.02 million in Q3 2022. The companys cash and cash equivalents increased to $20.41 million from $17.11 million at the end of 2022. Protalix continues to advance its clinical trial of PRX-115, a potential treatment for severe gout, with top-line results expected in mid-2024. The company, along with its partner Chiesi Global Rare Diseases, continued to attain marketing authorizations worldwide for Elfabrio, a treatment for adult patients with Fabry disease.","partners":"Chiesi Global Rare Diseases","customers":"N/A","investors":"N/A","confidence":9,"key_topics":["Q3 2023 Financial Results","Clinical Trial","Drug Approval","Partnership","Revenue Growth"],"date_of_event":"November 6, 2023","valuation_amount":"N/A","impact_on_company":"Growth-Positive","investment_amount":"N/A","structured_issues":["Customers"],"acquisition_amount":"N/A","structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"Growth-Positive","analysisId":"xQ26iKu1LEeSrCF4iJHEO5AywChJWfvevvvDgp5iMAXRNdCaGAVy0P","news_summary":"Protalix BioTherapeutics Inc (PLX) Reports Q3 2023 Financial Results","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"tmOvD3lV1WP5ZriKEt2lfCPkHPhRSp5E3oWrCrdEz1M8QbVV4nWmtA","date":"Nov 6, 2023","link":"https://www.prnewswire.com/news-releases/protalix-biotherapeutics-reports-third-quarter-2023-financial-and-business-results-301978381.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"Financial Results, Clinical Development, Management Changes","company":"Protalix BioTherapeutics, Inc.","layoffs":"N/A","summary":"Protalix BioTherapeutics, Inc. has reported its financial results for Q3 2023, showing an increase in revenues from selling goods of $10.2 million, a 16% increase compared to the same period in 2022. The company also highlighted its partnership with Chiesi Global Rare Diseases for the commercialization of Elfabrio, a drug for the treatment of adult patients with Fabry disease. Additionally, Protalix announced the appointment of Eliot Richard Forster, Ph.D. as the new Chairman of the companys Board of Directors.","partners":"Chiesi Global Rare Diseases","customers":"Chiesi Global Rare Diseases, Pfizer, Brazil","investors":"N/A","confidence":9,"key_topics":["Financial Results","Clinical Trials","Partnership","Management Change","Drug Approval"],"date_of_event":"September 30, 2023","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":["Customers","Partners","Management Changes"],"acquisition_amount":"N/A","structuredIssuesShow":"#Customers  #Partners  #Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"f4GBDnWFOCiyrJ9uSKrzGuyg6GGG7EcukISkxSPDR5gjlpc5F4cZjo","news_summary":"Protalix BioTherapeutics Reports Third Quarter 2023 Financial and Business Results","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"Nxrp5uYsLtUf4Qyx9oPlzwMbIyYmQued5heWrjdPVPSV2pWslYzaRU","date":"Oct 30, 2023","link":"https://www.prnewswire.com/news-releases/protalix-biotherapeutics-to-announce-third-quarter-2023-financial-and-business-results-on-november-6-2023-301971169.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"Financial Results, Business Update","company":"Protalix BioTherapeutics, Inc.","layoffs":"Not mentioned","summary":"Protalix BioTherapeutics, Inc., a biopharmaceutical company, announced that it will release its financial results for the third quarter ended September 30, 2023, and provide a business update on Monday, November 6, 2023. The company is focused on the development, production, and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx plant cell-based protein expression system. The company has partnered with Chiesi Farmaceutici S.p.A. for the global development and commercialization of Elfabrio.","partners":"Chiesi Farmaceutici S.p.A.","customers":"Not mentioned","investors":"Not mentioned","confidence":9,"key_topics":["Financial Results","Business Update","Conference Call","Webcast","Partnership"],"date_of_event":"November 6, 2023","valuation_amount":"Not mentioned","impact_on_company":"Neutral","investment_amount":"Not mentioned","structured_issues":"Management Changes","acquisition_amount":"Not mentioned","structuredIssuesShow":"#Management Changes","entityGrowthIconPath":"none;"},"sentiment":"Neutral","analysisId":"B7YZIx728oNpFcns0G5fjJdxBQG5XZF8cgOqKuZ4XVf6p532JJgd9r","news_summary":"Protalix BioTherapeutics to Announce Third Quarter 2023 Financial and Business Results on November 6, 2023","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"1yBO6fJDGNUplIQhfbStyW9aYh3a4wu2K9kMOKqlNrRIRdLGpjZWML","date":"Oct 9, 2023","link":"https://www.prnewswire.com/news-releases/protalix-biotherapeutics-issues-statement-regarding-security-situation-in-israel-301950666.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"Security Situation","company":"Protalix BioTherapeutics, Inc.","layoffs":"Not mentioned","summary":"Protalix BioTherapeutics, Inc., a biopharmaceutical company, has issued a statement regarding the current security situation in Israel. The companys President and CEO, Dror Bashan, reassured employees, partners, and stockholders that the companys operations have not been adversely affected by the situation. He stated that hostilities have not taken place where Protalixs facilities are located and they do not anticipate any disruption to the supply of their products, Elfabrio and Elelyso. The company has also expressed gratitude to all partners and stockholders for their support and continued confidence in Protalix.","partners":"Chiesi Farmaceutici S.p.A., Pfizer Inc.","customers":"Not mentioned","investors":"Not mentioned","confidence":9,"key_topics":["Security Situation","Operations Continuity","Employee Support","Product Supply","Partnership"],"date_of_event":"Not mentioned","valuation_amount":"Not mentioned","impact_on_company":"Neutral","investment_amount":"Not mentioned","structured_issues":["Partners"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Partners","entityGrowthIconPath":"none;"},"sentiment":"Neutral","analysisId":"kv3sWCjHTqFfiQybVbsNQxOAY6vtBcGS7g7iR79e3mDL22vCzqZmAk","news_summary":"Protalix BioTherapeutics Issues Statement Regarding Security Situation in Israel","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"b83MMgzRKr3I39orCIOtbzEJHrK88OJx63fS5cf6Kw0JwRO2YkqhDc","date":"Sep 12, 2023","link":"https://finance.yahoo.com/news/protalix-biotherapeutics-appoints-eliot-richard-105000998.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Management Changes","company":"Protalix BioTherapeutics, Inc.","layoffs":"N/A","summary":"Protalix BioTherapeutics, Inc. has announced the appointment of Eliot Richard Forster, Ph.D. to serve on its Board of Directors as Chairman, effective from September 14, 2023. The current Chairman, Zeev Bronfeld, will retire on the same day. Dr. Forster brings a wealth of experience in the life sciences field, with successful experience in the United States, European Union, and Asia. He currently serves as the Non-Executive Chairman of Avacta Group PLC, a Non-Executive Director of Immatics NV, and the Non-Executive Chairman of Ochre Bio, Inc.","partners":["Pfizer Inc.","Chiesi Farmaceutici S.p.A."],"customers":"N/A","investors":"N/A","confidence":10,"key_topics":["Board Appointment","Retirement"],"date_of_event":"September 14, 2023","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":["Management Changes"],"acquisition_amount":"N/A","structuredIssuesShow":"#Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"w728Ey6H2nopl9yRfY2GKBKWzTtRuIWZ4oGY2Gi1AIpmdCh34NhUkO","news_summary":"Protalix BioTherapeutics Appoints Eliot Richard Forster, Ph.D. as Chairman of its Board of Directors","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"dWrgUIYgNyzIW41sDJ71rsZWLcJljjzSbrQnngdBeBvuGZb9CtUjV6","date":"Sep 6, 2023","link":"https://www.prnewswire.com/news-releases/protalix-biotherapeutics-to-present-at-the-hc-wainwright-25th-annual-global-investment-conference-301919041.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"Investment Conference, Product Development","company":"Protalix BioTherapeutics, Inc.","layoffs":"Not specified","summary":"Protalix BioTherapeutics, a biopharmaceutical company, announced that its President and CEO, Dror Bashan, will present at the H.C. Wainwright 25th Annual Global Investment Conference on September 13, 2023. Bashan will provide a corporate overview and participate in one-on-one meetings with registered investors. Protalix focuses on the development and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx plant cell-based protein expression system. It has licensed to Pfizer the worldwide development and commercialization rights to taliglucerase alfa for Gaucher disease treatment, excluding Brazil. Protalix has also partnered with Chiesi Farmaceutici for the global development and commercialization of Elfabrio.","partners":["Pfizer Inc.","Chiesi Farmaceutici S.p.A."],"customers":"Not specified","investors":"Not specified","confidence":9,"key_topics":["Investment Conference","Product Development","Partnership","Management","Pipeline"],"date_of_event":"September 13, 2023","valuation_amount":"Not specified","impact_on_company":"growth-positive","investment_amount":"Not specified","structured_issues":["Management Changes","Partners"],"acquisition_amount":"Not specified","structuredIssuesShow":"#Management Changes  #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"BIfawnlWzhmHL4nDfUZxwkBzLnNrKXW4wqvSwZ6T0aRlN2sORRIVbr","news_summary":"Protalix BioTherapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"LwuAmlG7hzEPBoYpqqKSnryS4hcNetbBDgQPhHLQwEZ52FWXJYb5Om","date":"Aug 8, 2023","link":"https://finance.yahoo.com/news/plx-second-quarter-results-105100924.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Financial Performance, Regulatory Approval","company":"Protalix Biotherapeutics, Inc.","layoffs":"Not mentioned","summary":"Protalix Biotherapeutics, Inc. announced its Q2 2023 financial and operational results, highlighting several positive events that have increased the companys value. These include the approval of Elfabrio by the European Commission and the FDA for marketing in the EU and US respectively, and a $20 million milestone payment from partner Chiesi. The company also reported revenues of $35.1 million for Q2 2023, a significant increase from $8.7 million in Q2 2022. This was largely due to a $20 million milestone, $11.7 million in revenues from Chiesi, and $3.4 million in revenues from Pfizer.","partners":"Chiesi","customers":"Chiesi, Pfizer","investors":"Chiesi, Pfizer","confidence":9,"key_topics":["Financial Results","Regulatory Approval","Partnership","Investment","Product Sales"],"date_of_event":"August 7, 2023","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"$20 million","structured_issues":["Customers","Partners","Investment"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Customers  #Partners  #Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"bIfM9OllJGd4Xv2QMIvzXXKD3iNdO9ryMbqp9HwJaHs0R2rGnEroa3","news_summary":"PLX: Second Quarter Results","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"7WPCgnIGf0Xv0nikLelcqzPGGcnwgwov4eeIDhbX0WO9R7MTjWt2ze","date":"Aug 8, 2023","link":"https://finance.yahoo.com/news/protalix-biotherapeutics-inc-amex-plx-131428532.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Earnings Call, Drug Approval","company":"Protalix BioTherapeutics, Inc.","layoffs":"Not mentioned","summary":"Protalix BioTherapeutics, Inc. reported its Q2 2023 financial results and business updates. The company announced that the European Commission and the U.S. FDA approved Elfabrio for the treatment of adult patients with Fabry disease. This approval triggered a $20 million U.S. milestone payment from Chiesi Global Rare Diseases. The company also reported an increase in revenues from selling goods of $15.1 million during Q2 2023, an increase of $11.7 million or 344% compared to Q2 2022. The company is also making progress on PRX-115 and PRX-119, drugs in development for the treatment of severe gout and NETs-related diseases respectively.","partners":"Chiesi Global Rare Diseases","customers":"Not mentioned","investors":"Chiesi Global Rare Diseases","confidence":9,"key_topics":["Earnings Call","Drug Approval","Financial Results","Partnership","Pipeline Development"],"date_of_event":"August 7, 2023","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"$20 million","structured_issues":["Customers","Partners","Investment"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Customers  #Partners  #Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"LU392dhD2xyLNEojTSYWGfqInEhfMldwSh28udihJvP0Zv2xRZmUSj","news_summary":"Protalix BioTherapeutics, Inc. (AMEX:PLX) Q2 2023 Earnings Call Transcript","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"3PDikefl3B60c3kXfhOyFKGQFG9BUViltcBr6W387pa1o5dN9CrLRd","date":"Aug 7, 2023","link":"https://www.prnewswire.com/news-releases/protalix-biotherapeutics-reports-second-quarter-2023-financial-and-business-results-301894457.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"Financial Report, Regulatory Approval, Partnership","company":"Protalix BioTherapeutics, Inc.","layoffs":"Not mentioned","summary":"Protalix BioTherapeutics, Inc. has reported its financial results for Q2 2023, highlighting a transformational year with significant regulatory approvals for its drug Elfabrio in the US and EU. The companys commercial partner, Chiesi Global Rare Diseases, has launched the product in the US. Protalix also announced that it is eligible to receive a $20 million milestone payment from Chiesi following the FDAs approval of Elfabrio. The company recorded revenues from selling goods of $15.1 million during Q2 2023, an increase of 344% compared to the same period in 2022.","partners":"Chiesi Global Rare Diseases","customers":"Not mentioned","investors":"Chiesi Global Rare Diseases","confidence":9,"key_topics":["Financial Results","Regulatory Approval","Clinical Developments","Corporate Developments","Partnership"],"date_of_event":"June 30, 2023","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"$20 million milestone payment from Chiesi Global Rare Diseases","structured_issues":["Customers","Partners","Investment"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Customers  #Partners  #Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"qFioyuZNoVDyUyRmJj3FZUSWX0Rc7fcwgAQohwNdrh4y7zjqgytUpI","news_summary":"Protalix BioTherapeutics Reports Second Quarter 2023 Financial and Business Results","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"1JC9sf3Zdwm4Yg54O030YQluNb2C0PtCFAQkNfmri9IJ5jtcCBqF6r","date":"Aug 1, 2023","link":"https://www.prnewswire.com/news-releases/protalix-biotherapeutics-to-present-at-the-canaccord-genuity-43rd-annual-growth-conference-301890119.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"Conference Presentation","company":"Protalix BioTherapeutics, Inc.","layoffs":"Not mentioned","summary":"Protalix BioTherapeutics, Inc. announced that its President and CEO, Dror Bashan, will present at the Canaccord Genuity 43rd Annual Growth Conference on August 9, 2023. The companys management will also participate in one-on-one meetings with registered investors. A live and archived webcast of the presentation will be available. The company is focused on the development and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx plant cell-based protein expression system. It has licensed to Pfizer Inc. the worldwide development and commercialization rights to taliglucerase alfa for the treatment of Gaucher disease, excluding in Brazil, where Protalix retains full rights.","partners":"Pfizer Inc., Chiesi Farmaceutici S.p.A.","customers":"Not mentioned","investors":"Not mentioned","confidence":9,"key_topics":["Conference Presentation","Investor Meetings","Webcast","Product Pipeline","Partnership"],"date_of_event":"August 9, 2023","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":"Management Changes","acquisition_amount":"Not mentioned","structuredIssuesShow":"#Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"SXu955sFbxtuBhazOdgktEZNH5ItOWFP9jfYZkNehEjTHX3nJuSOFL","news_summary":"Protalix BioTherapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"I02ivcX7mkOSh6bqjDbP5hRWh2oHgdjs60ackCoP1xBctbZaFoTsiS","date":"Jul 31, 2023","link":"https://www.prnewswire.com/news-releases/protalix-biotherapeutics-to-announce-second-quarter-2023-financial-and-business-results-on-august-7-2023-301889126.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"Financial Results, Business Update","company":"Protalix BioTherapeutics, Inc.","layoffs":"Not mentioned","summary":"Protalix BioTherapeutics, Inc., a biopharmaceutical company, has announced that it will release its financial results for the second quarter ended June 30, 2023, and provide a business update on Monday, August 7, 2023. The company will host a conference call and webcast to discuss the financial results and provide an update on recent corporate and regulatory developments. Protalix is focused on the development and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system. It has partnered with Pfizer Inc. and Chiesi Farmaceutici S.p.A. for the global development and commercialization of its products.","partners":["Pfizer Inc.","Chiesi Farmaceutici S.p.A."],"customers":"Not mentioned","investors":[],"confidence":9,"key_topics":["Financial Results","Business Update","Conference Call","Webcast","Partnership"],"date_of_event":"Monday, August 7, 2023","valuation_amount":"Not mentioned","impact_on_company":"Neutral","investment_amount":"Not mentioned","structured_issues":[],"acquisition_amount":"Not mentioned","entityGrowthIconPath":"none;"},"sentiment":"Neutral","analysisId":"iCkfRW8Azl1U0rcvbynSdSjzFP6W0P9tJXpU1EPuTB8UvujQjwI2Iy","news_summary":"Protalix BioTherapeutics to Announce Second Quarter 2023 Financial and Business Results on August 7, 2023","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"NKxR7S3hx0HXPPsE2bkf2SRxOadVRJKRk6g3RKjoiAKHjzRauKcDVQ","date":"Jun 8, 2023","link":"https://www.prnewswire.com/news-releases/protalix-biotherapeutics-to-host-in-person-kol-breakfast-following-the-approval-of-elfabrio-in-both-the-united-states-and-the-european-union-for-adults-with-fabry-disease-301845932.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"KOL breakfast","company":"Protalix BioTherapeutics, Inc.","layoffs":null,"summary":"Protalix BioTherapeutics, Inc. will host an in-person KOL breakfast in New York to discuss the recent FDA approval of Elfabrio for the treatment of Fabry disease. The event will feature presentations by medical professionals and the companys commercial partner. The companys leadership will also provide insight into the companys strategy and future plans. The event will include a live question and answer session. Protalix BioTherapeutics is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins.","partners":"Chiesi Farmaceutici S.p.A.","customers":null,"investors":null,"confidence":8,"key_topics":["FDA approval","Fabry disease","commercial partner","strategy","future plans"],"date_of_event":"2023-06-27","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"8YMvi5GZDiu5iKwjrnbPu6NdZwFFW55N8pmwPJFGh5H3v8wC43NyES","news_summary":"Protalix BioTherapeutics to Host In-Person KOL Breakfast following the Approval of Elfabrio® in both the United States and the European Union for Adults with Fabry Disease","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"NTF1hDxa54UTuX2G8QXyMRHOkGcELoL43WaSAY6YpsfkmZRgVBfptZ","date":"May 30, 2023","link":"https://www.prnewswire.com/news-releases/protalix-biotherapeutics-issues-letter-to-stockholders-301837044.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":["biopharmaceutical","recombinant therapeutic proteins","FDA approval","commercialization","pipeline programs","investors event","growth","value creation"],"company":"Protalix BioTherapeutics, Inc.","layoffs":null,"summary":"Protalix BioTherapeutics, Inc. has announced the approval of its primary development candidate, Elfabrio, for the treatment of Fabry disease in the US and EU. This marks a significant milestone for the company and demonstrates its commitment to delivering innovative solutions to patients. Elfabrio is the second therapy based on Protalixs proprietary ProCellEx plant cell-based protein expression system. The companys commercial partner for Elfabrio, Chiesi Global Rare Diseases, is prepared for a successful commercial launch. Protalix is now focusing on its pipeline programs for future growth and plans to share insights and strategic initiatives at an upcoming investors event. The company expresses gratitude to its stockholders for their continued support and commitment to creating value for investors and patients.","partners":["Chiesi Farmaceutici S.p.A."],"customers":null,"investors":null,"confidence":9,"key_topics":["Elfabrio","ProCellEx","development programs","commercial launch","investors event"],"date_of_event":"May 30, 2023","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers","Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Customers  #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"z9jDQLv0OTkp9h0ptqdSsJiFZRSJY0DIEzwcSL2rGfNhbyizJs46Zw","news_summary":"Protalix BioTherapeutics Issues Letter to Stockholders","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"H3T0WZgausbbZu2npxP8qWVNJ98MWQxOttOcT4LWurYN1kXOsfzMZf","date":"May 30, 2023","link":"https://finance.yahoo.com/news/plx-back-envelope-150000398.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":["valuation","FDA approval","European Commission","milestone","Russell 3000 Index"],"company":"Protalix Biotherapeutics, Inc.","layoffs":null,"summary":"Protalix Biotherapeutics has received FDA approval and European Commission approval for its product Elfabrio. The company also announced a $20 million milestone payment from commercialization partner Chiesi. In addition, Protalix will be included in the Russell 3000 Index. These positive developments have not been reflected in the companys share price, which has remained low. A conservative valuation analysis suggests a significantly higher valuation for Protalix. The companys target price is $16 per share. Protalix is expected to hold an investor day in June to discuss its development candidates and Chiesis commercialization efforts. The companys future looks promising, with ongoing clinical trials and potential market share gains for Elfabrio.","partners":["Chiesi"],"customers":null,"investors":null,"confidence":8,"key_topics":["Valuation","FDA approval","European Commission approval","Milestone payment","Inclusion in Russell 3000 Index"],"date_of_event":"May 2023","valuation_amount":"$645 million","impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers","Partners","Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Customers  #Partners  #Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"IkhP5iviFkujCCs9bvncDnaOnXVLKjycw4h1ByaCtH9cfMu8HfJ8Ik","news_summary":"PLX: Back of the Envelope","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"R7ZLrfw2GqVOod6LDvg7H1jFbcwIe9kHfopsU5TDQAgbffdXabw12z","date":"May 23, 2023","link":"https://www.prnewswire.com/news-releases/protalix-biotherapeutics-set-to-join-russell-3000-index-301831972.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":["inclusion","Russell U.S. Indexes","milestone","progress","product candidates"],"company":"Protalix BioTherapeutics, Inc.","layoffs":null,"summary":"Protalix BioTherapeutics, Inc. is set to join the broad-market Russell 3000 Index, which is a growth-positive impact on the company. The key theme of the article is the inclusion of Protalix in the Russell U.S. Indexes, which is seen as a milestone in the companys progress. The article discusses the approval of PRX–102 for the treatment of Fabry disease and the focus on product candidates in Protalixs pipeline. The structured issue is Public Trading, as the company will be included in the Russell 3000 Index. The event described in the article is set to happen on June 26, 2023. The confidence level of the answer is 8.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["Russell 3000 Index","recombinant therapeutic proteins","ProCellEx plant cell–based protein expression system","approval of PRX–102","strategic path"],"date_of_event":"2023-06-26","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Public Trading"],"acquisition_amount":null,"structuredIssuesShow":"#Public Trading","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"kkSWWxuoPmzbmLD15lH1PpNSQS4hoB8sJIvMmMnxM4LAymKD7hcJ6w","news_summary":"Protalix BioTherapeutics set to join Russell 3000® Index","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"tWsccZE3qpR8mLI3ZhzY66KLc4TVJKUQjFUjVYrlS4eXFKqxOG8Mzw","date":"May 18, 2023","link":"https://www.prnewswire.com/news-releases/protalix-biotherapeutics-announces-20-million-milestone-payment-from-chiesi-global-rare-diseases-301828318.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"FDA approval","company":"Protalix BioTherapeutics, Inc.","layoffs":null,"summary":"Protalix BioTherapeutics is eligible to receive a $20 million milestone payment from its commercial partner, Chiesi Global Rare Diseases, triggered by the FDA approval of ELFABRIO for the treatment of Fabry disease. The payment will strengthen Protalixs financial position. Protalix has already received a total of $95.0 million in upfront payments and to cover development costs from Chiesi. The company is entitled to up to $1.0 billion in potential milestone payments and royalties as consideration for product supply. On a proforma basis, including the milestone payment, Protalixs cash and cash equivalents as of May 18, 2023, is $51.6 million.","partners":"Chiesi Global Rare Diseases, Chiesi Farmaceutici S.p.A.","customers":null,"investors":null,"confidence":8,"key_topics":["FDA approval","milestone payment","commercial partner","financial position","ProCellEx plant cell–based protein expression system"],"date_of_event":"May 10, 2023","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"sib7yixyHs2CseB6HXgQKLnvJYPotv92U5b2NFqywuhuA2U26hzWLr","news_summary":"Protalix BioTherapeutics Announces $20 Million Milestone Payment from Chiesi Global Rare Diseases","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"eRWkwFSYi9t5JT595prHN6hF0Ui0G9vX0GDs5ETsngmTB84Acy2Zz5","date":"May 11, 2023","link":"https://finance.yahoo.com/news/plx-fda-approval-elfabrio-115900201.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"FDA approval","company":"Protalix Biotherapeutics, Inc.","layoffs":null,"summary":"The FDA has granted approval to Protalix Biotherapeutics drug Elfabrio for the treatment of Fabry disease. This marks the companys 15th approved drug for the year. The European Medicines Agency has also provided authorization for the product. Protalixs valuation has been updated to reflect the approval, with a price target of $16.00 per share. The company is now focusing on its development assets, including PRX-115, PRX-102, and PRX-119. Protalix has started the Phase I clinical trial for PRX-115 and has submitted its BLA and MAA for PRX-102 to regulatory authorities. An investor day is planned for June 2023 to discuss the companys strategy. The approval of Elfabrio provides a new treatment option for around 15,000 Fabry patients in the associated regions.","partners":["Chiesi"],"customers":null,"investors":null,"confidence":8,"key_topics":["FDA approval","Elfabrio","PRX-115","PRX-102","PRX-119"],"date_of_event":"May 9, 2023","valuation_amount":"$16.00 per share","impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"o0jyrePlgQc3RiFs0UlTJjW68ayWTiZNZbwZD1tyCDHTAonDhSqrea","news_summary":"PLX: FDA Approval of Elfabrio","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"731Q0YlSt7gOfORLEVTM13W7l35AqEiQ0J9lV4aKZ1AORkFF3P8CX3","date":"May 10, 2023","link":"https://finance.yahoo.com/news/fabry-disease-treatment-showdown-protalix-201601855.html","source":"finance.yahoo.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"vzoogAqJ8vU79ntxm9FCnMjVoOmXRyIGPNQ2VCMS1mPIL3ShCe1iFk","news_summary":"Fabry Disease Treatment Showdown: Protalix Bio's Elfabrio Joins the Ranks of Sanofi and Amicus Therapeutics","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"hIH07Y42MCnLzDqeyw6gKWQQxtvQxMiUEB0iXWGbiwxszoq6GSmzhs","date":"May 10, 2023","link":"https://finance.yahoo.com/news/chiesi-global-rare-diseases-protalix-100000335.html","source":"finance.yahoo.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"6ZzINWupQ4ICXTzxSJjYxIjw2GPlpK0v1TuSoWwg1es88G1QaIdesG","news_summary":"Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce FDA Approval of ELFABRIO® (pegunigalsidase alfa-iwxj) for the Treatment of Fabry Disease","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"NqcWIWqbFFCcdMTxXt6qUYQPfUUUrRQFkulwuY0JiVJHudLFCYQp2K","date":"May 10, 2023","link":"https://www.biospace.com/article/fda-approves-fabry-disease-treatment-from-chiesi-protalix/","source":"www.biospace.com","visible":1,"analysis":{"tags":"FDA approval, Fabry disease treatment","company":"Chiesi Global Rare Diseases, Protalix BioTherapeutics","layoffs":"N/A","summary":"The FDA has approved Elfabrio, a treatment for adult patients with Fabry disease, developed by Chiesi Global Rare Diseases and Protalix BioTherapeutics. Elfabrio is an enzyme replacement therapy that works by restoring the bodys ability to degrade a fatty substance that accumulates in patients with Fabry disease. The approval comes after a comprehensive clinical development program involving over 140 patients and several clinical trials. The treatment may cause hypersensitivity reactions and other side effects, and the FDA recommends having medical support measures on standby when administering it.","partners":"Chiesi Global Rare Diseases, Protalix BioTherapeutics","customers":"Adult patients with Fabry disease","investors":"N/A","confidence":9,"key_topics":["FDA approval","Fabry disease","Elfabrio","Clinical trials","Enzyme replacement therapy"],"date_of_event":"Not specified","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":["Partners"],"acquisition_amount":"N/A","structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"2fTG8D5El1HMAEoS4GMDCCq0iJYSk68rFQPPnp0AISKjYjQwSnoSRi","news_summary":"FDA Approves Fabry Disease Treatment from Chiesi, Protalix | BioSpace","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"EI9voi4h116mW9czV0fn3oaWzobxG6s6jiS2Sle7U1xLkDzNOmoaVo","date":"May 8, 2023","link":"https://finance.yahoo.com/news/weekly-biotech-pulse-big-catalysts-063256242.html","source":"finance.yahoo.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"VdQ5RawSR5bHj9ZIDc1EFTtmT3Gmi189BUFfyfmdKNnZfHgPCl2Vx2","news_summary":"Weekly biotech pulse: Big catalysts on tap for Sarepta, Roche, Eyenovia, and more","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"bA3EHczxy5ybgVqtAgK4IkMvs5oELz8qCPYVeRHPnORlgOaN0nTMk6","date":"May 5, 2023","link":"https://finance.yahoo.com/news/plx-one-down-one-112600835.html","source":"finance.yahoo.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"GVw9V88ICNCHGrmMQBKY6kt9fQJU3ucgrFjt5TJ3YFm6tfAOnElMVK","news_summary":"PLX: One Down, One to Go","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"MTypdnT02fISH8EfP6rV8JqHke9hZDBwwdU6Ss87tUbGLieSZZqTvR","date":"May 5, 2023","link":"https://finance.yahoo.com/news/chiesi-global-rare-diseases-protalix-104600663.html","source":"finance.yahoo.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"c6rgRPZDMfJ5PpnR7PHkuSLILc3HmjjtlPEZPqsegKOlvJAnmPQdmn","news_summary":"Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Authorization of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry Disease","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"UQL52HwFRcMxOqI2RgbKuo3CWJ1JNfdAt3UgY1ye6VB5lk7qkyfWIT","date":"May 4, 2023","link":"https://www.prnewswire.com/news-releases/protalix-biotherapeutics-reports-first-quarter-2023-financial-and-business-results-301815933.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"Financial Report, Clinical Trials","company":"Protalix BioTherapeutics, Inc.","layoffs":"N/A","summary":"Protalix BioTherapeutics, Inc. reported its financial results for Q1 2023, showing a decrease in revenues from selling goods and license and R&D services compared to the same period in 2022. The company also provided updates on its clinical and corporate developments, including progress in its PRX–115 program for severe gout and awaiting decisions from the European Commission and the U.S. FDA. Protalix and its partner, Chiesi, remain committed to bringing PRX-102 to market for patients with Fabry disease. The company also announced the voluntary delisting of its common stock from the Tel Aviv Stock Exchange.","partners":"Chiesi Global Rare Diseases","customers":"Brazil, Pfizer","investors":"N/A","confidence":9,"key_topics":["Financial Results","Clinical Trials","Partnership","Regulatory Advancements","Corporate Developments"],"date_of_event":"May 4, 2023","valuation_amount":"N/A","impact_on_company":"growth-negative","investment_amount":"N/A","structured_issues":["Customers","Partners"],"acquisition_amount":"N/A","structuredIssuesShow":"#Customers  #Partners","entityGrowthIconPath":"url(/assets/circle-red.svg);"},"sentiment":"growth-negative","analysisId":"FkidQ22UhAVHQawnvBBpoywkXqZ8fqYEHebbaef6W1DFBt6XTxBN8z","news_summary":"Protalix BioTherapeutics Reports First Quarter 2023 Financial and Business Results","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"lGT4P7t4kfErCp29lZbDxAobSknpCDNueMomOozZnIPnLu82Z4KylQ","date":"Apr 27, 2023","link":"https://www.prnewswire.com/news-releases/protalix-biotherapeutics-to-announce-first-quarter-2023-financial-and-business-results-on-may-4-2023-301809451.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"financial results, conference call, business update","company":"Protalix BioTherapeutics, Inc.","layoffs":null,"summary":"Protalix BioTherapeutics, Inc. will release its financial results for the first quarter of 2023 and provide a business update on May 4, 2023. The company will host a conference call with investors to discuss the financial results and recent corporate and regulatory developments. The conference call will be webcast live from the companys website. Protalix BioTherapeutics is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx plant cell-based protein expression system.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["financial results","business update","conference call","webcast","ProCellEx"],"date_of_event":"May 4, 2023","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"8b56LxmAsQKXGhe1ypwT1MyD6wkTClMRbB6uCMkJOdvjUQq2wptlfZ","news_summary":"Protalix BioTherapeutics to Announce First Quarter 2023 Financial and Business Results on May 4, 2023","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"YQTNLvTYnCw3w3WSvvXI4lzLKEcSGro4kY5mhPhchVhjSOOtCOdPVd","date":"Mar 21, 2023","link":"https://www.prnewswire.com/news-releases/protalix-biotherapeutics-announces-first-patient-dosed-in-first-in-human-phase-i-clinical-trial-of-prx-115-for-the-treatment-of-severe-gout-301777178.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":["clinical trial","recombinant uricase","severe gout","biopharmaceutical company"],"company":"Protalix BioTherapeutics, Inc.","layoffs":null,"summary":"Protalix BioTherapeutics has announced the initiation of a phase I clinical trial for PRX-115, a recombinant PEGylated uricase product candidate for the treatment of severe gout. The trial will evaluate the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of PRX-115 in patients with elevated uric acid levels. The trial is being conducted in New Zealand and is expected to enroll approximately 56 patients. Protalix BioTherapeutics is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx plant cell–based protein expression system.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["PRX-115","clinical trial","recombinant uricase","severe gout","ProCellEx"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"wGCLRJY2KxapIBWMqNt2CT5aCcPGuYLMC5arEpfppXC35dl0bR1Gdw","news_summary":"Protalix BioTherapeutics Announces First Patient Dosed in First in Human Phase I Clinical Trial of PRX-115 for the Treatment of Severe Gout","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"n3WujnzhECJvl0uSQLHSRBiuCZGvMzQggzIQX2bWNmXzGzyGiJOvzx","date":"Mar 13, 2023","link":"https://www.prnewswire.com/news-releases/protalix-biotherapeutics-issues-statement-related-to-silicon-valley-bank-and-signature-bank-301769979.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":["financial","partners"],"company":"Protalix BioTherapeutics, Inc.","layoffs":null,"summary":"Protalix BioTherapeutics, Inc. announced that it does not hold cash deposits or securities at Silicon Valley Bank or Signature Bank, and it does not have any financial relationship with either institution. The closure of these banks is not expected to have any impact on the companys operations. Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins produced through its proprietary plant cell-based expression system, ProCellEx.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["biopharmaceutical","recombinant therapeutic proteins","ProCellEx","cash deposits","bank relationships"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-neutral","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Partners","entityGrowthIconPath":"none;"},"sentiment":"growth-neutral","analysisId":"JrJV0Pi4w3frULEEIY8Duy8Zf8jybp0bt2Ru0VWbH7vorI64xvgZNU","news_summary":"Protalix BioTherapeutics Issues Statement Related to Silicon Valley Bank and Signature Bank","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"KqW3RFFFNrZvsXSdFftJF1TLflmV3lh0HMEdUfkXUe2cRlnsAEOBu9","date":"Mar 1, 2023","link":"https://finance.yahoo.com/news/protalix-biotherapeutics-inc-amex-plx-015221512.html","source":"finance.yahoo.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"HKc20hfdNOTLgCpn79CwOaUibSFcKEVU4Doy3Iyx4I4ulZOoBlIc1O","news_summary":"Protalix BioTherapeutics, Inc. (AMEX:PLX) Q4 2022 Earnings Call Transcript","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"Yeu9adF4tcLAAIMcrtUweFVPBJe6UtAjsQFVFtm7CDry1e6GBLsbXj","date":"Feb 28, 2023","link":"https://finance.yahoo.com/news/plx-may-big-month-093200585.html","source":"finance.yahoo.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"nvrXlANbvQUdnYzWVdmvyf8qpOUvbkyhfO3J2OCznxKExuo98HYHbf","news_summary":"PLX: May is a Big Month","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"FoTbw2tGRaryZjrMamYjBE2qrnUYPs0BmUiOEwErkiyA6xRnLNO3EX","date":"Feb 27, 2023","link":"https://www.prnewswire.com/news-releases/protalix-biotherapeutics-reports-fiscal-year-2022-financial-and-business-results-301756357.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"Financial Results, Regulatory Advancements, Clinical Advancements","company":"Protalix BioTherapeutics, Inc.","layoffs":"Not mentioned","summary":"Protalix BioTherapeutics, Inc. reported its financial results for the fiscal year ended December 31, 2022, and provided a business update. The company recorded revenues from selling goods of $25.3 million, an increase of 51% compared to the previous year. The company also announced regulatory advancements, including the European Medicines Agencys positive opinion recommending marketing authorization for PRX–102 for adult patients with Fabry disease. The company also announced clinical advancements and corporate developments, including the appointment of a new member to the Board of Directors.","partners":"Chiesi Global Rare Diseases","customers":"Pfizer Inc., Brazil, Chiesi","investors":"Not mentioned","confidence":9,"key_topics":["Financial Results","Regulatory Advancements","Clinical Advancements","Corporate Developments","Conference Call"],"date_of_event":"February 27, 2023","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":["Customers","Partners"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Customers  #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"JxST3gc9rvg6Ix9izcOALa7XiOpya0fRHCXmPeq41oO0X7VfV2sdGR","news_summary":"Protalix BioTherapeutics Reports Fiscal Year 2022 Financial and Business Results","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"2DZXgwpY1v9Ap40r3jSchH1aAHvdR0xfviPpyiQf7lS7EGKXAN11F8","date":"Feb 24, 2023","link":"https://www.prnewswire.com/news-releases/chiesi-global-rare-diseases-and-protalix-biotherapeutics-receive-positive-chmp-opinion-for-pegunigalsidase-alfa-for-treatment-of-fabry-disease-301755440.html","source":"www.prnewswire.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"rxHf8ctIoMxkOTOxrYUAW911hPBgorJoB8p6aHMOII9kH4EH2wY4C4","news_summary":"Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for Pegunigalsidase Alfa for Treatment of Fabry Disease","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"SLkOUByxL0RIEwSEaSs7XWaBAXp2sEwam6P3mblC5p4txykXBfAiR8","date":"Feb 21, 2023","link":"https://www.prnewswire.com/news-releases/protalix-biotherapeutics-to-participate-in-the-19th-annual-worldsymposium-2023-301751587.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"participation in symposium","company":"Protalix BioTherapeutics, Inc.","layoffs":null,"summary":"Protalix BioTherapeutics, Inc. will be participating in the 19th Annual WORLDSymposium™ 2023. The company will be hosting an informational booth at the symposium, while its commercialization partner, Chiesi Global Rare Diseases, will also be participating and presenting on PRX-102 and Fabry disease. Protalix BioTherapeutics focuses on the development and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® system. The companys first product, taliglucerase alfa, was approved by the FDA in 2012. Protalix has licensed the development and commercialization rights for taliglucerase alfa to Pfizer Inc. The company has a development pipeline of other product candidates and has partnered with Chiesi Farmaceutici for the development and commercialization of pegunigalsidase alfa.","partners":"Chiesi Global Rare Diseases","customers":null,"investors":null,"confidence":8,"key_topics":["WORLDSymposium","PRX-102","Fabry disease","ProCellEx","taliglucerase alfa"],"date_of_event":"February 22–26, 2023","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners","Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Partners  #Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"Uy0ipCy9zybIsCgk5BXcJ1UMLqQIFMP9jDncON4OqoiiWfC49XQAA4","news_summary":"Protalix BioTherapeutics to Participate in the 19th Annual WORLDSymposium™ 2023","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"PS35wecFNxpvjHF1Gyn9U3eSDHjTr9yxJRZXtQzAKqG6pc6soKb1W0","date":"Dec 21, 2022","link":"https://www.prnewswire.com/il/news-releases/protalix-biotherapeutics-to-delist-its-common-stock-from-the-tel-aviv-stock-exchange-301708595.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"delisting","company":"Protalix BioTherapeutics, Inc.","layoffs":null,"summary":"Protalix BioTherapeutics has announced its decision to voluntarily delist its common stock from the Tel Aviv Stock Exchange (TASE). The company believes that focusing on a single exchange will be in the best interest of the company and its stockholders, allowing for better market activity concentration and reduced operational costs. The delisting process is expected to take three months. However, trading of the companys common stock on the NYSE American will be unaffected. Protalix BioTherapeutics will continue to file public reports and disclosures in accordance with US regulations. The companys common stock traded on the TASE is expected to transfer to the NYSE American once the delisting becomes effective.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["delisting","stock exchange","capital market","listing rules","regulations"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-negative","investment_amount":null,"structured_issues":["Public Trading"],"acquisition_amount":null,"structuredIssuesShow":"#Public Trading","entityGrowthIconPath":"url(/assets/circle-red.svg);"},"sentiment":"growth-negative","analysisId":"JMWahAwYap1osA5A5tl5qRfpJl4TfseSLqiefLFQ6ADmEir3SXTAsS","news_summary":"Protalix BioTherapeutics to Delist its Common Stock from the Tel Aviv Stock Exchange","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"GCdWNYlRuVSMyZyti1jl1w0R4KzgCWGLGWf7F4tswhlmtFRk3mCFpD","date":"Dec 5, 2022","link":"https://www.prnewswire.com/news-releases/protalix-biotherapeutics-and-chiesi-global-rare-diseases-announce-us-food-and-drug-administration-acceptance-of-a-resubmitted-biologics-license-application-for-pegunigalsidase-alfa-for-the-proposed-treatment-of-fabry-disease-301694436.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":["FDA acceptance","Biologics License Application","Fabry disease","pegunigalsidase alfa","Chiesi Global Rare Diseases"],"company":"Protalix BioTherapeutics, Inc.","layoffs":null,"summary":"Protalix BioTherapeutics and Chiesi Global Rare Diseases announced that the U.S. Food and Drug Administration (FDA) has accepted the resubmitted Biologics License Application (BLA) for pegunigalsidase alfa (PRX-102) for the proposed treatment of adult patients with Fabry disease. The FDA set an action date of May 9, 2023, for the BLA. The resubmission includes comprehensive clinical and manufacturing data. Protalix will be eligible to receive a milestone payment from Chiesi if the drug is approved. Fabry disease is an X-linked inherited disease that results in the accumulation of abnormal deposits in blood vessel walls. PRX-102 is an investigational enzyme replacement therapy for Fabry disease.","partners":["Chiesi Global Rare Diseases"],"customers":null,"investors":null,"confidence":8,"key_topics":["FDA acceptance","Biologics License Application","Fabry disease","pegunigalsidase alfa","Chiesi Global Rare Diseases"],"date_of_event":"November 9, 2022","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"dDfV2RJSQM392fbkALTcXURBOxdEpXram7zlJthpkVZS6nmM6IIYiF","news_summary":"Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce U.S. Food and Drug Administration Acceptance of a Resubmitted Biologics License Application for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"WZmuDbcI9UFOvt0KdJ6SK95BiM99isy0AxzDG3OpSlb3nn95HAkakW","date":"Sep 12, 2022","link":"https://www.prnewswire.com/il/news-releases/protalix-biotherapeutics-to-present-in-person-at-the-hc-wainwright-24th-annual-global-investment-conference-301622194.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"presentation","company":"Protalix BioTherapeutics, Inc.","layoffs":null,"summary":"Protalix BioTherapeutics, Inc. announced that its President and CEO will present at the H.C. Wainwright 24th Annual Global Investment Conference. The live presentation will replace the pre-recorded presentation previously announced. The companys management will also participate in one-on-one meetings with investors at the conference. Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx plant cell-based expression system.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["presentation","webcast","recombinant therapeutic proteins","ProCellEx","development pipeline"],"date_of_event":"September 14, 2022","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Investment","Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Investment  #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"WqJy4oZqANSHIDuYsMaRKiuHh9V2wZNtq298TRZLmE28RX0gRvHs4O","news_summary":"Protalix BioTherapeutics to Present in Person at the H.C. Wainwright 24th Annual Global Investment Conference","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"Igo7KyIcNM2KTkYeHlP8MhYr6Wp4PJn0sqAnHbiRdhdASg93Of29dp","date":"Aug 15, 2022","link":"https://www.prnewswire.com/il/news-releases/protalix-biotherapeutics-reports-second-quarter-2022-financial-and-business-results-301605555.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"Financial Report, Clinical Trials","company":"Protalix BioTherapeutics, Inc.","layoffs":"Not mentioned","summary":"Protalix BioTherapeutics, Inc. has reported its financial results for Q2 2022, revealing an increase in revenues from selling goods and licenses and R&D services. The company also announced positive topline results from its phase III BALANCE clinical trial of PRX-102 for the treatment of adult patients with Fabry disease. Additionally, the company appointed Shmuel Muli Ben Zvi, Ph.D. to the Board of Directors. Despite the positive developments, the company reported a net loss of approximately $5.3 million for the quarter.","partners":"Chiesi Farmaceutici S.p.A.","customers":"Not mentioned","investors":"Not mentioned","confidence":9,"key_topics":["Financial Results","Clinical Trials","Management Changes","Revenue Increase","Net Loss"],"date_of_event":"June 30, 2022","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":["Management Changes","Investment"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Management Changes  #Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"0oTpzn2zRrCyS79tC8xzzAlTWixpKD5Z7Lin3p8mPKSA8vmkGfD9Pg","news_summary":"Protalix BioTherapeutics Reports Second Quarter 2022 Financial and Business Results","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"c1d0f527-6987-45ee-9297-1f1938e5f7ad","date":"Apr 4, 2022","link":"https://www.prnewswire.com/news-releases/protalix-biotherapeutics-and-chiesi-global-rare-diseases-announce-topline-results-from-the-24-month-phase-iii-balance-clinical-trial-of-prx-102-for-the-treatment-of-fabry-disease-301516555.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"Clinical Trials, Drug Development","company":"Protalix BioTherapeutics, Inc.","layoffs":"N/A","summary":"Protalix BioTherapeutics, Inc. and Chiesi Global Rare Diseases have announced positive topline results from the BALANCE pivotal Phase III clinical trial evaluating pegunigalsidase alfa (PRX–102) for the treatment of Fabry disease. The study met its pre-specified primary endpoint and demonstrated that PRX-102 was statistically non-inferior to agalsidase beta. The companies plan to work with regulatory agencies on the applicable submissions, potentially bringing PRX–102 to approval as a new PEGylated enzyme replacement therapy for all adult Fabry patients.","partners":"Chiesi Global Rare Diseases","customers":"N/A","investors":"N/A","confidence":9,"key_topics":["Clinical Trial Results","Fabry Disease","Drug Development","Partnership","Regulatory Approval"],"date_of_event":"April 4, 2022","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":["Partners"],"acquisition_amount":"N/A","structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"WIN3ur60O9hllhvpXP0ZYscdtXdv2aytn3dMc8VlLlzmMa4CNf1nOl","news_summary":"Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Topline Results from the 24-Month Phase III BALANCE Clinical Trial of PRX-102 for the Treatment of Fabry Disease","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"b2b83eeb-6d68-44df-9a96-7e813390121b","date":"Mar 31, 2022","link":"https://www.prnewswire.com/il/news-releases/protalix-biotherapeutics-reports-fiscal-year-2021-financial-and-business-results-301514653.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"Financial Results, Clinical Developments","company":"Protalix BioTherapeutics, Inc.","layoffs":"Not mentioned","summary":"Protalix BioTherapeutics, Inc. has reported its financial results for the fiscal year ended December 31, 2021, and provided a business update on recent corporate and clinical developments. The company has made significant progress towards its key operational, clinical, and regulatory goals in 2021. It has also strengthened its balance sheet through exchanges of a substantial majority of its then outstanding 7.50% Senior Secured Convertible Notes due 2021 for a combination of cash and new notes. The company has also entered into a Sales Agreement with H.C. Wainwright & Co., LLC, as sales agent, pursuant to which the company may sell from time to time up to $20.0 million worth of shares of its common stock in at-the-market transactions through the Agent.","partners":["Chiesi Farmaceutici S.p.A"],"customers":"Not mentioned","investors":["H.C. Wainwright & Co., LLC","BofA Securities","Oppenheimer & Co."],"confidence":9,"key_topics":["Financial Results","Clinical Trials","Partnership","Investment","Regulatory Advancements"],"date_of_event":"March 31, 2022","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"$40.2 million","structured_issues":["Investment","Partners"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment  #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"Be4HEhW10vp2kGJmYT06qxWMtoF4PAtFa1KjYOQ0y5fyvsLiULtw2j","news_summary":"Protalix BioTherapeutics Reports Fiscal Year 2021 Financial and Business Results","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"5d47358d-ebd7-4807-86d9-2003e8ab653c","date":"Nov 15, 2021","link":"https://www.prnewswire.com/news-releases/protalix-biotherapeutics-reports-third-quarter-2021-financial-results-and-provides-financial-and-business-update-301423815.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"Financial results, Clinical developments","company":"Protalix BioTherapeutics, Inc.","layoffs":"Not mentioned","summary":"Protalix BioTherapeutics, Inc. has reported its financial results for Q3 2021 and provided updates on recent corporate, clinical, and regulatory developments. The company has made progress with the regulatory path for PRX-102 for the treatment of Fabry disease with both the U.S. Food and Drug Administration and the European Medicines Agency. The company has also completed a note exchange agreement in August, providing additional financial flexibility and sufficient capital to fund operations through important milestones in 2022. The company has also partnered with Chiesi Farmaceutici S.p.A. for the development and commercialization of PRX-102.","partners":"Chiesi Farmaceutici S.p.A.","customers":"Not mentioned","investors":"Not mentioned","confidence":9,"key_topics":["Financial results","Clinical developments","Regulatory updates","Partnership with Chiesi","Product development"],"date_of_event":"Nov. 15, 2021","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":["Investment","Partners"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment  #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"BUUNoGL43RXK4fvio7fCt50dhoeuy6WWsj9ao54CXbKcvW8a9cl8YX","news_summary":"Protalix BioTherapeutics Reports Third Quarter 2021 Financial Results and Provides Financial and Business Update","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"3437d07e-2c93-4f88-8c4f-d188475e3042","date":"Jun 2, 2021","link":"https://www.prnewswire.com/news-releases/protalix-biotherapeutics-and-chiesi-global-rare-diseases-provide-update-regarding-clinical-development-of-prx-102-for-treatment-of-fabry-disease-301303773.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"Partnership, Clinical Development","company":"Protalix BioTherapeutics, Inc.","layoffs":"Not mentioned","summary":"Protalix BioTherapeutics, Inc. and Chiesi Global Rare Diseases, a unit of Chiesi Farmaceutici S.p.A., have provided an update on the clinical development of pegunigalsidase alfa (PRX–102) for the proposed treatment of Fabry disease. The BALANCE study is ongoing and assignment to treatment arm remains blinded. Based on the interim analysis of the 12-month data generated from the BALANCE study, and in combination with previously reported positive data from the Phase III BRIGHT and BRIDGE clinical trials of PRX–102, Protalix and Chiesi intend to submit a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for the review of PRX–102 for the proposed treatment of Fabry disease.","partners":"Chiesi Global Rare Diseases, Chiesi Farmaceutici S.p.A.","customers":"Not mentioned","investors":"Chiesi Farmaceutici S.p.A.","confidence":9,"key_topics":["Clinical Development","Fabry Disease","PRX-102","Partnership","Regulatory Approval"],"date_of_event":"June 2, 2021","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":["Partners","Expand"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Partners  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"lA2nf6UOYgBDKp6HHGZeShjDNqccTOc1cZXyT6GZjdsuQkX6sy1ChU","news_summary":"Protalix Biotherapeutics and Chiesi Global Rare Diseases Provide Update Regarding Clinical Development of PRX-102 for Treatment of Fabry Disease","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"db3a4198-ba53-4987-ba57-44df06b60e9d","date":"Apr 28, 2021","link":"https://www.prnewswire.com/il/news-releases/protalix-biotherapeutics-and-chiesi-global-rare-diseases-receive-complete-response-letter-for-pegunigalsidase-alfa-from-fda-301278658.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":["FDA response","drug approval","Fabry disease"],"company":"Protalix BioTherapeutics, Inc.","layoffs":null,"summary":"Protalix BioTherapeutics and Chiesi Global Rare Diseases received a Complete Response Letter (CRL) from the FDA regarding the Biologics License Application (BLA) for the proposed treatment of Fabry disease. The CRL is a setback for the company, but they remain confident in the strength of their data and program. Protalix and Chiesi are studying the CRL to determine the best regulatory approach to obtain approval for PRX-102. Fabry disease is an X-linked inherited disease that causes the accumulation of abnormal deposits in the body. The PRX-102 BLA was initially submitted for accelerated approval and was granted Priority Review by the FDA. Protalixs development pipeline includes other product candidates for various diseases. Chiesi provides access to pegunigalsidase alfa through its Expanded Access Program for Fabry disease patients.","partners":["Chiesi Global Rare Diseases"],"customers":null,"investors":null,"confidence":8,"key_topics":["FDA response","drug approval","Fabry disease","clinical trials","partnership"],"date_of_event":"April 28, 2021","valuation_amount":null,"impact_on_company":"growth-negative","investment_amount":null,"structured_issues":["Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-red.svg);"},"sentiment":"growth-negative","analysisId":"QCe6lUNEfRHdmxYucpOEPAt6rxSw5xd28xFF4WLl2zZTC1N9HPU4vc","news_summary":"Protalix BioTherapeutics and Chiesi Global Rare Diseases Receive Complete Response Letter for Pegunigalsidase Alfa from FDA","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"cef5de96-29b1-447a-84b5-28b3c192601e","date":"Apr 28, 2021","link":"https://www.prnewswire.com/news-releases/protalix-biotherapeutics-and-chiesi-global-rare-diseases-receive-complete-response-letter-for-pegunigalsidase-alfa-from-fda-301278658.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":["FDA response","drug approval","Fabry disease"],"company":"Protalix BioTherapeutics, Inc.","layoffs":null,"summary":"Protalix BioTherapeutics and Chiesi Global Rare Diseases received a Complete Response Letter (CRL) from the FDA regarding the Biologics License Application (BLA) for the proposed treatment of Fabry disease. The CRL is a setback for the company, but they remain confident in the strength of their data and program. Protalix and Chiesi are studying the CRL to determine the best regulatory approach to obtain approval. Fabry disease is an X-linked inherited disease that causes the accumulation of abnormal deposits in the body. The PRX-102 BLA was initially submitted for accelerated approval and was granted Priority Review by the FDA. Protalixs development pipeline includes other product candidates for various diseases. Chiesi provides access to pegunigalsidase alfa through its Expanded Access Program for Fabry disease patients.","partners":["Chiesi Global Rare Diseases"],"customers":null,"investors":null,"confidence":8,"key_topics":["FDA response","drug approval","Fabry disease","clinical trials","partnership"],"date_of_event":"April 28, 2021","valuation_amount":null,"impact_on_company":"growth-negative","investment_amount":null,"structured_issues":["Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-red.svg);"},"sentiment":"growth-negative","analysisId":"bm1ND63ytfNobojgyJLk4FlnI3GeEQBE6FMpls4Lvr5dgGnjhjPJVz","news_summary":"Protalix BioTherapeutics and Chiesi Global Rare Diseases Receive Complete Response Letter for Pegunigalsidase Alfa from FDA","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"d50d2f4a-a54a-4749-b502-0ffd45139223","date":"Feb 23, 2021","link":"https://www.prnewswire.com/il/news-releases/protalix-biotherapeutics-and-chiesi-global-rare-diseases-announce-positive-topline-results-from-bright-phase-iii-open-label-switch-over-clinical-trial-evaluating-pegunigalsidase-alfa-2-mgkg-every-four-weeks-for-treatment-of-fabr-301233318.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"Clinical Trials, Drug Development","company":"Protalix BioTherapeutics, Inc.","layoffs":"N/A","summary":"Protalix BioTherapeutics and Chiesi Global Rare Diseases have announced positive results from the BRIGHT Phase III clinical trial of pegunigalsidase alfa (PRX-102) for the treatment of Fabry disease. The trial found that 2 mg/kg of PRX-102 administered every four weeks was well tolerated among patients, and stable clinical presentation was maintained in adult Fabry patients. No new patients developed treatment-induced anti-drug antibodies following the switch to PRX-102 treatment. The companies plan to report final data on the BRIGHT study in the second half of 2021.","partners":"Chiesi Global Rare Diseases","customers":"N/A","investors":"N/A","confidence":9,"key_topics":["Clinical Trial","Fabry Disease","PRX-102","Treatment","Partnership"],"date_of_event":"Feb. 23, 2021","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":"Partners","acquisition_amount":"N/A","structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"34bLSyfenXG9EoExsgbeq8OKNXdRga6l1lflPODjbTqGCHRCxGhD3z","news_summary":"Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Positive Topline Results from BRIGHT Phase III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa 2 mg/kg every Four Weeks for Treatment of Fabry Disease","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"5fdef41c-75ed-4c96-8ffc-52af94fbb323","date":"Feb 18, 2021","link":"https://www.prnewswire.com/news-releases/protalix-biotherapeutics-completes-raise-of-approximately-40-million-in-gross-proceeds-301230926.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":["fundraising","clinical trials","strategic plans","commercial launch","pipeline","balance sheet"],"company":"Protalix BioTherapeutics, Inc.","layoffs":null,"summary":"Protalix BioTherapeutics has completed a fundraising round, raising approximately $40 million in gross proceeds. The company plans to use the funds to support clinical trials for its product candidates, as well as for research and development activities and general corporate purposes. The fundraising round involved the participation of new institutional investors, which will help strengthen Protalixs balance sheet and accelerate clinical trial development. The company is focused on the development and commercialization of recombinant therapeutic proteins using its proprietary plant cell-based expression system. Protalix has a pipeline of product candidates and is preparing for a potential commercial launch in a significant market.","partners":null,"customers":null,"investors":["BofA Securities","Oppenheimer & Co."],"confidence":9,"key_topics":["fundraising","clinical trials","strategic plans","commercial launch","pipeline"],"date_of_event":"February 18, 2021","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$40 million","structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"xSbghWFEGIKfm16yGS4u4upNAgi06D0Kg63UjYxIditwuM71RxKJi6","news_summary":"Protalix BioTherapeutics Completes Raise of Approximately $40 Million in Gross Proceeds","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"c4c55324-b9be-482b-bd53-bb93841b82a3","date":"Feb 11, 2021","link":"https://www.prnewswire.com/il/news-releases/protalix-biotherapeutics-enters-into-an-exclusive-partnership-with-sarcomed-usa-to-develop-alidornase-alfa-for-the-treatment-of-pulmonary-sarcoidosis-and-related-respiratory-diseases-via-inhaled-delivery-301226728.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"license agreement","company":"Protalix BioTherapeutics, Inc.","layoffs":null,"summary":"Protalix BioTherapeutics has announced an exclusive worldwide license agreement with SarcoMed USA for alidornase alfa, a treatment for respiratory diseases. SarcoMed will be responsible for the identification and selection of pharmaceutical candidates under the license, as well as clinical research and development. Protalix will receive an initial cash payment of $3.5 million, with additional milestone payments and royalties on net sales. The agreement validates Protalixs development pipeline of drug candidates produced through its ProCellEx system. Alidornase alfa has received Orphan Drug Designation from the FDA for the treatment of sarcoidosis. Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins.","partners":"SarcoMed USA Inc.","customers":null,"investors":null,"confidence":8,"key_topics":["license agreement","alidornase alfa","respiratory disease","SarcoMed USA","treatment"],"date_of_event":"2021-02-11","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"X5XJTLHiRgJuIKpQlrw16VtHdndGxTeO6jIxvLOtACpU4t2eLCiMLS","news_summary":"Protalix BioTherapeutics Enters into an Exclusive Partnership with SarcoMed USA to Develop alidornase alfa for the Treatment of Pulmonary Sarcoidosis and Related Respiratory Diseases Via Inhaled Delivery","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"bfbacc57-03c5-4056-b246-98d988df38d3","date":"Feb 11, 2021","link":"https://www.prnewswire.com/il/news-releases/protalix-biotherapeutics-announces-proposed-public-offering-of-common-stock-301227308.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":["public trading","investment"],"company":"Protalix BioTherapeutics, Inc.","layoffs":null,"summary":"Protalix BioTherapeutics, Inc. plans to make a public offer of 6,500,000 shares of its common stock. The company intends to use the net proceeds from the offering to fund clinical trials for its product candidates, research and development activities, and for working capital and general corporate purposes. The offering is being made pursuant to an effective shelf registration statement. BofA Securities is acting as the book-running manager and Oppenheimer & Co. is acting as the co-manager for the offering.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["public offering","common stock","clinical trials","research and development","working capital"],"date_of_event":"2021-02-11","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"LD9YGFYs76jXajVGskLaxVojXvzPlAdbLU3flkJn1d8ge437pMd6Ar","news_summary":"Protalix BioTherapeutics Announces Proposed Public Offering of Common Stock","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"02a6d705-564c-43bf-a28d-7d4d02281af6","date":"Dec 30, 2020","link":"https://www.prnewswire.com/news-releases/protalix-biotherapeutics-issues-2020-letter-to-shareholders-301199296.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"biopharmaceutical","company":"Protalix BioTherapeutics, Inc.","layoffs":null,"summary":"Protalix BioTherapeutics, Inc. has announced its accomplishments in 2020, including the submission of a Biologics License Application (BLA) for PRX-102 for the treatment of Fabry disease. The company has also strengthened its financial foundation, advanced its pipeline of candidates, and sought collaborative partnerships. Protalix expects the FDA to make a decision on the BLA by April 27, 2021. The company has completed two studies for PRX-102 and expects to release topline data from a third study in the first quarter of 2021. Protalix has also entered into a non-binding term sheet with SarcoMed USA Inc. for the development and commercialization of PRX-110. The company raised approximately $44 million in a private placement and established an at-the-market offering to raise up to $30 million. Protalix has enhanced its management team with the appointment of a new Vice President of Research and Development.","partners":["Chiesi Global Rare Diseases","SarcoMed USA Inc.","Kirin Holdings Company, Limited"],"customers":null,"investors":null,"confidence":8,"key_topics":["PRX-102","Fabry disease","partnerships","financial balance sheet","management team"],"date_of_event":"2020-12-30","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners","Investment","Management Changes"],"acquisition_amount":null,"structuredIssuesShow":"#Partners  #Investment  #Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"kb6Uon4xg1GhQYconYGuawr5O5X8MX7DnLhSS9qdpNsyP30ByCjjnL","news_summary":"Protalix BioTherapeutics Issues 2020 Letter to Shareholders","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"20128496-d96c-4bab-877b-1d13edd3cb69","date":"Dec 22, 2020","link":"https://fabrydiseasenews.com/2020/12/22/fda-extends-review-date-to-april-for-u-s-approval-of-prx-102-fabry-disease-enzyme-replacement-therapy/","source":"fabrydiseasenews.com","visible":1,"analysis":{"tags":"FDA, biologics license application, accelerated approval, enzyme replacement therapy, Fabry disease","company":"Protalix BioTherapeutics","layoffs":null,"summary":"The U.S. Food and Drug Administration (FDA) has extended the review date for Protalix BioTherapeutics biologics license application (BLA) for PRX-102, an enzyme replacement therapy for Fabry disease. The FDAs accelerated approval pathway program allows medications that address an unmet need to rapidly obtain conditional approval. The new review date is April 27, 2021. PRX-102 is a stabilized version of a man-made form of alpha-galactosidase A and requires less frequent infusions than existing enzyme replacement therapies. The BLA submission included data from clinical trials showing the effectiveness of PRX-102 in decreasing disease biomarkers, improving kidney function, and slowing disease progression. The FDA had already granted PRX-102 priority review designation.","partners":["Chiesi Global Rare Diseases"],"customers":null,"investors":null,"confidence":8,"key_topics":["FDA review date extension","PRX-102","Fabry disease","enzyme replacement therapy","clinical trials"],"date_of_event":"spring 2021","valuation_amount":null,"impact_on_company":"growth-negative","investment_amount":null,"structured_issues":["Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-red.svg);"},"sentiment":"growth-negative","analysisId":"5VqsKizeDEL1j6YLYY5IEU0f3VHOvTRtQBJY5mVR978HMHPfFoJUNm","news_summary":"FDA Extends Review Date to April for US Approval of PRX-102","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"1f6b13ff-c39b-42b9-8ce0-710ac1e56b08","date":"Nov 27, 2020","link":"https://www.prnewswire.com/news-releases/protalix-biotherapeutics-and-chiesi-global-rare-diseases-announce-extension-of-pdufa-date-for-pegunigalsidase-alfa-for-the-proposed-treatment-of-fabry-disease-301181112.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"FDA approval","company":"Protalix BioTherapeutics, Inc.","layoffs":null,"summary":"Protalix BioTherapeutics and Chiesi Global Rare Diseases announced that the FDA has extended the review date for Protalixs Biologics License Application (BLA) seeking accelerated approval of pegunigalsidase alfa for the treatment of Fabry disease. The FDA extended the PDUFA action date by three months to April 27, 2021. The BLA submission includes data from clinical trials and manufacturing data. Protalix BioTherapeutics is a biopharmaceutical company focused on the development, production, and commercialization of recombinant therapeutic proteins.","partners":["Chiesi Global Rare Diseases"],"customers":null,"investors":null,"confidence":8,"key_topics":["FDA approval","Biologics License Application","Fabry disease","PDUFA date","pegunigalsidase alfa"],"date_of_event":"April 27, 2021","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"iriinA8DDMlkHRFSivD7a6SKfkyCdYRVyleVcMFusbtiEiMkLhpDh4","news_summary":"Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Extension of PDUFA Date for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"d9c79923-ee39-45fc-8b86-cce482f89c51","date":"Oct 2, 2020","link":"https://www.globenewswire.com/news-release/2020/10/02/2102895/0/en/Chiesi-Global-Rare-Diseases-and-Protalix-BioTherapeutics-Announce-Launch-of-Expanded-Access-Program-in-the-United-States-for-Pegunigalsidase-Alfa-for-the-Proposed-Treatment-of-Fabr.html","source":"www.globenewswire.com","visible":1,"analysis":{"tags":["Expanded Access Program","Fabry disease","pegunigalsidase alfa","Chiesi Global Rare Diseases","Protalix BioTherapeutics"],"company":"Protalix BioTherapeutics, Inc.","layoffs":null,"summary":"Protalix BioTherapeutics, Inc. and Chiesi Global Rare Diseases have announced the launch of an Expanded Access Program (EAP) in the United States for pegunigalsidase alfa, a proposed treatment for Fabry disease. The EAP will run concurrently with Protalixs ongoing Phase III clinical program. The program will provide access to pegunigalsidase alfa for patients with Fabry disease who have no comparable or satisfactory alternative treatment options. The EAP is open to eligible patients who will receive infusions of pegunigalsidase alfa every two weeks. The launch of the EAP demonstrates the commitment of Chiesi and Protalix to support patients with Fabry disease. Pegunigalsidase alfa is currently under review by the U.S. Food and Drug Administration (FDA).","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["Expanded Access Program","Fabry disease","pegunigalsidase alfa","Chiesi Global Rare Diseases","Protalix BioTherapeutics"],"date_of_event":"October 2, 2020","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"h64EqwawSrsA8kWFmXQTRHy79S50mvK8lAUzR8Ijrs7JFBjdo1aVQY","news_summary":"Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce Launch of Expanded Access Program in the United States for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"10d55bfa-f916-443c-ac3a-4052f9327d59","date":"Sep 8, 2020","link":"https://www.prnewswire.com/news-releases/protalix-biotherapeutics-regains-compliance-with-nyse-american-continued-listing-standards-301125357.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":["compliance","listing standards","biopharmaceutical","recombinant therapeutic proteins","ProCellEx","FDA approval","taliglucerase alfa","pegunigalsidase alfa","Chiesi Farmaceutici","development pipeline","forward-looking statements"],"company":"Protalix BioTherapeutics, Inc.","layoffs":null,"summary":"Protalix BioTherapeutics has regained compliance with all of the continued listing standards set forth by the NYSE American. The company had previously received a deficiency letter stating that it was not in compliance with the standards. However, through its efforts, Protalix has resolved the deficiency and regained compliance. Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx plant cell-based expression system. The companys first product, taliglucerase alfa, was approved by the FDA in 2012, and it has also developed pegunigalsidase alfa for the treatment of Fabry disease. Protalix has partnered with Chiesi Farmaceutici for the development and commercialization of pegunigalsidase alfa. The companys development pipeline includes other proprietary versions of recombinant therapeutic proteins.","partners":["Chiesi Farmaceutici S.p.A."],"customers":null,"investors":null,"confidence":8,"key_topics":["compliance","listing standards","biopharmaceutical","recombinant therapeutic proteins","FDA approval"],"date_of_event":"September 3, 2020","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Public Trading"],"acquisition_amount":null,"structuredIssuesShow":"#Public Trading","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"HME2erCToNq3wiHzo6F4udxSyAULrPEBCmsXM8KaZ3j2BUZTkmBjZH","news_summary":"Protalix BioTherapeutics Regains Compliance with NYSE American Continued Listing Standards","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"1c879e35-4452-45ab-b9cf-dca1d6b40589","date":"Aug 11, 2020","link":"https://www.prnewswire.com/il/news-releases/protalix-biotherapeutics-and-chiesi-global-rare-diseases-announce-us-food-and-drug-administration-acceptance-of-biologics-license-application-bla-for-pegunigalsidase-alfa-for-the-proposed-treatment-of-fabry-disease-and-grants--301109844.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":["FDA approval","Biologics License Application","Priority Review","pegunigalsidase alfa","Fabry disease"],"company":"Protalix BioTherapeutics, Inc.","layoffs":null,"summary":"Protalix BioTherapeutics, Inc. and its partner Chiesi Global Rare Diseases announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) and granted Priority Review designation for pegunigalsidase alfa for the proposed treatment of adult patients with Fabry disease. The FDA set an action date of January 27, 2021, for the review. This development represents a significant achievement for Protalix and Chiesi as they aim to establish a new treatment option for the Fabry patient community. Fabry disease is an X-linked inherited disease that results in the progressive accumulation of abnormal deposits in blood vessel walls. Pegunigalsidase alfa is an investigational product candidate designed to address the unmet clinical need in Fabry patients.","partners":["Chiesi Global Rare Diseases"],"customers":null,"investors":null,"confidence":9,"key_topics":["FDA acceptance","Priority Review designation","pegunigalsidase alfa","Fabry disease","BLA filing"],"date_of_event":"August 11, 2020","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"5KLypC2I3aSdzy9lRhHtAkdOldU4kzUMOzt95a7yVWDiwUPVfreA2K","news_summary":"Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce U.S. Food and Drug Administration Acceptance of Biologics License Application (BLA) for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease and Grants Priority Review","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"4596a427-deed-4e9d-95ff-70b32d942866","date":"Jun 8, 2020","link":"https://www.prnewswire.com/news-releases/protalix-biotherapeutics-appoints-yael-hayon-phd-as-its-new-vice-president-research-and-development-301072291.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"management changes","company":"Protalix BioTherapeutics, Inc.","layoffs":null,"summary":"Protalix BioTherapeutics has announced the appointment of Yael Hayon, Ph.D. as the new Vice President of Research and Development, effective July 5, 2020. Yoseph Shaaltiel, Ph.D. has retired from his position as the Executive Vice President of Research and Development. The company expressed gratitude to Shaaltiel for his contributions in founding and building Protalix. Dr. Hayon brings over a decade of experience in pharmaceutical research and development. Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins. They use a proprietary plant cell-based expression system called ProCellEx. Their first product, taliglucerase alfa, was approved by the FDA in 2012 and they have licensed the development and commercialization rights to Pfizer Inc. for this product.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["appointment","retirement","research and development","pharmaceutical","expression system"],"date_of_event":"2020-06-08","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Management Changes"],"acquisition_amount":null,"structuredIssuesShow":"#Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"0o85dTZtbqufHSAtNFlzDMlSQkahgANBE6GTqb3zLIt9uCrNc3A26F","news_summary":"Protalix BioTherapeutics Appoints Yael Hayon, Ph.D. as its New Vice President, Research and Development","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"b47dbaaa-97f0-4e45-a9f8-2452d5bd70a5","date":"May 28, 2020","link":"https://www.prnewswire.com/il/news-releases/protalix-biotherapeutics-and-chiesi-global-rare-diseases-announce-submission-of-biologics-license-application-to-us-food-and-drug-administration-for-pegunigalsidase-alfa-for-the-treatment-of-fabry-disease-301066794.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":["Biologics License Application","FDA","pegunigalsidase alfa","Fabry disease","accelerated approval","milestone payment","Chiesi Global Rare Diseases","partnership","rare diseases","Fabry patient community"],"company":"Protalix BioTherapeutics, Inc.","layoffs":null,"summary":"Protalix BioTherapeutics, Inc. and Chiesi Global Rare Diseases have submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for pegunigalsidase alfa for the treatment of adult patients with Fabry disease. The submission includes data from clinical trials and studies of PRX-102. If approved, Protalix will receive a milestone payment from Chiesi. The submission represents a significant milestone for Chiesi Global Rare Diseases, which was established earlier this year to focus on rare diseases. The partnership between Protalix and Chiesi aims to bring new treatment options to patients with Fabry disease and other rare diseases.","partners":["Chiesi Global Rare Diseases"],"customers":null,"investors":null,"confidence":8,"key_topics":["Biologics License Application","FDA submission","pegunigalsidase alfa","Fabry disease","Chiesi Global Rare Diseases"],"date_of_event":"May 27, 2020","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners","Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Partners  #Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"TiDwO5XXndVcm2bv7n4eTMaSQcBV6OAekrAzqowDznaIQIgoTsqL0D","news_summary":"Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Submission of Biologics License Application to U.S. Food and Drug Administration for Pegunigalsidase Alfa for the Treatment of Fabry Disease","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"b16faf0e-4f3a-4f50-abdd-45ee64f9a4fc","date":"Mar 12, 2020","link":"http://www.finsmes.com/2020/03/protalix-biotherapeutics-raises-43-7m-in-financing.html","source":"www.finsmes.com","visible":1,"analysis":{"tags":"financing","company":"Protalix BioTherapeutics","layoffs":null,"summary":"Protalix BioTherapeutics has raised $43.7 million in financing through a private equity investment. The funds will be used to advance the companys clinical programs and commercialization of PRX-102 for the treatment of Fabry disease, as well as to further develop its early stage pipeline of therapeutics. Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx plant cell-based protein expression system. The company has licensed the worldwide development and commercialization rights for taliglucerase alfa to Pfizer Inc. and has partnered with Chiesi Farmaceutici for the development and commercialization of pegunigalsidase alfa.","partners":["Chiesi Farmaceutici"],"customers":null,"investors":["Psagot Investment House","More Investment House","Highbridge Capital","UBS O’Connor","Rosalind Capital","Alrov Properties"],"confidence":9,"key_topics":["Financing","Private equity investment","Clinical programs","Commercialization","Therapeutic proteins"],"date_of_event":"12/03/2020","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$43.7 million","structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"94IraGcHLdSFXLxGcrp6P2ViraH2t7g9Ors16ITZw7gGDEovgzEG3V","news_summary":"Protalix BioTherapeutics Raises $43.7M in Financing - FinSMEs","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"484d580a-c194-4580-bf21-5ccbb2bf5d58","date":"Feb 6, 2020","link":"https://www.prnewswire.com/news-releases/protalix-biotherapeutics-and-chiesi-farmaceutici-announce-receipt-of-agreement-letter-for-initial-pediatric-study-plan-for-prx-102-for-the-treatment-of-fabry-disease-301000200.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"FDA agreement","company":"Protalix BioTherapeutics, Inc.","layoffs":null,"summary":"Protalix BioTherapeutics and Chiesi Farmaceutici have announced an agreement with the U.S. Food and Drug Administration (FDA) for the Initial Pediatric Study Plan (iPSP) for PRX-102, a treatment for Fabry disease. The agreement marks an important milestone for Protalix in bringing a new treatment option to the Fabry patient community. The companies expect to submit a Biologics License Application (BLA) to the FDA under an Accelerated Approval pathway. Fabry disease is an X-linked inherited disease that results in the progressive accumulation of abnormal deposits in blood vessel walls. PRX-102 has the potential to be approved for adult patients with Fabry disease. Protalix BioTherapeutics is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins.","partners":"Chiesi Farmaceutici","customers":null,"investors":null,"confidence":9,"key_topics":["Pediatric Study Plan","Fabry disease","PRX-102","Chiesi Farmaceutici","Accelerated Approval pathway"],"date_of_event":"2020-02-06","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"PDAZbdmIjSkTButkXhdkSbg27QPrmNNuf4boHRNQBiIuT0gZNk79kZ","news_summary":"Protalix BioTherapeutics and Chiesi Farmaceutici Announce Receipt of \"Agreement Letter\" for Initial Pediatric Study Plan for PRX-102 for the Treatment of Fabry Disease","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"203d65b0-6634-4465-9017-eec173b123dd","date":"Dec 19, 2019","link":"https://www.prnewswire.com/il/news-releases/protalix-biotherapeutics-adds-two-accomplished-biopharmaceutical-executives-to-its-board-of-directors-300977495.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"appointment","company":"Protalix BioTherapeutics, Inc.","layoffs":null,"summary":"Protalix BioTherapeutics has announced the appointment of Pol F. Boudes, MD, and Gwen A. Melincoff to its Board of Directors. The new appointments will expand the size of the Board from five to seven directors. Pol Boudes brings over 25 years of experience in medical research and development, with a special emphasis on orphan drugs and translational medicine. Gwen Melincoff has over 25 years of business development and venture capital leadership experience in the biotechnology and pharmaceutical industries. Protalix expects their valuable insights and contributions to guide the company forward as it continues to advance its clinical pipeline towards commercialization.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["Board of Directors","Appointments","Experience","Development","Commercialization"],"date_of_event":"January 1, 2020","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Management Changes"],"acquisition_amount":null,"structuredIssuesShow":"#Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"e5L1jeq4Yl5OAPCegKAxFOtZG9OoB813fMImGR8Jn5dJm9fNIyDRPG","news_summary":"Protalix BioTherapeutics Adds Two Accomplished Biopharmaceutical Executives to its Board of Directors","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"2621814c-d703-4d61-92c8-8305d1272b90","date":"Dec 18, 2019","link":"https://www.prnewswire.com/il/news-releases/protalix-biotherapeutics-and-chiesi-farmaceutici-announce-successful-pre-bla-meeting-with-fda-for-accelerated-approval-of-pegunigalsidase-alfa-for-the-treatment-of-fabry-disease-in-the-united-states-300959878.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":["biopharmaceutical","FDA","accelerated approval","Fabry disease","clinical trials"],"company":"Protalix BioTherapeutics, Inc.","layoffs":null,"summary":"Protalix BioTherapeutics and Chiesi Farmaceutici have completed a successful meeting with the FDA regarding the Accelerated Approval pathway for pegunigalsidase alfa (PRX‑102) for the treatment of Fabry disease. The FDA has confirmed the proposed BLA submission and the alignment on the Accelerated Approval pathway. The BLA, expected to be submitted by April 2020, will include data from completed and ongoing clinical trials. The ongoing BALANCE study will serve as the confirmatory trial for PRX‑102. The FDA indicated that no additional clinical trials will be required. Protalix and Chiesi expect to bring an approved product to market to help Fabry patients. The companys pipeline also includes other product candidates for various diseases.","partners":["Chiesi Farmaceutici S.p.A."],"customers":null,"investors":null,"confidence":8,"key_topics":["FDA meeting","Accelerated Approval pathway","pegunigalsidase alfa","Fabry disease","clinical trials"],"date_of_event":"October 15, 2019","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Investment","Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Investment  #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"uib1THArtLx6c9Y4s9OWTZez26xQkTgaIMqwvijVX0zAYpeU8plDVv","news_summary":"Protalix BioTherapeutics and Chiesi Farmaceutici Announce Successful pre-BLA Meeting with FDA for Accelerated Approval of pegunigalsidase alfa for the Treatment of Fabry Disease in the United States","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"c83f4a13-8489-4355-bc4d-3ae6c257c52d","date":"Oct 18, 2019","link":"https://en.globes.co.il/en/article-protalix-up-74-after-positive-fabry-disease-trial-results-1001304087","source":"en.globes.co.il","visible":1,"analysis":{"tags":"drug development","company":"Protalix Biotherapeutics Inc.","layoffs":null,"summary":"Protalix Biotherapeutics Inc. has announced positive 12-month on-treatment data from its BRIDGE Phase III study. The results suggest a strong potential benefit of pegunigalsidase alfa on renal function for Fabry patients. The interim data from the first 16 adult patients enrolled demonstrate a mean improvement in kidney function when switched from agalsidase alfa to pegunigalsidase alfa.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["drug development","BRIDGE Phase III study","renal function","Fabry patients","kidney function"],"date_of_event":"October 18, 2019","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"cIL5lFn3PSu0EqSDdBhJe6w45ZpSTznVXtqMIiMxaeHCVNwM7BdUAI","news_summary":"Protalix up 74% after positive Fabry disease trial results","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"d1449abc-6aba-4672-b4a4-837670dad01e","date":"Sep 24, 2019","link":"https://www.prnewswire.com/il/news-releases/protalix-biotherapeutics-and-chiesi-group-complete-enrollment-in-the-third-phase-iii-clinical-trial-of-pegunigalsidase-alfa-prx102-for-the-treatment-of-fabry-disease-300924080.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"Clinical Trials, Biopharmaceutical","company":"Protalix BioTherapeutics, Inc.","layoffs":"N/A","summary":"Protalix BioTherapeutics, Inc., a biopharmaceutical company, and its partner, Chiesi Farmaceutici S.p.A., have announced the completion of enrollment in their Phase III BALANCE clinical study of pegunigalsidase alfa, or PRX-102, for the treatment of Fabry disease. The study is designed to evaluate the safety and efficacy of PRX-102 compared to agalsidase beta on renal function in Fabry patients with progressing kidney disease previously treated with agalsidase beta. The company is targeting a BLA submission under an accelerated approval pathway for PRX-102 in the first quarter of 2020.","partners":"Chiesi Farmaceutici S.p.A.","customers":"N/A","investors":"N/A","confidence":9,"key_topics":["Clinical Study","Fabry Disease","PRX-102","Enrollment Completion","Treatment"],"date_of_event":"Sept. 24, 2019","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":["Partners"],"acquisition_amount":"N/A","structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"CMr5pnO1rX30IgYsyfl6qK9iHpgyfIIxbnmjltSogT7nbpLz6RCr1d","news_summary":"Protalix BioTherapeutics and Chiesi Group Complete Enrollment in the Third Phase III Clinical Trial of pegunigalsidase alfa (PRX‑102) for the Treatment of Fabry Disease","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"36a34bbd-7d2d-4775-98e3-f59280f81a3f","date":"Aug 22, 2019","link":"https://www.globenewswire.com/news-release/2019/08/22/1905424/0/en/Protalix-BioTherapeutics-Focuses-on-Evaluating-and-Pursuing-Alternatives-to-Maximize-Shareholder-Value-through-Refinancing-Strategic-Partnerships.html","source":"www.globenewswire.com","visible":1,"analysis":{"tags":"strategic alternatives, partnerships, pipeline, commercialization","company":"Protalix BioTherapeutics, Inc.","layoffs":null,"summary":"Protalix BioTherapeutics has engaged a financial advisory firm to evaluate strategic alternatives and maximize stakeholder value. The company is actively pursuing potential partnerships for its pipeline candidates and its ProCellEx platform. Protalixs unique expression system allows for cost-effective development of recombinant proteins. The companys first product, taliglucerase alfa, was approved by the FDA in 2012. Protalix has licensed the worldwide development and commercialization rights for taliglucerase alfa to Pfizer, excluding Brazil. The companys pipeline includes pegunigalsidase alfa, OPRX-106, alidornase alfa, and others. Protalix has partnered with Chiesi Farmaceutici for the development and commercialization of pegunigalsidase alfa. The company aims to improve its capital structure, pursue strategic partnerships, and move its pipeline towards commercialization.","partners":["Chiesi Farmaceutici S.p.A."],"customers":null,"investors":null,"confidence":8,"key_topics":["strategic alternatives","pipeline candidates","partnerships","commercialization","expression system"],"date_of_event":"August 22, 2019","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners","Expand"],"acquisition_amount":null,"structuredIssuesShow":"#Partners  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"2eT3ZHmErNJ5lEKnuCPPU8dUnpLjHg1csIkatLsMl19nLb4AA4NTmQ","news_summary":"Protalix BioTherapeutics Focuses on Evaluating and Pursuing Alternatives to Maximize Shareholder Value through Refinancing & Strategic Partnerships","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"507cff03-ecc7-4300-afb2-10ba4c7b7bca","date":"Aug 13, 2019","link":"https://www.globenewswire.com/news-release/2019/08/13/1901384/0/en/Shlomo-Yanai-Resigns-as-Chairman-of-the-Board-of-Protalix-BioTherapeutics.html","source":"www.globenewswire.com","visible":1,"analysis":{"tags":"resignation","company":"Protalix BioTherapeutics, Inc.","layoffs":null,"summary":"Shlomo Yanai has resigned from Protalix BioTherapeutics Board of Directors for personal reasons. Zeev Bronfeld, a current independent director, has been elected as the new Chairman of the Board. Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["resignation","board of directors","chairman","biopharmaceutical company","recombinant therapeutic proteins"],"date_of_event":"August 13, 2019","valuation_amount":null,"impact_on_company":"growth-negative","investment_amount":null,"structured_issues":["Management Changes"],"acquisition_amount":null,"structuredIssuesShow":"#Management Changes","entityGrowthIconPath":"url(/assets/circle-red.svg);"},"sentiment":"growth-negative","analysisId":"6j4Obc6R1vrCdNs1V9eX8VLEQnCdz7fWjVrUxK6gShwvI4D2pQVpU8","news_summary":"Shlomo Yanai Resigns as Chairman of the Board of Protalix BioTherapeutics","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"696c5f5f-cd3c-49a7-9b7b-707d969194c0","date":"Jul 29, 2019","link":"https://www.globenewswire.com/news-release/2019/07/29/1892732/0/en/Protalix-BioTherapeutics-Appoints-Eyal-Rubin-as-its-New-Senior-Vice-President-and-Chief-Financial-Officer.html","source":"www.globenewswire.com","visible":1,"analysis":{"tags":"management changes","company":"Protalix BioTherapeutics, Inc.","layoffs":null,"summary":"Protalix BioTherapeutics has announced the appointment of Eyal Rubin as the new Senior Vice President and Chief Financial Officer. Rubin will assume the role on September 22, 2019, and will bring over 20 years of finance and capital markets experience to the company. He most recently served as the Executive Vice President and CFO of BrainStorm Cell Therapeutics Inc. Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins. The companys first product, taliglucerase alfa, was approved by the FDA in 2012 and Protalix has licensed the worldwide development and commercialization rights to Pfizer Inc.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["appointment","financial and accounting","pipeline development","accelerated approval","finance and capital markets"],"date_of_event":"2019-09-22","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Management Changes"],"acquisition_amount":null,"structuredIssuesShow":"#Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"zA5QS3fifzPAFcsIYKCWeNPQPv490QtdqeDp50NRPal0kkTCGM5bXy","news_summary":"Protalix BioTherapeutics Appoints Eyal Rubin as its New Senior Vice President and Chief Financial Officer","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"de1a8fa8-0ae4-438f-a939-a3c3786512db","date":"Jul 17, 2019","link":"https://www.globenewswire.com/news-release/2019/06/17/1869487/0/en/Protalix-BioTherapeutics-Completes-Enrollment-in-the-Phase-III-BRIGHT-Clinical-Trial-of-pegunigalsidase-alfa-PRX-102-for-the-Treatment-of-Fabry-Disease.html","source":"www.globenewswire.com","visible":1,"analysis":{"tags":"clinical trial","company":"Protalix BioTherapeutics, Inc.","layoffs":null,"summary":"Protalix BioTherapeutics has announced the completion of enrollment in the phase III BRIGHT clinical trial of pegunigalsidase alfa for the treatment of Fabry disease. The trial is assessing the safety, efficacy, and pharmacokinetics of the drug candidate, which has the potential to double the time between infusions for patients with Fabry disease. The completion of enrollment marks a key milestone for the company, as it has the potential to greatly enhance the quality of life for some patients. Protalix BioTherapeutics is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["clinical trial","Fabry disease","enzyme replacement therapy","pegunigalsidase alfa","ProCellEx"],"date_of_event":"June 17, 2019","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"xnUDFjQ0GOs3XXZIpbqsEo02PbGmqhRkshz2IrDDP8hbPLM2qXOlb7","news_summary":"Protalix BioTherapeutics Completes Enrollment in the Phase III BRIGHT Clinical Trial of pegunigalsidase alfa (PRX 102) for the Treatment of Fabry Disease","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"99c2e280-3b9f-4d65-b4e1-03600ad9fd01","date":"Jun 6, 2019","link":"https://www.globenewswire.com/news-release/2019/06/06/1865179/0/en/Protalix-BioTherapeutics-and-Chiesi-Farmaceutici-S-p-A-to-Apply-for-Accelerated-Approval-of-pegunigalsidase-alfa-for-the-Treatment-of-Fabry-Disease-in-the-United-States.html","source":"www.globenewswire.com","visible":1,"analysis":{"tags":"biologics license application","company":"Protalix BioTherapeutics, Inc.","layoffs":null,"summary":"Protalix BioTherapeutics and Chiesi Farmaceutici plan to file a biologics license application (BLA) for pegunigalsidase alfa for the treatment of Fabry disease in the first quarter of 2020. The BLA will be submitted via the FDAs Accelerated Approval pathway. If approved, Protalix will be eligible to receive a milestone payment from Chiesi. The company remains optimistic about the FDAs approval of pegunigalsidase alfa on an accelerated basis.","partners":["Chiesi Farmaceutici S.p.A"],"customers":null,"investors":null,"confidence":8,"key_topics":["BLA submission","pegunigalsidase alfa","Fabry disease","FDA","accelerated approval"],"date_of_event":"2020-01-01","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"aHAQlEAbsCnINgwZjGswBBot4rFp44WETh14ou1gdWjXvBjkxdVcZH","news_summary":"Protalix BioTherapeutics and Chiesi Farmaceutici S.p.A to Apply for Accelerated Approval of pegunigalsidase alfa for the Treatment of Fabry Disease in the United States","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"ad23ad6f-bf4f-4b5c-8762-fc7de71db700","date":"May 21, 2019","link":"https://www.globenewswire.com/news-release/2019/05/21/1833240/0/en/Protalix-BioTherapeutics-Appoints-Dror-Bashan-as-its-New-President-and-Chief-Executive-Officer-and-Director.html","source":"www.globenewswire.com","visible":1,"analysis":{"tags":"management changes","company":"Protalix BioTherapeutics, Inc.","layoffs":null,"summary":"Protalix BioTherapeutics, Inc. has announced the appointment of Dror Bashan as the new President and CEO, effective June 30, 2019. Bashan will replace Moshe Manor, who is stepping down for personal reasons. Manor will assist with the transition and continue to work with the company on a consultant basis. Bashan brings valuable experience and knowledge in the pharmaceutical industry to Protalix. He has over 20 years of experience in various senior positions at Teva Pharmaceutical Industries. Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins. Their first product, taliglucerase alfa, was approved by the FDA in 2012. Protalixs development pipeline includes other product candidates such as pegunigalsidase alfa and alidornase alfa.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["Dror Bashan","Moshe Manor","pharmaceutical industry","Protalixs future development","ProCellEx"],"date_of_event":"June 30, 2019","valuation_amount":null,"impact_on_company":"growth-negative","investment_amount":null,"structured_issues":["Management Changes"],"acquisition_amount":null,"structuredIssuesShow":"#Management Changes","entityGrowthIconPath":"url(/assets/circle-red.svg);"},"sentiment":"growth-negative","analysisId":"Mokke215zLxMdOgjFCqtgE1LuplIXpkjOBXPqUHrRlx3brnx51UATl","news_summary":"Protalix BioTherapeutics Appoints Dror Bashan as its New President and Chief Executive Officer and Director","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"bde25720-b2b1-4b9c-a52b-b3c34a8cc432","date":"Oct 18, 2017","link":"https://globenewswire.com/news-release/2017/10/18/1149106/0/en/Protalix-BioTherapeutics-Enters-into-an-Exclusive-Ex-US-Partnership-with-Chiesi-Farmaceutici-for-the-Development-and-Commercialization-of-PRX-102-pegunigalsidase-alfa-for-the-Treat.html","source":"globenewswire.com","visible":1,"analysis":{"tags":"license agreement","company":"Protalix BioTherapeutics, Inc.","layoffs":null,"summary":"Protalix BioTherapeutics has entered into an Ex-US license and collaboration agreement with Chiesi Farmaceutici for PRX-102, a chemically modified version of the recombinant protein alpha-Galactosidase-A protein. Under the agreement, Protalix will receive $25 million upfront, up to $25 million in development costs, and up to $320 million in potential regulatory and commercial milestone payments. Protalix will also receive tiered royalties ranging from 15% to 35% on net sales. The agreement allows Protalix to secure significant funding while maintaining full rights to PRX-102 in the U.S. market. Chiesi is an international pharmaceutical company with a focus on the development and commercialization of innovative medicines. PRX-102 is being evaluated in phase III clinical trials for the treatment of Fabry disease.","partners":"Chiesi Farmaceutici S.p.A.","customers":null,"investors":null,"confidence":9,"key_topics":["license agreement","PRX-102","Chiesi","Fabry disease","recombinant protein"],"date_of_event":"October 18, 2017","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"WIxRASQQfP1PWbcOJz5nQwuFmNYuNIre66e9HXVuYIMyu4GgjTQP6l","news_summary":"Protalix BioTherapeutics Enters into an Exclusive Ex-US Partnership with Chiesi Farmaceutici for the Development and Commercialization of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry Disease","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"e87334f0-9616-41aa-9514-73e18d83ed7a","date":"Oct 14, 2015","link":"https://nocamels.com/2015/10/pfizer-invests-10m-in-protalix-pays-36m-for-commercial-rights/","source":"nocamels.com","visible":1,"analysis":{"tags":"investment, acquisition","company":"Pfizer","layoffs":null,"summary":"Pharma giant Pfizer has invested $10 million in Protalix Biotherapeutics and acquired full commercial rights to the Gaucher disease treatment Elelyso, except in Brazil, in exchange for $36 million cash. Protalix has undergone management changes and a new business strategy under the leadership of CEO Moshe Manor. The Israeli bio-medical company was founded by Yoseph Shaaltiel in 1993.","partners":null,"customers":null,"investors":"Pfizer","confidence":9,"key_topics":["Pfizer","Protalix Biotherapeutics","Gaucher disease treatment","Elelyso","Moshe Manor"],"date_of_event":"October 14, 2015","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$10 million","structured_issues":["Investment","Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Investment  #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"B02Dly0EqekO3GVcBW2LVEwPFrcwVraLnC44VK4U9qRDPvLuL2uKPg","news_summary":"Pfizer Invests $10M In Protalix, Pays $36M For Commercial Rights","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"26fdfc9a-8de6-4910-b9bb-683daa2b1d2a","date":"Oct 13, 2015","link":"http://www.fiercebiotech.com/financials/protalix-flips-its-gaucher-drug-to-pfizer-for-46m-r-d-cash","source":"www.fiercebiotech.com","visible":1,"analysis":{"tags":"Legal","company":"Questex LLC","layoffs":"N/A","summary":"The article does not provide any specific information about Questex LLC.","partners":"N/A","customers":"N/A","investors":"N/A","confidence":10,"key_topics":[],"date_of_event":"N/A","valuation_amount":"N/A","impact_on_company":"N/A","investment_amount":"N/A","structured_issues":[],"acquisition_amount":"N/A","entityGrowthIconPath":"none;"},"sentiment":"N/A","analysisId":"H6CLxhvIAHbfgbPdYxELMvB2pcNvbjNu78WYjTv1yqWtwa8r9dOqC7","news_summary":"Protalix flips its Gaucher drug to Pfizer for $46M in R&D cash","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"}],"newsNumber":155,"techcommunityinvolvement":null,"mediagallery":[{"id":"10c5c256-eadb-4e88-9673-2ea2430e9d4e","timestamp":"2019-11-17 08:31:32.000000","resources_type":1,"resources_title":"Protalix","resources_file_name":"$MkEaMcAfwh6Q5EHak9UHXJR9eG45UoPZHAy3N47dsiASjHRArQwUk8","alt":"Protalix logo","cleanBucketUrl":"https://storage.googleapis.com/clean-finder-353810","imageurl":"https://storage.googleapis.com/clean-finder-353810/$MkEaMcAfwh6Q5EHak9UHXJR9eG45UoPZHAy3N47dsiASjHRArQwUk8","url":"https://storage.googleapis.com/clean-finder-353810/$MkEaMcAfwh6Q5EHak9UHXJR9eG45UoPZHAy3N47dsiASjHRArQwUk8"}],"tags":["antibodies","oral-drugs","pharmaceuticals","proteins","genetic-disorders","plant-protein","inflammatory-diseases","pharma-companies","drug-development"],"classificationIDs":["agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Jvz7ewLDA"],"technologysuccessstory":null,"usecases":[],"businessmodels":["B2B"],"productstage":"Released","products":["ELELYSO","OPRX-106","PRX-119","PRX-110","UPLYSO","PRX-102","PRX-115","ProCellEx"],"geomarkets":["Mexico","Uruguay","Chile","Canada","Australia","United States","Brazil"],"targetmarkets":[],"marketcapital":79181384,"marketcapitaldate":"2024-07-30T00:00:00.000Z","funding":{"investors":5,"lastfunding":"$40M","totalrounds":11,"fundingstage":"Public","totalfunding":"$159.9M","publicinvestors":5,"lastpublicfunding":40000000,"totalpublicrounds":11,"totalpublicfunding":159900000},"team":[{"name":"Dror Bashan","email":"dror.bashan@protalix.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4KqIlPcIDA","bounced":false,"claimed":0,"founder":0,"urlname":"dror-bashan-1","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDgmvicswoM","position":"President, CEO & Director","last_name":"Bashan","claimtoken":"N1OLpQB0pAZn7JwKEvNtHASku14JTNiA3Ck9uTzt8EbCCmwuEVQY7M","first_name":"Dror","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/dror-bashan-801272/","unsubscribed":false,"is_activeuser":1,"additionalemail":"drorb@protalix.com","claimedemaildate":"2024-03-18 16:00:25.000000","initials":"DB","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Eyal Rubin","email":"eyal.rubin@protalix.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4OqWvZMKDA","bounced":false,"claimed":0,"founder":0,"urlname":"eyal-rubin","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDg6s3BkwkM","position":"SVP & CFO","last_name":"Rubin","claimtoken":"YkM1WwSsNWs4oyY4wzopnBDfl3qjGsTaXwgjoViFrGO7SFOrKzPldG","first_name":"Eyal","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/eyal-rubin-8b39282/","unsubscribed":false,"is_activeuser":1,"additionalemail":"eyalr@protalix.com","claimedemaildate":"2022-12-27 18:16:39.000000","initials":"ER","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Yaron Naos","email":"yaron.naos@protalix.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4Jr4q5cJDA","bounced":true,"claimed":0,"founder":0,"urlname":"yaron-naos","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDg2p3kwgoM","position":"SVP Operations","last_name":"Naos","claimtoken":"KxeB9CPiYmmrj0tE1uqZIh1FAurrmC3P9pWRBgrZTLxWabH6EzvJW4","first_name":"Yaron","picturekey":null,"claimeddate":null,"linkedinurl":null,"unsubscribed":false,"is_activeuser":1,"additionalemail":"yaronn@protalix.com","claimedemaildate":"2024-03-18 16:00:55.000000","initials":"YN","pictureurl":"/assets/empty-state.svg","linkedin-display":"none","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"William Taylor","email":"william.taylor@protalix.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4Kqvl7YLDA","bounced":false,"claimed":0,"founder":0,"urlname":"william-taylor","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDg2sK76ggM","position":"VP Business Development","last_name":"Taylor","claimtoken":"932aef30439937060f13c4d82674d7771ee2b614e4ba1129d26a656980c14a5c","first_name":"William","picturekey":null,"claimeddate":null,"linkedinurl":null,"unsubscribed":false,"is_activeuser":1,"additionalemail":"williamt@protalix.com","claimedemaildate":"2021-06-03 07:49:29.000000","initials":"WT","pictureurl":"/assets/empty-state.svg","linkedin-display":"none","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Dafna Shelly","email":"dafna.shelly@protalix.com","phone":"","gender":"Female","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4Krv34QJDA","bounced":false,"claimed":0,"founder":0,"urlname":"dafna-shelly","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDg2p2y0wgM","position":"VP HR","last_name":"Shelly","claimtoken":"ZazrHo6xW0Kz1B8E4bGHsVQYID8V02XHTxkXzO0JHHwpSy8vPn0Xx2","first_name":"Dafna","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/dafnashelly/","unsubscribed":true,"is_activeuser":1,"additionalemail":"dafnas@protalix.com","claimedemaildate":"2024-03-18 16:00:34.000000","initials":"DS","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Michal Kahana","email":"michal.kahana@protalix.com","phone":"","gender":"Female","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4OrcpsELDA","bounced":false,"claimed":0,"founder":0,"urlname":"michal-kahana","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDgqoj5wQkM","position":"VP QA","last_name":"Kahana","claimtoken":"B0pM3XIubZ2zems9xWQUw6tzaVbF2NERniZDjxl0n4mJOStlTN95km","first_name":"Michal","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/michal-kahana-5359b378/","unsubscribed":true,"is_activeuser":1,"additionalemail":"michalk@protalix.com","claimedemaildate":"2024-03-18 16:00:36.000000","initials":"MK","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""}],"description_edited":1,"tag_line_edited":1,"sector":"Pharmaceuticals","sectorverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgPGylJ0IDA","fullname":"Natalia Golczar"},"biverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgMGgoMMJDA","fullname":"Yanina Wainscheinker"},"biverifydate":"2020-06-09T00:00:00.000Z","crunchbaseid":"protalix-biotherapeutics","lastupdator":"Yanina Wainscheinker","lastupdator_email":"yanina.wainscheinker@sncentral.org","creator":"Rebecca Mack","creator_email":"rebeccamack26@gmail.com","createdate":"2014-07-29T00:00:00.000Z","biverification":"Yanina Wainscheinker","sectorverification":"Natalia Golczar","affiliatedOrganizations":null,"timeline":[{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCbrJqzCww","date":"Feb 2021","amount":"Undisclosed","source":"https://www.prnewswire.com/news-releases/protalix-biotherapeutics-completes-raise-of-approximately-40-million-in-gross-proceeds-301230926.html","ticker":"PLX","eventtype":"POEvent","valuation":"Undisclosed","investment":[],"capitalraised":"$40M","stockexchange":"AMEX","eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","stockexchange_key":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgODIksPaCww","stockexchange_logokey":"$zLkoGjSZ2iwmjx8lpl9xx8TXKntEawNVBzTB2CWom32JzD4JlkJRZ2","style":"","hiddenCompanyTooltip":"","stockexchange_logourl":"https://storage.googleapis.com/clean-finder-353810/$zLkoGjSZ2iwmjx8lpl9xx8TXKntEawNVBzTB2CWom32JzD4JlkJRZ2","exit_label":"","po_label":"Public Offering","acquireddesc":"Was acquired by","sectionname":"Public Offerings & Exit","amountnumber":null,"capitalraisednumber":40000000,"valuationnumber":null},{"id":"y8hGe6PENoWfrw8mvC3fYhXIfTS59qqnBjtPDFnQ4A9unBwQC8CkEw","date":"Mar 2020","amount":"$43.7M","source":"https://www.finsmes.com/2020/03/protalix-biotherapeutics-raises-43-7m-in-financing.html","eventtype":"FundingRoundEvent","investment":[{"name":" Psagot Investment House","type":"Investor","amount":null,"hidden":false,"country":"Israel","fullurl":"/investor_page/-psagot-investment-house","logokey":"$BYesuTgR7TGjgy0XJfYyJk04Gf4TnyXXIvZYqnPN6NKXh0ogg3KkWL.jpeg","tagline":" institutional investors","urlname":"/investor_page/-psagot-investment-house","isisraeli":1,"investorid":"5mLo5cqyUJE7JQ56qtC25kBje5NuCpKRrdzUYdT3QRAhmWzRpip9ub","fundingtype":"Institutional Investor","leadpartner":null,"investmentid":"bg5mMTrP4vkTT2wn5juLLaqebMcBuzvjpOTDUfPKFHPrjnfhY3TQb9","fundingsubtype":"Institutional Investor","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$BYesuTgR7TGjgy0XJfYyJk04Gf4TnyXXIvZYqnPN6NKXh0ogg3KkWL.jpeg","leadcaption":"","followupcaption":""},{"name":"More Investment House","type":"Investor","amount":null,"hidden":false,"country":"Israel","fullurl":"/investor_page/more-investment-house-2","logokey":"$6tGZXu84loSYEHBumfBqR3DvLN7Dz5KmF4rbAYxVxKbKHRhYxDiSme","tagline":"","urlname":"/investor_page/more-investment-house-2","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgODaqoLZCAw","fundingtype":"Institutional Investor","leadpartner":null,"investmentid":"yxxvCWjPe9BmySwh9LowNMsPvHvDjmTT8GekhSPn4ZSNPYKvQo3T76","fundingsubtype":"Institutional Investor","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$6tGZXu84loSYEHBumfBqR3DvLN7Dz5KmF4rbAYxVxKbKHRhYxDiSme","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"PIPE","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":43700000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOC3mOGiCww","date":"Oct 2015","amount":"$10M","source":"https://nocamels.com/2015/10/pfizer-invests-10m-in-protalix-pays-36m-for-commercial-rights/","eventtype":"FundingRoundEvent","investment":[{"name":"Pfizer","type":"Multinational","amount":0,"hidden":false,"country":"United States","fullurl":"/mnc_page/pfizer","logokey":"$D6uV7p6McKATLj4MXI6KiTZ1RD2zsZhYEW95YoziAyC8GorLHQkfFZ","tagline":"Pharmaceuticals","urlname":"/mnc_page/pfizer","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4ITru4IKDA","fundingtype":"Multinational","leadpartner":null,"investmentid":"67f9d1d9-3dc8-4e95-a05a-cb7b8c16ebf4","fundingsubtype":null,"investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$D6uV7p6McKATLj4MXI6KiTZ1RD2zsZhYEW95YoziAyC8GorLHQkfFZ","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"PIPE","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":10000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"WxwM891nT5QV3QVP5OSXjZjj9fHGijb21eOd2muHWTGSSBNP6eXnkj","date":"Feb 2012","amount":"Undisclosed","source":"https://protalixbiotherapeutics.gcs-web.com/news-releases/news-release-details/protalix-biotherapeutics-announces-closing-public-offering-and","ticker":"PLX","eventtype":"POEvent","valuation":"Undisclosed","investment":[],"capitalraised":"$25.4M","stockexchange":"NYSE","eventvisibility":"Public","amountvisibility":null,"fundingvisibility":null,"stockexchange_key":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgODIgdygCww","stockexchange_logokey":"$gCUzHIIl5WdaUySSBVfr4ukCJPjuwKJMFXjiY09JCLUNERZRom14T0","style":"","hiddenCompanyTooltip":"","stockexchange_logourl":"https://storage.googleapis.com/clean-finder-353810/$gCUzHIIl5WdaUySSBVfr4ukCJPjuwKJMFXjiY09JCLUNERZRom14T0","exit_label":"","po_label":"Public Offering","acquireddesc":"Was acquired by","sectionname":"Public Offerings & Exit","amountnumber":null,"capitalraisednumber":25400000,"valuationnumber":null},{"id":"YYVPGnXmvv4GMvlJT1EookQXPqPul16W61QuLuJWoYMr8WQtBykRdv","date":"Mar 2011","amount":"Undisclosed","source":"https://protalixbiotherapeutics.gcs-web.com/news-releases/news-release-details/protalix-biotherapeutics-announces-pricing-public-offering","ticker":"PLX","eventtype":"POEvent","valuation":"Undisclosed","investment":[],"capitalraised":"$22M","stockexchange":"NYSE","eventvisibility":"Public","amountvisibility":null,"fundingvisibility":null,"stockexchange_key":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgODIgdygCww","stockexchange_logokey":"$gCUzHIIl5WdaUySSBVfr4ukCJPjuwKJMFXjiY09JCLUNERZRom14T0","style":"","hiddenCompanyTooltip":"","stockexchange_logourl":"https://storage.googleapis.com/clean-finder-353810/$gCUzHIIl5WdaUySSBVfr4ukCJPjuwKJMFXjiY09JCLUNERZRom14T0","exit_label":"","po_label":"Public Offering","acquireddesc":"Was acquired by","sectionname":"Public Offerings & Exit","amountnumber":null,"capitalraisednumber":22000000,"valuationnumber":null},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODIn4zTCgw","date":"Nov 2010","amount":"Undisclosed","source":"","ticker":"PLX","eventtype":"POEvent","valuation":"Undisclosed","investment":[],"capitalraised":"Undisclosed","stockexchange":"TASE","eventvisibility":"Public","amountvisibility":null,"fundingvisibility":null,"stockexchange_key":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCot526Cgw","stockexchange_logokey":"$lbzaT2u1ZZsaxZoI8dlPGaVypdtKjf7mkYzKR0EFwkK0sKlf9u3hyJ","style":"","hiddenCompanyTooltip":"","stockexchange_logourl":"https://storage.googleapis.com/clean-finder-353810/$lbzaT2u1ZZsaxZoI8dlPGaVypdtKjf7mkYzKR0EFwkK0sKlf9u3hyJ","exit_label":"","po_label":"Public Offering","acquireddesc":"Was acquired by","sectionname":"Public Offerings & Exit","amountnumber":null,"capitalraisednumber":null,"valuationnumber":null},{"id":"GPNQU2Zram8BuzEjwz4Qo1RmeQROfLDD486BY7UYPMAxYd6oVflvEi","date":"Mar 2009","amount":"$6M","source":"https://protalixbiotherapeutics.gcs-web.com/news-releases/news-release-details/protalix-biotherapeutics-receives-research-grant-6-million","eventtype":"GrantEvent","granttype":1,"investment":[{"name":"Office of the Chief Scientist","type":"Investor","amount":null,"hidden":false,"country":"Israel","fullurl":"/investor_page/office-of-the-chief-scientist","logokey":null,"tagline":"","urlname":"/investor_page/office-of-the-chief-scientist","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCEv8qRCgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"Zr4vNeiuzW5C6ZC8DPGUpRKG23Sici3Rf6lCw46yHnrFKHEH51ZQgm","fundingsubtype":"VC and Private Equity","investorislead":1,"amountvisibility":"Public","isextensionround":null,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","leadcaption":"Lead ","followupcaption":"Follow on "}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"isjointventuregrant":0,"fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Non-Equity Funding","isgrant":true,"isicoevent":false,"amountnumber":6000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"0v1P5EQoHiRgTcFTp1yoUv0SFABNJSONueoAF3OYNuVSFPd6Bajka0","date":"Apr 2008","amount":"$4M","source":"https://protalixbiotherapeutics.gcs-web.com/news-releases/news-release-details/protalix-biotherapeutics-receives-research-grant-office-chief","eventtype":"GrantEvent","granttype":1,"investment":[{"name":"Office of the Chief Scientist","type":"Investor","amount":null,"hidden":false,"country":"Israel","fullurl":"/investor_page/office-of-the-chief-scientist","logokey":null,"tagline":"","urlname":"/investor_page/office-of-the-chief-scientist","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCEv8qRCgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"6baYakt7zmDNtYkOA08F54L7PnzFrdvrlAMGDMBdizh6QPOoEA79pp","fundingsubtype":"VC and Private Equity","investorislead":1,"amountvisibility":"Public","isextensionround":null,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","leadcaption":"Lead ","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"isjointventuregrant":0,"fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Non-Equity Funding","isgrant":true,"isicoevent":false,"amountnumber":4000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODwq5eUCgw","date":"Dec 2006","amount":"Undisclosed","source":"https://mayafiles.tase.co.il/RPdf/569001-570000/P569095-00.pdf","ticker":"PLX","eventtype":"POEvent","valuation":"Undisclosed","investment":[],"capitalraised":"Undisclosed","stockexchange":"AMEX","eventvisibility":"Public","amountvisibility":null,"fundingvisibility":null,"stockexchange_key":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgODIksPaCww","stockexchange_logokey":"$zLkoGjSZ2iwmjx8lpl9xx8TXKntEawNVBzTB2CWom32JzD4JlkJRZ2","style":"","hiddenCompanyTooltip":"","stockexchange_logourl":"https://storage.googleapis.com/clean-finder-353810/$zLkoGjSZ2iwmjx8lpl9xx8TXKntEawNVBzTB2CWom32JzD4JlkJRZ2","exit_label":"EXIT","po_label":"Initial Public Offering","acquireddesc":"Was acquired by","sectionname":"Public Offerings & Exit","amountnumber":null,"capitalraisednumber":null,"valuationnumber":null},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODE2_uQCww","date":"Dec 2005","amount":"$5.3M","source":"Migrated","eventtype":"FundingRoundEvent","investment":[{"name":"Aliment Capital","type":"Investor","amount":0,"hidden":true,"country":"United States","fullurl":"/investor_page/aliment-capital","logokey":"$LwYLFRw2HlMwKVQOw1ws3SkVCFy5oBFjxN4akpfxpRlHrk9J2zgcS6","tagline":null,"urlname":"/investor_page/aliment-capital","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgMng7YsJDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"d552c8f4-4fd3-48af-afbd-32507ff70940","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$LwYLFRw2HlMwKVQOw1ws3SkVCFy5oBFjxN4akpfxpRlHrk9J2zgcS6","leadcaption":"","followupcaption":""},{"name":"Docor International Management","type":"Investor","amount":null,"hidden":false,"country":"Israel","fullurl":"/investor_page/docor","logokey":"$OfHtk8MQpXyjuEfISyRNC2I0FArnwi7SC4uowUIF3xWUco4YnAg2VW","tagline":null,"urlname":"/investor_page/docor","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgMnYj5YKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"vg38EC9dEe2qFKDU9lnVMoKSIADLp6HYAmvpVsHNAYLtHX1AJ7XVUe","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$OfHtk8MQpXyjuEfISyRNC2I0FArnwi7SC4uowUIF3xWUco4YnAg2VW","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"C Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":5300000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODEtfqMCAw","date":"Oct 2004","amount":"$3.5M","source":"Migrated","eventtype":"FundingRoundEvent","investment":[],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"B Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":3500000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"investmentstage":[],"exits":[],"investments":[],"portfolio":[],"funds":[],"founded":"1/1994","databases":[],"sharedspaces":[],"utilities":[],"contributors":[],"employeesworldwide":"","fundingtype":"Startup","parsedName":"Protalix BioTherapeutics","logourl":"https://storage.googleapis.com/clean-finder-353810/$Fh4vCEadZAfTP5ZZNbudPyVHatYvtFo3F2XHvMoM5PmIkjwUU5Js0T","oglogourl":"https://storage.googleapis.com/clean-finder-353810/$Fh4vCEadZAfTP5ZZNbudPyVHatYvtFo3F2XHvMoM5PmIkjwUU5Js0T","seoabout":"Protalix BioTherapeutics is a biopharmaceutical company focused on the development, production, and commercialization of recombinant therapeutic proteins p...","seoTitle":"Israeli Startup","solutions":[],"teamMembersNumber":6,"primarySector":"Health Tech & Life Sciences","primary-sector-display":"block","classifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drugs Discovery & Development","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","classificationName":"sectorclassification"},{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Biologicals","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","classificationName":"coretechnology"},{"depth":2,"name":"Molecules","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Jvz7ewLDA","classificationName":"coretechnology"},{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"}],"classificationDelimited":["SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA>Drugs Discovery & Development#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA>Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA>Molecules#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Jvz7ewLDA"],"classificationsViewModel":"|0:>SectorClassificationModel|1:>SectorClassificationModel/Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA|2:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA/Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA|3:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA/Drugs Discovery & Development#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA|0:>IndustryClassificationModel|1:>IndustryClassificationModel/Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA|2:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA/Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA/Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA|0:>TechnologyClassificationModel|1:>TechnologyClassificationModel/Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA|2:>TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA/Molecules#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Jvz7ewLDA|","classificationTrees":{"sector":[{"title":"Health Tech & Life Sciences","key":"0-0","path":"SectorClassificationModel>Health Tech & Life Sciences","children":[{"title":"Pharma & Medical Biotechnology","key":"0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology","children":[{"title":"Drugs Discovery & Development","key":"0-0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology>Drugs Discovery & Development"}]}]}],"targetCustomer":[{"title":"Healthcare & Life Sciences","key":"0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences","children":[{"title":"Life Sciences","key":"0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences","children":[{"title":"Pharmaceuticals","key":"0-0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences>Pharmaceuticals"}]}]}],"coreTechnology":[{"title":"Biologicals","key":"0-0","path":"TechnologyClassificationModel>Biologicals","children":[{"title":"Molecules","key":"0-0-0","path":"TechnologyClassificationModel>Biologicals>Molecules"}]}]},"sectorClassifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drugs Discovery & Development","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","classificationName":"sectorclassification"}],"coreTechnologyClassifications":[{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Biologicals","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","classificationName":"coretechnology"},{"depth":2,"name":"Molecules","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Jvz7ewLDA","classificationName":"coretechnology"}],"targetCustomerClassifications":[{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"}],"classificationNames":{"sector":["Health Tech & Life Sciences","Pharma & Medical Biotechnology","Drugs Discovery & Development"],"coreTechnology":["Biologicals","Molecules"],"targetCustomer":["Healthcare & Life Sciences","Life Sciences","Pharmaceuticals"]},"section":null,"sectionParams":"","queryParams":"","popup_claim_profile":"false","claimedBadge":"none","display":{"mainContact":"none","climateTag":"none","seeMoreSimilarCompanisDisplay":"none","similarCompaniesTitleFontSize":"3.2rem","similarCompaniesTitle":"Similar Companies","similar_companies":[]},"mainContact":{},"_eventview":{"publicoffering_exit":[{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCbrJqzCww","date":"Feb 2021","amount":"Undisclosed","source":"https://www.prnewswire.com/news-releases/protalix-biotherapeutics-completes-raise-of-approximately-40-million-in-gross-proceeds-301230926.html","ticker":"PLX","eventtype":"POEvent","valuation":"Undisclosed","investment":[],"capitalraised":"$40M","stockexchange":"AMEX","eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","stockexchange_key":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgODIksPaCww","stockexchange_logokey":"$zLkoGjSZ2iwmjx8lpl9xx8TXKntEawNVBzTB2CWom32JzD4JlkJRZ2","style":"","hiddenCompanyTooltip":"","stockexchange_logourl":"https://storage.googleapis.com/clean-finder-353810/$zLkoGjSZ2iwmjx8lpl9xx8TXKntEawNVBzTB2CWom32JzD4JlkJRZ2","exit_label":"","po_label":"Public Offering","acquireddesc":"Was acquired by","sectionname":"Public Offerings & Exit","amountnumber":null,"capitalraisednumber":40000000,"valuationnumber":null},{"id":"WxwM891nT5QV3QVP5OSXjZjj9fHGijb21eOd2muHWTGSSBNP6eXnkj","date":"Feb 2012","amount":"Undisclosed","source":"https://protalixbiotherapeutics.gcs-web.com/news-releases/news-release-details/protalix-biotherapeutics-announces-closing-public-offering-and","ticker":"PLX","eventtype":"POEvent","valuation":"Undisclosed","investment":[],"capitalraised":"$25.4M","stockexchange":"NYSE","eventvisibility":"Public","amountvisibility":null,"fundingvisibility":null,"stockexchange_key":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgODIgdygCww","stockexchange_logokey":"$gCUzHIIl5WdaUySSBVfr4ukCJPjuwKJMFXjiY09JCLUNERZRom14T0","style":"","hiddenCompanyTooltip":"","stockexchange_logourl":"https://storage.googleapis.com/clean-finder-353810/$gCUzHIIl5WdaUySSBVfr4ukCJPjuwKJMFXjiY09JCLUNERZRom14T0","exit_label":"","po_label":"Public Offering","acquireddesc":"Was acquired by","sectionname":"Public Offerings & Exit","amountnumber":null,"capitalraisednumber":25400000,"valuationnumber":null},{"id":"YYVPGnXmvv4GMvlJT1EookQXPqPul16W61QuLuJWoYMr8WQtBykRdv","date":"Mar 2011","amount":"Undisclosed","source":"https://protalixbiotherapeutics.gcs-web.com/news-releases/news-release-details/protalix-biotherapeutics-announces-pricing-public-offering","ticker":"PLX","eventtype":"POEvent","valuation":"Undisclosed","investment":[],"capitalraised":"$22M","stockexchange":"NYSE","eventvisibility":"Public","amountvisibility":null,"fundingvisibility":null,"stockexchange_key":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgODIgdygCww","stockexchange_logokey":"$gCUzHIIl5WdaUySSBVfr4ukCJPjuwKJMFXjiY09JCLUNERZRom14T0","style":"","hiddenCompanyTooltip":"","stockexchange_logourl":"https://storage.googleapis.com/clean-finder-353810/$gCUzHIIl5WdaUySSBVfr4ukCJPjuwKJMFXjiY09JCLUNERZRom14T0","exit_label":"","po_label":"Public Offering","acquireddesc":"Was acquired by","sectionname":"Public Offerings & Exit","amountnumber":null,"capitalraisednumber":22000000,"valuationnumber":null},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODIn4zTCgw","date":"Nov 2010","amount":"Undisclosed","source":"","ticker":"PLX","eventtype":"POEvent","valuation":"Undisclosed","investment":[],"capitalraised":"Undisclosed","stockexchange":"TASE","eventvisibility":"Public","amountvisibility":null,"fundingvisibility":null,"stockexchange_key":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCot526Cgw","stockexchange_logokey":"$lbzaT2u1ZZsaxZoI8dlPGaVypdtKjf7mkYzKR0EFwkK0sKlf9u3hyJ","style":"","hiddenCompanyTooltip":"","stockexchange_logourl":"https://storage.googleapis.com/clean-finder-353810/$lbzaT2u1ZZsaxZoI8dlPGaVypdtKjf7mkYzKR0EFwkK0sKlf9u3hyJ","exit_label":"","po_label":"Public Offering","acquireddesc":"Was acquired by","sectionname":"Public Offerings & Exit","amountnumber":null,"capitalraisednumber":null,"valuationnumber":null},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODwq5eUCgw","date":"Dec 2006","amount":"Undisclosed","source":"https://mayafiles.tase.co.il/RPdf/569001-570000/P569095-00.pdf","ticker":"PLX","eventtype":"POEvent","valuation":"Undisclosed","investment":[],"capitalraised":"Undisclosed","stockexchange":"AMEX","eventvisibility":"Public","amountvisibility":null,"fundingvisibility":null,"stockexchange_key":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgODIksPaCww","stockexchange_logokey":"$zLkoGjSZ2iwmjx8lpl9xx8TXKntEawNVBzTB2CWom32JzD4JlkJRZ2","style":"","hiddenCompanyTooltip":"","stockexchange_logourl":"https://storage.googleapis.com/clean-finder-353810/$zLkoGjSZ2iwmjx8lpl9xx8TXKntEawNVBzTB2CWom32JzD4JlkJRZ2","exit_label":"EXIT","po_label":"Initial Public Offering","acquireddesc":"Was acquired by","sectionname":"Public Offerings & Exit","amountnumber":null,"capitalraisednumber":null,"valuationnumber":null}],"privateequityfunding":[{"id":"y8hGe6PENoWfrw8mvC3fYhXIfTS59qqnBjtPDFnQ4A9unBwQC8CkEw","date":"Mar 2020","amount":"$43.7M","source":"https://www.finsmes.com/2020/03/protalix-biotherapeutics-raises-43-7m-in-financing.html","eventtype":"FundingRoundEvent","investment":[{"name":" Psagot Investment House","type":"Investor","amount":null,"hidden":false,"country":"Israel","fullurl":"/investor_page/-psagot-investment-house","logokey":"$BYesuTgR7TGjgy0XJfYyJk04Gf4TnyXXIvZYqnPN6NKXh0ogg3KkWL.jpeg","tagline":" institutional investors","urlname":"/investor_page/-psagot-investment-house","isisraeli":1,"investorid":"5mLo5cqyUJE7JQ56qtC25kBje5NuCpKRrdzUYdT3QRAhmWzRpip9ub","fundingtype":"Institutional Investor","leadpartner":null,"investmentid":"bg5mMTrP4vkTT2wn5juLLaqebMcBuzvjpOTDUfPKFHPrjnfhY3TQb9","fundingsubtype":"Institutional Investor","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$BYesuTgR7TGjgy0XJfYyJk04Gf4TnyXXIvZYqnPN6NKXh0ogg3KkWL.jpeg","leadcaption":"","followupcaption":""},{"name":"More Investment House","type":"Investor","amount":null,"hidden":false,"country":"Israel","fullurl":"/investor_page/more-investment-house-2","logokey":"$6tGZXu84loSYEHBumfBqR3DvLN7Dz5KmF4rbAYxVxKbKHRhYxDiSme","tagline":"","urlname":"/investor_page/more-investment-house-2","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgODaqoLZCAw","fundingtype":"Institutional Investor","leadpartner":null,"investmentid":"yxxvCWjPe9BmySwh9LowNMsPvHvDjmTT8GekhSPn4ZSNPYKvQo3T76","fundingsubtype":"Institutional Investor","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$6tGZXu84loSYEHBumfBqR3DvLN7Dz5KmF4rbAYxVxKbKHRhYxDiSme","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"PIPE","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":43700000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOC3mOGiCww","date":"Oct 2015","amount":"$10M","source":"https://nocamels.com/2015/10/pfizer-invests-10m-in-protalix-pays-36m-for-commercial-rights/","eventtype":"FundingRoundEvent","investment":[{"name":"Pfizer","type":"Multinational","amount":0,"hidden":false,"country":"United States","fullurl":"/mnc_page/pfizer","logokey":"$D6uV7p6McKATLj4MXI6KiTZ1RD2zsZhYEW95YoziAyC8GorLHQkfFZ","tagline":"Pharmaceuticals","urlname":"/mnc_page/pfizer","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4ITru4IKDA","fundingtype":"Multinational","leadpartner":null,"investmentid":"67f9d1d9-3dc8-4e95-a05a-cb7b8c16ebf4","fundingsubtype":null,"investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$D6uV7p6McKATLj4MXI6KiTZ1RD2zsZhYEW95YoziAyC8GorLHQkfFZ","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"PIPE","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":10000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODE2_uQCww","date":"Dec 2005","amount":"$5.3M","source":"Migrated","eventtype":"FundingRoundEvent","investment":[{"name":"Aliment Capital","type":"Investor","amount":0,"hidden":true,"country":"United States","fullurl":"/investor_page/aliment-capital","logokey":"$LwYLFRw2HlMwKVQOw1ws3SkVCFy5oBFjxN4akpfxpRlHrk9J2zgcS6","tagline":null,"urlname":"/investor_page/aliment-capital","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgMng7YsJDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"d552c8f4-4fd3-48af-afbd-32507ff70940","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$LwYLFRw2HlMwKVQOw1ws3SkVCFy5oBFjxN4akpfxpRlHrk9J2zgcS6","leadcaption":"","followupcaption":""},{"name":"Docor International Management","type":"Investor","amount":null,"hidden":false,"country":"Israel","fullurl":"/investor_page/docor","logokey":"$OfHtk8MQpXyjuEfISyRNC2I0FArnwi7SC4uowUIF3xWUco4YnAg2VW","tagline":null,"urlname":"/investor_page/docor","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgMnYj5YKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"vg38EC9dEe2qFKDU9lnVMoKSIADLp6HYAmvpVsHNAYLtHX1AJ7XVUe","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$OfHtk8MQpXyjuEfISyRNC2I0FArnwi7SC4uowUIF3xWUco4YnAg2VW","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"C Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":5300000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODEtfqMCAw","date":"Oct 2004","amount":"$3.5M","source":"Migrated","eventtype":"FundingRoundEvent","investment":[],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"B Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":3500000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"nonequityfunding":[{"id":"GPNQU2Zram8BuzEjwz4Qo1RmeQROfLDD486BY7UYPMAxYd6oVflvEi","date":"Mar 2009","amount":"$6M","source":"https://protalixbiotherapeutics.gcs-web.com/news-releases/news-release-details/protalix-biotherapeutics-receives-research-grant-6-million","eventtype":"GrantEvent","granttype":1,"investment":[{"name":"Office of the Chief Scientist","type":"Investor","amount":null,"hidden":false,"country":"Israel","fullurl":"/investor_page/office-of-the-chief-scientist","logokey":null,"tagline":"","urlname":"/investor_page/office-of-the-chief-scientist","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCEv8qRCgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"Zr4vNeiuzW5C6ZC8DPGUpRKG23Sici3Rf6lCw46yHnrFKHEH51ZQgm","fundingsubtype":"VC and Private Equity","investorislead":1,"amountvisibility":"Public","isextensionround":null,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","leadcaption":"Lead ","followupcaption":"Follow on "}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"isjointventuregrant":0,"fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Non-Equity Funding","isgrant":true,"isicoevent":false,"amountnumber":6000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"0v1P5EQoHiRgTcFTp1yoUv0SFABNJSONueoAF3OYNuVSFPd6Bajka0","date":"Apr 2008","amount":"$4M","source":"https://protalixbiotherapeutics.gcs-web.com/news-releases/news-release-details/protalix-biotherapeutics-receives-research-grant-office-chief","eventtype":"GrantEvent","granttype":1,"investment":[{"name":"Office of the Chief Scientist","type":"Investor","amount":null,"hidden":false,"country":"Israel","fullurl":"/investor_page/office-of-the-chief-scientist","logokey":null,"tagline":"","urlname":"/investor_page/office-of-the-chief-scientist","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCEv8qRCgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"6baYakt7zmDNtYkOA08F54L7PnzFrdvrlAMGDMBdizh6QPOoEA79pp","fundingsubtype":"VC and Private Equity","investorislead":1,"amountvisibility":"Public","isextensionround":null,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","leadcaption":"Lead ","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"isjointventuregrant":0,"fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Non-Equity Funding","isgrant":true,"isicoevent":false,"amountnumber":4000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"merger_acquisitions":[],"others":[]}}